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Abstract 
 
Development of antinociceptive tolerance in the clinic after repeated administration of 
morphine limits its chronic use. Despite knowledge about the molecular mechanisms of 
morphine tolerance, we know little about the influence of dosage regimen (starting dose, 
follow-up dose, dosing and duration of treatment) for its development. I hypothesised that 
morphine dose, as well as dose increments, contribute to tolerance development. In addition, 
morphine-induced behavioural changes also might follow a similar pattern of antinociception 
and tolerance. Four groups of male Sprague Dawley rats received different daily doses of 
intermittent subcutaneous morphine for 14 days. After the development of antinociceptive 
tolerance, different increments of morphine doses were administered until tolerance 
redeveloped. Animals treated with lower starting-doses of morphine developed 
antinociceptive tolerance faster than those started on higher doses. Higher starting-doses and 
higher dose-increments after tolerance development resulted in more sustained 
antinociception and delayed the re-development of tolerance. These results were replicated in 
two anti-nociceptive assays and were therefore not assay-specific. The kinetics of morphine-
induced motor suppression and desensitisation were similar to those of antinociception and 
antinociceptive-tolerance respectively. Overall, morphine dosing regimen in rats appears to 
significantly influence antinociceptive tolerance and total antinociception. My results also 
indicate that repetitive morphine dosing leads to desensitisation of motor suppression in all 
major motor behavioural parameters and manifests behavioural tolerance in conjunction with 
antinociceptive tolerance. Therefore, the results highlight that an optimised morphine dosing 
strategy can delay antinociceptive tolerance and reduce behavioural adverse effects.  
 
xxiii 
 
Morphine and most other clinical opioids are MOP receptor agonists. The MOP receptor is 
responsible for both antinociception and generation of antinociceptive tolerance. Previous 
studies showed that an opioid ligand with mixed activity on multiple opioid receptor can 
reduce antinociceptive tolerance compared to morphine or other clinical opioids. Several 
novel opioids synthesised at the University of Tasmania were characterised for their in vitro 
specificity for major opioid receptors (MOP, DOP, KOP and NOP receptors) before one 
selected mixed activity opioid was tested for its antinociceptive effect, antinociceptive 
tolerance and motor behavioural effects in vivo. Collectively, UTA1003 acted as a MOP and 
KOP receptor agonist and a DOP receptor partial agonist. Therefore, I expected the ligand to 
reduce tolerance and motor suppression over a repeated treatment regimen. In rats, UTA1003 
showed a mild antinociceptive effect with no noticeable motor suppression after subcutaneous 
administration. After repeated treatment over a period of eight days, UTA1003 displayed no 
tolerance and no motor behavioural adverse effect. In addition, the ligand maintained 
approximately 50% antinociception over the 8 days treatment without affecting morphine-
induced motor suppression or hyper-excitation. Therefore, my study showed that co-
administration of morphine and an opioid with mixed activity profile on multiple receptors 
can delay antinociceptive tolerance.  
Worldwide, the elderly suffer from chronic pain while being the highest users of opioids. In 
current clinical practice, morphine is dosed in older patients based on patient-weight, with 
different calculations for adjustment. However, neither clinical experience nor the literature 
offers a clear evidence base for the relationship between antinociception, behavioural effects 
and morphine administration in older patients. In this study, I compared the nociceptive 
response of 8 and 24 week old rats after subcutaneous administration of morphine per body 
weight and analysed their motor behaviour. Residual morphine in all major tissues was 
determined. I observed prolonged morphine-induced antinociception in older rats compared 
xxiv 
 
to younger rats. Moreover, morphine significantly stimulated locomotor and rearing 
behaviour 180 min after injection, which was significantly higher in the 8-week compared to 
24-week old rats. Tissue analysis from animals extracted during the stimulatory phase 
revealed a significantly higher concentration of residual morphine in the brain of older versus 
younger animals when standardised on tissue weight. Collectively, morphine exhibited higher 
antinociception and increased behavioural inhibition in older compared to younger animals, 
likely due to the significantly higher accumulation of morphine in the brain of older animals. 
Therefore, my findings would suggest that a lower dose of morphine is sufficient to provide 
sufficient pain-relief in older patients.   
Diabetes patients increase worldwide and elderly people are highly susceptible for diabetes 
mellitus. Apart from pain-relief and behavioural effects, opioids also affect insulin secretion 
in pancreatic β-cells. Therefore, a pancreatic β-cell line (RIN-5F) was exposed to different 
selective agonists and antagonists of the major opioid receptors. My findings suggest that 
MOP and DOP receptors are mainly responsible for pancreatic insulin release. Therefore, my 
findings along with previous studies contribute to a better treatment strategy for the 
management of insulin homeostasis and diabetic neuropathy.  
Overall, proper dosing of an opioid can show better analgesia, less tolerance and less 
behavioural adverse effects. My study identified “age of patient” as an important parameter 
for opioid dosing. The novel opioid UTA1003 could serve as an adjuvant with morphine to 
reduce morphine tolerance over a long-term treatment. Follow-up studies with structural 
modifications are required to increase its potency as a pain-killer as well as a pharmacokinetic 
study would help to understand its mechanism of action. 
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1. Introduction  
1.1. Opioid system 
According to International Association for the Study of Pain (IASP), pain is a distressing 
sensory experience derived from a tissue damage (1). Pain can be categorised as nociceptive, 
neuropathic or a combination of both (mixed). Nociceptive pain is generated as a warning 
signal to inform about the possible damage of a non-neural tissue (1,2). In contrast, neuropathic 
pain usually results from damage to a neural tissue by a disease, toxin or an infection (1,3). A 
combination of nociceptive and neuropathic pain is commonly observed in situations like 
cancer and other indications that are characterised by long-term pain.  
The opioid system is a physiological control system that modulates pain, emotions, immune 
defence and various other physiological responses. The opioid system involvesthe 
communication and coordination of a significant number of endogenous opioid peptides and 
several types of opioid receptors in the central and peripheral nervous system. This system also 
significantly modulates numerous sensory, emotional, motivational, cognitive functions as 
well as addictive behaviours (4,5,6). It is also involved in other physiological functions, 
including responses to stress, respiration, gastrointestinal transit, as well as endocrine and 
immune functions (7). These responses are orchestrated by opioids that bind to specific opioid 
receptors to induce analgesic and behavioural effects in vivo. Therefore, to understand the 
pharmacological effects of specific opioids, it is essential to first clarify the specific roles of 
each opioid receptor.  
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1.1.1. Opioid receptors and pain-relief 
Analgesic responses are regulated by different neuronal signals, which are controlled by 
different types of opioid receptors. The presence of opioid receptors was first proposed in 1954  
(8). However, the first evidence for different types of opioid receptors was only described in 
1976 (9). According to the International Union of Basic and Clinical Pharmacology (IUPHAR) 
and the British Pharmacological Society (BPS) joint IUPHAR/BPS Guide to Pharmacology, 
opioid receptors are classified into μ (Mu: MOP), δ (delta: DOP) and κ (kappa: KOP)  receptors 
as well as the non-classical opioid (NOP) receptors (10) (Table 1).  
Opioid receptors belong to the family of seven-transmembrane helical G protein-coupled 
receptors (GPCRs). These receptors display an extracellular N-terminus and intracellular C-
terminus and are coupled with heterotrimeric Gi/Go proteins (11,12,13). Opioid ligands bind to 
opioid receptors by ligand-receptor interactions in the binding pockets of the receptor, which 
are situated in the transmembrane helices. The binding pocket of opioid receptors can be 
divided into two distinct regions: the lower part (intracellular side) is highly conserved for 
opioids (non-specific ‘message’-region) and the higher part of the pocket (extracellular side) 
contains divergent residues that confer selectivity (‘address’ region) of opioid receptor types 
and binding depends on the type of the opioid ligand as well (14,15). In 2012, the molecular 
structures of all four opioid receptors were described by several reports (14,16,17,18) and 
overall displayed around 60% similarity.  
Although all of these opioid receptors (OR) modulate antinociception, the MOP receptor is 
thought to be dominant for its antinociceptive effects in vivo (19,20,21,22). The major 
limitation of targeting the MOP receptor for analgesia is that it is also responsible for the 
induction of tolerance (23) and other side-effects like respiratory depression (24) or 
constipation (25). MOP receptor-related adverse events are of great clinical concern and justify 
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the characterisation of other opioid receptors as suitable drug targets to induce analgesia. 
Unfortunately, the other three receptors do not show the same efficacy to transmit drug-induced 
analgesia compared to the MOP-receptor. DOP-receptor agonists are generally less effective 
to treat acute thermal pain compared to inflammatory (26,27,28), neuropathic (29,30) and 
cancer -associated bone pain (31). SNC80 and Deltorphin II (both DOP receptor agonists) 
showed significant anti-hyperalgesic effects, but these compounds were less potent or less 
efficacious to induce thermal antinociceptive effects (27).  In addition, the use of DOP-receptor 
agonists is limited since DOP receptor-induced analgesia appears to require the presence of a 
pro-inflammatory state (32,33). While DOP-receptor agonists only produce moderate analgesia 
in non-human primates (34,35,36), despite being effective in rodent models of chronic pain 
(37), they are associated with convulsions in mice (38) and non-human primates (34,35,36). 
KOP-receptor agonists are reported to reduce inflammatory (39) and neuropathic pain (40) to 
some extent but are limited to non-systemic use to avoid CNS-associated adverse events 
(41,42,43). While selective KOP or DOP receptor agonists lack some of the MOP receptor 
agonist- (e.g. morphine) associated side-effects such as constipation, respiratory depression 
and addiction, they display a side-effect profile of their own that includes diuresis, sedation 
and dysphoria (45).  In a recent study, two KOP receptor agonist ligands, HS665 and HS666 
showed dose-dependent thermal antinociception similar to U50,488 after i.c.v. administration 
(44). The authors showed that the effects were mediated by the KOP receptor and HS665 did 
not show any dysphoric effects, as it showed low efficacy in the β-arrestin2 signalling pathway 
(44). Several NOP receptor agonists are reported to show antinociceptive effects in rodent 
(46,47) and primate models (48,49,50) and are associated with a reduced risk for abuse (51). 
However, systemic administration of these NOP agonists did not produce spinal analgesia in 
rodents (52,53), while showing efficacy using intrathecal administration in primates and rodent 
models of neuropathic pain (47,48,51,54). Overall, MOP-receptor agonists, despite their 
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adverse-effects, therefore appear superior to provide pain relief and are thus widely used in the 
clinic (22,55). 
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Table 1. Classification of opioid receptors.  Keys: β‐funaltrexamine (β‐FNA), [D‐Ala2, N‐MePhe4, Gly‐ol]‐enkephalin (DAMGO), norbinaltorphimine 
(norBNI), [D‐Pen2,D‐Pen5]‐enkephalin (DPDPE), nociceptin/orphanin‐FQ (N/OFQ), H‐Tyr‐Tic‐Phe‐Phe‐OH (TIPP).  
 
Receptor 
Nomenclature1 
Gene  Most common  
location  in the CNS2 
 
Most common 
roles and functions 
Selective 
Agonist 3 
 
Selective 
Antagonist4 
 
μ, mu, MOP 
 
 
 
OPRM1  thalamus, amygdala, dorsal horn, 
cerebral cortex, striatum, 
hippocampus, locus coeruleus 
analgesia, intestinal transit, 
feeding, mood, hormone 
secretion, thermoregulation, 
cardiovascular function 
 
DAMGO, 
sufentanil, 
PL017, 
 
CTAP, 
CTOP, 
β‐FNA, 
 
δ, delta, DOP 
 
 
 
OPRD1  olfactory bulb, thalamus, cortex, 
caudate putamen, nucleus 
accumbens, amygdala, dorsal horn 
analgesia, mood,  
gastrointestinal motility, 
behaviour, cardiovascular 
regulation 
 
DPDPE, 
[D‐Ala2]deltorphin I , 
[D‐Ala2]deltorphin II, 
SNC80  
Naltrindole, 
TIPPᴪ, 
Naltriben 
κ, kappa, KOP 
 
OPRK1  olfactory bulb, nucleus accumbens, 
cerebral cortex, claustrum,  amygdala, 
caudate nucleus, hypothalamus, 
subthalamic nucleus, thalamus, 
corpus callosum. 
 
analgesia in inflammation, 
diuresis, feeding, 
neuroprotection,  
neuroendocrine functions 
  
Enadoline, 
U50488, 
U69593, 
salvinorin A 
norBNI, 
GNTI 
 
N/OFQ, NOP  OPRL1  hippocampus, hypothalamus, 
amygdala, substantia nigra, dorsal 
horn, lateral septum 
spinal analgesia, anxiety, 
mood, memory, feeding, 
locomotor activity 
UFP‐102, 
Ro64‐6198, 
N/OFQ‐(1‐13)‐NH2, 
UFP‐112 
UFP‐101, 
SB 612111, 
J‐113397, 
JTC‐801 
 1Recommended and alternative nomenclature for opioid receptors as defined by IUPHAR/BPS guide to pharmacology (http://www.guidetopharmacology.org). 
 2For full information on receptor location in the CNS, see the IUPHAR/BPS database on http://www.guidetopharmacology.org 
 3,4 As published by Alexander and colleagues (56) and from IUPHAR/BPS receptor database (http://www.guidetopharmacology.org). 
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To investigate the role of specific opioid receptors or ligands in pain modulation, 
antinociceptive tolerance and adverse behavioural effects, knock-out animals are frequently 
used. It is not surprising that opioid ligands show different effects in particular opioid receptor 
knock-out mice. For example, in MOP receptor knock-out mice, MOP receptor agonist-
induced antinociception and their associated side-effects (e.g. hyperlocomotion, respiratory 
depression, inhibition of GI transit, reward and withdrawal effect) were effectively abolished 
(19,57,58). At the same time, morphine efficiently induced analgesia in DOP (59) and KOP 
(60) receptor knock-out mice, albeit with reduced side-effects (tolerance and withdrawal 
response). Similarly, KOP receptor agonists are also reported to induce analgesia in MOP (61) 
and DOP (59) receptor knock-out mice, while predictably in KOP receptor knock-out animals 
this effect was not observed (60). Similarly, DOP receptor agonists show only reduced levels 
of analgesia in DOP receptor knock-out mice (59), although a mixed effect 
(decreased/maintained) on analgesia was observed in MOP receptor knock-out mice (61,62).  
1.1.2. Opioid ligands 
A ligand is a compound that can form complex with a protein to initiate a biological effect. 
Opioid ligands (OL) are from both endogenous and exogenous origins. Once an agonistic 
ligand binds a receptor, it activates a G-protein (a trimeric protein has three different subunits 
(α, β and γ)) and dissociates the α unit to activate different downstream transduction pathways 
such as adenylyl cyclase (63). This activation modulates voltage-gated calcium, sodium and 
potassium channels (64,65) and cellular levels of cyclic adenosine monophosphate (cAMP) or 
protein kinase A (PKA) (66). Moreover, these receptors can signal through different pathways, 
such as β-arrestin (67,68), which can vary according to the chemical properties of the ligand 
(69). Opioid peptides activate receptors on sensory nerve fibres and produce acute analgesia 
by reducing the excitability of sensory neurons. MOP receptor activation by both endogenous 
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and exogenous opioids in post-synaptic neurons dissociates the Gα subunit from the Gβγ 
subunits of the G protein which increases potassium conductance in neurons. The resulting 
efflux of potassium ions (K+) hyperpolarise the neuronal cells and reduces their excitability 
(70,71,72). However, chronic opioid treatment can induce hyperalgesia. This adverse effect is 
associated with Gα-induced hyper-excitability of tetrodotoxin-resistant sodium channels (TTX-
R Na+) and transient receptor potential vanilloid 1 (TRPV1) channels of the dorsal root ganglia 
neurons (73,74). Therefore, activation of opioid receptors by endogenous and pharmacological 
molecules can differentially alter neuronal excitability by modifying different ion channels 
after acute and chronic treatment.       
The signalling processes initiated by the activation of opioid receptors also include gene 
transcription events that control cell differentiation, proliferation and survival (70,75). When 
an opioid ligand binds with an opioid receptor, a Gα subunit is dissociated and activates 
adenylyl cyclase to synthesise cyclic adenosine monophosphate (cAMP). cAMP binds with 
regulatory proteins of protein kinase A (PKA) and activates PKA. The activated PKA 
translocate to the nucleus where it induces the phosphorylation of cAMP response element 
binding protein (CREB). The phosphorylated CREB facilitates desired gene expression levels 
as the promoters contains cAMP response elements (CRE) and control different cellular 
functions (76). Increased activity of CREB was observed in cancer cells and blocking CREB 
can block cell proliferation, differentiation and survival (77,78). However, another study shows 
CREB has dual role in cell proliferation (simulate or inhibit) and its role depends on the way 
of its activation (79). For example, cAMP activated CREB stimulates mitosis (cell 
proliferation) but growth factor activated CREB inhibits mitosis (79). Prolonged administration 
of morphine reduces both MOP and NOP receptor gene expressions, while prolonged exposure 
of fentanyl induces upregulation of MOP receptor gene expression without affecting NOP 
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receptor gene expressions (80). A KOP receptor agonist dynorphin B also showed to increase 
opioid peptide gene transcription (81). Therefore, opioid receptor activation by a ligand can 
lead to gene transcription events in neuronal cells.  
Several chemically distinct compounds (ligands) can activate opioid receptors and these 
ligand-receptor interactions result in cellular adaptation and altered physiological outcome. 
This phenomenon is termed as biased agonism (82,83,84,85). Biased agonism of MOP receptor 
is studied to avoid antinociceptive tolerance and other adverse effects with particular focus on 
the development of ligands with no β-arrestin-2 (β-arr2) recruitment (86,87,88). Increased 
antinociceptive response and reduced adverse effects were observed in ligands with decreased 
β-arr2 recruitment or in β-arr2 knockout mice (88,89,90,91,92,93). Biased agonists for the 
KOP receptor with reduced β-arr2 recruitment also showed antinociception with less adverse 
effects compared to selective KOP receptor agonists (44). The development of biased ligands 
are at a preclinical stage and it is expected that in the clinic these drugs will be safer than 
conventional opioids (83).  
1.1.2.1. Endogenous opioid ligands 
Evidence for endogenous ligands of opioid receptors was obtained in the 1970s and the 
structures of [Leu]enkephalin and [Met]enkephalin were reported in 1975 (94). Endogenous 
opioid peptides are found in the central and peripheral nervous system and the gastrointestinal 
tract (95). These peptides are derived from the four different precursors pro-enkephalin, pro-
dynorphin, pro-opiomelanocortin, and prepro-nociceptin (11,96,97,98). Pro-enkephalin 
contains two hundred sixty seven amino acid polypeptides (99) and mainly produce the 
pentapeptides [met]- and [leu]-enkephalins (100,101) with a selectivity for MOP and DOP 
receptors. Dynorphins are mainly big dynorphin, dynorphin A, dynorphin B and α-Neo-
endorphin and interact mainly with the KOP receptor (102,103).  Endorphins are derived from 
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pro-opiomelanocortin (104) and are expressed as α, β and γ- endorphins (105). While 
endorphins activate the MOP receptor, the prepro-nociceptin derived neuropeptide 
nociceptin/orphanin FQ binds to the NOP receptor (5). Endogenous opioids affect a multitude 
of physiological functions such as pain modulation and analgesia, stress and emotional 
responses, tolerance and dependence, learning and memory, addiction, sexual activity and 
control of hormone levels, neurological disorders, eating and drinking behaviour, 
gastrointestinal, renal and hepatic functions, cardiovascular responses, respiration, 
thermoregulation and immunological responses (106,107).  
1.1.2.2. Exogenous opioid ligands 
Over a period of approximately 8000 years, the poppy plant (Papaver somniferum) and the 
opioids derived from it have been used for pain relief. In a Sumerian ideogram, the poppy plant 
was known as a “plant of joy”(107). Crude opium admixtures were widely used in different 
British and German medicines from the 16th century and effects like pain tolerance and physical 
dependence to opioids were noted at this time. In 1805, Friedrich Sertürner isolated morphium 
(morphine), named after the Greek god Morpheus (god of sleep and dreams). Within two 
decades after the initial isolation of morphine, commercial production of morphine started and 
became available on the European market. Subsequently, after the invention of hypodermic 
syringes in the middle of the 19th century, morphine was injected locally into painful areas 
(107).  
Currently, different alkaloid extracts from the poppy plant (Papaver somniferum), such as 
opium, morphine and codeine are still used for pain relief, mood disorders and palliative care. 
In addition, several semi-synthetic and synthetic opioids, such as buprenorphine, 
dextropropoxyphene, hydromorphone, oxycodone, pethidine, fentanyl, methadone, tapentadol 
and tramadol are widely used in patients that suffer from surgical or chronic pain (108).  
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1.1.3. Clinical use of opioids 
Opioid drugs are typically receptor-specific and display different advantages as well as adverse 
effects in clinical use. Opioids are very effective against moderate to severe intensive acute, 
surgical and chronic pain. Most of the clinically used opioids are MOP receptor agonists and 
are associated with a significant number of side-effects such as tolerance, dependence, 
desensitisation or withdrawal symptoms (109).  The use of clinical opioids in a particular 
patient depends on the severity of pain and the adverse effects profile of that particular drug. 
Currently, morphine sulphate, morphine hydrochloride, oxymorphone hydrochloride, 
hydromorphone hydrochloride, hydrocodone bitartrate, fentanyl, tapentadol hydrochloride, 
methadone hydrochloride, buprenorphine, naltrexone hydrochloride, naloxone hydrochloride 
and some other opioids are available for human use, either alone or in combination as an 
immediate release or controlled release formulations (108,110).  
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1.1.4. Opioid-induced adverse-effects 
1.1.4.1. Analgesic tolerance 
The development of analgesic tolerance of opioids after repetitive administration is one of the 
major limitations for their chronic use in the clinic. Morphine is one of the most effective and 
widely prescribed drugs against chronic pain (22). However, long-term morphine treatment is 
discouraged in the clinic due to the risk of adverse side-effects including analgesic tolerance 
(111,112). Tolerance manifests as decreased drug efficacy following repeated administration 
(113). Therefore to maintain efficacy dose-increments are required, which in turn contribute to 
generate additional adverse effects. In the clinic, patients frequently receive inadequate doses 
of opioids, due to an insufficient understanding regarding opioid formulation, dose titration 
and analgesic tolerance (114).  In addition, increased morphine dosing is frequently required 
due to increased disease progression, rather than analgesic tolerance (115).  
The clinical management of analgesic tolerance involves opioid rotation and the combination 
of opioids with adjuvants (116,117,118,119). Adjuvants, like gabapentin, pregabalin, 
dexamethasone, naproxen, ibuprofen, carbamazepine, aspirin, venlafaxine and acetaminophen 
are combined with opioid analgesics in patients that require long-term analgesic treatment 
(120,121). Similarly, in preclinical studies, a combination of opioids and non-opioid adjuvants 
or combinations of opioid agonist and antagonist are used to prevent antinociceptive tolerance 
(122,123,124,125). In response to an opioid ligand binding to an opioid receptor, inhibition of 
adenylyl cyclase (AC) reduces the levels of the second messenger cAMP (86,130,131). In 
addition, activation of opioid receptors leads to their phosphorylation by GPCR kinases, which 
promotes the interaction with β-arrestins (βarr) (130,131). Both phosphorylation and 
interaction with βarr are required for subsequent receptor internalisation (130,131). This 
internalised receptor can be proteolytically degraded. However, some receptors can also be 
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recycled in endosomes to be returned to the cell membrane (131,132). This process in called 
receptor trafficking. In addition, de novo receptor synthesis ensures that new opioid receptors 
are produced and transported to the cell membrane via the trans-Golgi network (131). 
Prolonged treatment with opioids either increase the numbers of inactive (phosphorylated) 
receptors in the membrane or increases the number of de novo produced receptors (131,132). 
Specifically, chronic exposure to morphine leads to the selective recruitment of β-arrestin-2 
(βarr2) but not β-arrestin-1 (βarr1) (68). In contrast to the interaction with βarr1, which leads 
to receptor recycling, βarr2 does not lead to opioid receptor recycling but increases the number 
of inactive receptors in the cell membrane. This process is associated with insufficient 
analgesia (68). Although the molecular mechanisms that leads to opioid tolerance are not 
entirely clear, both desensitisation and trafficking are suspected to be the key factors that lead 
to insufficient analgesia (68,86,131,133). Although it is important to delineate the exact 
molecular mechanisms leading to opioid tolerance (68,126,127,128,129), it is also important 
to understand how chronic morphine dosing itself can influence tolerance (chapter 2).  
Pain-relief or analgesia is measured in preclinical studies as nociceptive and neuropathic pain. 
The antinociceptive effects of morphine and other opioids in preclinical studies are commonly 
measured as central (brain and spinal cord) or peripheral antinociception (134,135). The 
commonly used tail-flick test potentially measures the spinal-mediated nociception while the 
hot-plate assay largely measures a supra-spinal-mediated nociception (135,136). Generally, 
one antinociception test is performed in preclinical studies with repeated morphine treatment 
(Table 2). As a result, the progression of antinociceptive tolerance measured by a single assay 
may be different when using another assay (137). Therefore, more than one antinociception 
assay is required to represent the true extent of antinociceptive tolerance.  
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Table 2. Preclinical Analgesic tolerance studies of morphine. Keys: M.HCl: morphine hydrochloride, MS: morphine sulphate, M: morphine base, TF: 
tail  flick test, WWTW: warm water tail withdrawal test, HP: hot plate test, PLH: planter heat (by radiation) test, VFF (von Frey test, mechanical 
allodynia). i.t.: intrathecal, i.c.v.: intracerebroventricular, i.v.: intravenous, s.c.: subcutaneous, os.pump: osmotic pump, wks: weeks, D: day.   
Sl   Assay 
(⁰C) 
Morphine 
used 
(route) 
Treatment 
procedure 
Adjusted 
morphine dose* 
(mg/kg or as 
stated) 
Tolerance 
from day 
(time)   
Tolerance: 
as changes 
in 
Animal 
species 
(male, or as 
stated)  
Cut‐
off 
Lat. 
[s] 
Basal 
Lat. 
[s] 
Ref. 
1  WWTW (52⁰C)  MS (s.c.)  Once daily for 14 days  7.52  7  Latency 
Wister rats 
(220‐260 g)  12  3‐5  (138) 
2  HP (58⁰C)  MS (s.c.) 
M. pellets for 7 
days (induction); 
tested with MS 
(s.c.) every day 
75 mg (for 
induction);  
11.28 (test) 
3 (60 min)  Latency 
Holtzman 
rats  
(150‐200 g) 
30  ‐  (139) 
3  HP (55 ⁰C)  MS (s.c.) 
Twice daily for 5 
days (tested days: 
1, 6) 
7.52  
6 (15,30 
and 60  
min) 
MPE%  Swiss mice (25‐30 g)  15  ‐  (140) 
4  HP (55 ⁰C)  MS (s.c.) 
Twice daily for 5 
days (tested days: 
1, 6) 
7.52   6 (30  min)  MPE%  Swiss mice (25‐30 g)  45  ‐  (141) 
5  HP (54 ⁰C)  MS (s.c.) 
Once daily for 8 
days (tested days: 
1,4,8) 
7.52   8 (30 min)  MPE%  SD rats  (200‐250 g)  45  ‐  (142) 
6  HP (55 ⁰C)  MS (s.c.)  Once daily for 8 days (tested daily)  7.52   8 (30 min)  MPE% 
C57Bl/6 
mice  
(8‐10 wks) 
30   ‐  (143) 
7  HP (54 ⁰C)  MS (s.c.) 
Once daily for 7 
days (tested days: 
1, 4, 7) 
7.52  7 (60 min)  MPE%  SD rats  (275‐300 g)  45  ‐  (144) 
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Sl   Assay 
(⁰C) 
Morphine 
used 
(route) 
Treatment 
procedure 
Adjusted 
morphine dose* 
(mg/kg or as 
stated) 
Tolerance 
from day 
(time)   
Tolerance: 
as changes 
in 
Animal 
species 
(male, or as 
stated)  
Cut‐
off 
Lat. 
[s] 
Basal 
Lat. 
[s] 
Ref. 
8  TF  MS (s.c.)  Twice daily for 7 days  7.52  5 (30 min)  MPE% 
C57BL/6 
Mice   12  2‐4.5  (145) 
9  WWTW (52 ⁰C)   MS (s.c.) 
Twice daily for 5 
days (tested days: 
1, 6) 
7.52  6 (30 min)  MPE%  ICR mice (21‐25)  12  ‐  (146) 
10  TF  MS (s.c. os.pump) 
Continuous 
delivery for 4 
weeks (induction); 
tested once per 
week 
7.52 or 15.04 
/day (induction); 
7.52 (test) 
7   ED50  SD rats  (250‐275 g)  6  2‐2.5 
 
(147) 
 
 
11  TF  MS (s.c.) 
Once daily for 7 
days 
(or, morphine 
base pellets for 7 
days) 
13.91 ‐ 139.12 
(or, 25 mg, 50 mg 
and 75 mg) 
7 
(or, 2 for 
pellets) 
ED50  SW mice (26‐40 g)  10  1‐3 
 
(148) 
 
 
12  TF  MS (s.c.) 
Twice daily for 6 
weeks (tested 
once a week) 
3.76, 7.52, 15.04, 
or 30.08 (4 
groups) 
7 (all 
groups)  ED50  CD1 mice  10  ‐  (149) 
13  TF, HP (53 ⁰C)  MS (s.c.)  Twice daily for 5 days  11.28  5 
MPE%, 
ED50 
SW mice 
(21‐30 g) 
10 
(TF); 
30 
(HP) 
2‐4 
(TF); 8‐
10 (HP) 
(150) 
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Sl   Assay 
(⁰C) 
Morphine 
used 
(route) 
Treatment 
procedure 
Adjusted 
morphine dose* 
(mg/kg or as 
stated) 
Tolerance 
from day 
(time)   
Tolerance: 
as changes 
in 
Animal 
species 
(male, or as 
stated)  
Cut‐
off 
Lat. 
[s] 
Basal 
Lat. 
[s] 
Ref. 
14  WWTW (55 ⁰C)   MS (s.c.) 
Twice daily for 3 
days (induction), 
(tested days 1 and 
4) 
ED90 dose 
(unknown) of MS 
(induction), ED50 
dose (test) 
4  ED50  ICR mice (25‐35 g)  10  <5  (151) 
15  TF  MS (s.c.) 
Once daily for 9 
days (tested days: 
1,2,4 and 9) 
7.52  9  MPE%  ICR mice (25‐30 g)  15 
4.32± 
0.12   (152) 
16  TF  MS (s.c.) 
Three times daily 
for 20 days; tested 
days: 1 and 21 
Started with 7.52 
and increased 
continuously  
3.76‐7.52 (in 
every 2 days) and 
last 2 days 
(112.8) 
21  ED50 
SW mice 
(20‐23 g) 
(both sexes) 
‐  1.1± 0.2 
 
(153) 
 
 
 
17  TF  MS (i.p.) 
Three times daily 
for 3 days 
(induction); tested 
day: 4 
37.6, 37.6 or 56.4 
(induction); 5.26 
(test) 
4  Latency  Mice  (25‐30 g)  10  ‐  (154) 
18  WWTW (55 ⁰C)  MS (i.p.) 
Twice or thrice 
daily for 3 days; 
tested day: 1, 4 
4.51  (induction); 
1.73 (test)  4  ED50  
ICR mice 
(20‐30 g)  15  < 5 
(155) 
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Sl   Assay 
(⁰C) 
Morphine 
used 
(route) 
Treatment 
procedure 
Adjusted 
morphine dose* 
(mg/kg or as 
stated) 
Tolerance 
from day 
(time)   
Tolerance: 
as changes 
in 
Animal 
species 
(male, or as 
stated)  
Cut‐
off 
Lat. 
[s] 
Basal 
Lat. 
[s] 
Ref. 
19  WWTW (52 ⁰C)  MS (i.t.)  
Continuous 
delivery for 5 days 
by osmotic pump 
(induction), tested 
days: 1,5  
11.28 µg/h 
(induction);  
11.28 µg (test) 
5  MPE%, latency 
Wister rats 
(350‐400g)  10   2.0± 0.3  (156) 
20  HP (52.5 ⁰C)  MS (vIPAG) 
Twice daily on 
ventrolateral 
periaqueductal 
gray (vlPAG) for 3 
days. Tested 
days:1,4 
3.76 µg  4 (15 min)   ED50  SD rats (200‐340 g)  50  ‐  (157) 
21  TF  MS (i.t.) 
Twice daily for 6 
days; tested days: 
1,3,5 and 7 
7.52 µg  5 (30 min)  MPE%, ED50 
SD rats  
(300‐350 g)  10  4‐5  (158) 
22  TF  MS (i.t.)  Once daily for 8 days  7.52 µg  8  MPE% 
SD rats  
(350‐400 g)  10  3.5‐4.5  (159) 
23  WWTW (55 ⁰C)  MS (i.c.v.)  
Twice daily for 3 
days, tested days: 
1,4  
ED90 (not 
mentioned) 
(induction); 0.43 
µg (test) 
4  ED50, MPE%  ICR mice  10    (160) 
24  PLH  MS (i.t.) 
Twice daily for 4 
days, tested days: 
1, 5 
15.04 µg  5  MPE%, latency 
SD rats  
(250‐300 g)  20  ‐  (161) 
25  PLH (30 ⁰C)   MS (i.t.)  Once daily for 7 days  11.28 µg  7  MPE% 
SD rats  
(200‐250 g)  20  ‐  (162) 
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Sl   Assay 
(⁰C) 
Morphine 
used 
(route) 
Treatment 
procedure 
Adjusted 
morphine dose* 
(mg/kg or as 
stated) 
Tolerance 
from day 
(time)   
Tolerance: 
as changes 
in 
Animal 
species 
(male, or as 
stated)  
Cut‐
off 
Lat. 
[s] 
Basal 
Lat. 
[s] 
Ref. 
26  VFF  MS (i.t.) 
Once daily for 7 
days, tested every 
day 
15 µg  5 (30 min)  PWT  SD rats  (200‐250 g)  ‐  ‐  (163) 
27  TF   M.HCl (s.c.) 
Twice daily for 5 
days  53.20   6   MPE% 
Mice  
(6‐8 wks)  6   2.7‐3.3   (164) 
28  TF  M.HCl (s.c.) 
Once daily for 5 
days  8.87   3   AUC 
ddY mice 
(18‐20g)  10   _  (165) 
29  TF  M.HCl (s.c.) 
Twice daily for 5 
days; tested days: 
1, 3 and 5 
8.87   3   MPE% 
CFLP white 
mice  
(30±5 g) 
20     (166) 
30  TF, HP (52⁰ C)  M.HCl (s.c.) 
Twice daily for 4 
days  
8.87 (D1), 13.3 
(D2), 17.74 (D3), 
26.61    (D4) 
(induction); 4.44 
(test) 
5  
(60 min)   MPE% 
SD rats  
(300 g) 
10 
(TF); 
60 
(HP) 
2.1±0.5 
(TF);  
9.7±3.8 
(HP) 
 
(167) 
 
31  TF  M.HCl (s.c. implant) 
Continuous 
delivery for 5 days  5.32  5 
Latency, 
MPE% 
SD rats  
(300‐350 g) 
10   
 
6 
‐  (168) 
32  TF  M.HCl (s.c. implant) 
Once daily for 5 
days  8.87  5  AUC 
ddY mice  
(4‐5 wks)  10   2‐3   (169) 
33  TF  M.HCl (s.c.) 
Twice daily for 7 
days  8.87  5  MPE% 
Wister rats 
(200‐250 g)  10   2‐4   (170) 
34  TF  M.HCl (s.c.) 
Twice daily for 5 
days (test days: 1, 
3, 5) 
7.09  3  MPE%  ddY mice (25‐33 g) 
10 
(TF),  ‐  (171) 
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Sl   Assay 
(⁰C) 
Morphine 
used 
(route) 
Treatment 
procedure 
Adjusted 
morphine dose* 
(mg/kg or as 
stated) 
Tolerance 
from day 
(time)   
Tolerance: 
as changes 
in 
Animal 
species 
(male, or as 
stated)  
Cut‐
off 
Lat. 
[s] 
Basal 
Lat. 
[s] 
Ref. 
30 
(HP) 
35  HP (52⁰C)  M.HCl (s.c.) 
Once daily for 10 
days  2.22  10  MPE% 
Swiss mice 
(25‐30 g)  240  ‐  (172) 
36  TF  M.HCl (i.p., i.t.) 
Once daily (i.p.) for 
3 days; 
Osmotic pump 
(i.t.) 
8.87 (i.p.); 13.30 
µg/h (i.t.) 
3 (i.p.); 
5 (i.t.) 
AUC, 
MPE% 
SD rats  
(250‐275 g)  15  ‐  (173) 
37  WWTW (52⁰C)  M.HCl (i.p.) 
Twice daily for 9 
days 
13.3 (day: 1, 9); 
13.3 or  26.6 
(day: 2‐8) 
 
No 
tolerance; 
9th day (45 
min) 
Latency  C57 mice (wild type)  10  ‐  (174) 
38  WWTW (50 ⁰C)  M.HCl (i.t.)  Once daily for 7 days  13.3 µg  7  MPE% 
SD rats  
(250‐280 g)  15  ‐  (175) 
39  TF   M.HCl (i.t.)  Once daily for 7 days  17.73 µg  7  MPE% 
SD rats  
(250‐320 g)  10  2‐3  (176) 
40  HP (55⁰C)  M.HCl (i.t.) 
Twice daily for 7 
days (test days 
1,8) 
8.87 µg  8  Latency  SD rats  (150‐200 g)  30  3.8  (177) 
41  TF  M.HCl (i.t.; i.c.v.) 
Once daily for 8 
days (tested daily) 
3.55 nmol (i.t.); 
1.77 nmol (i.c.v.) 
 
4 (30 min 
i.t.; 15 min 
i.c.v.) 
MPE% 
Kunming 
mice  
(18‐22 g) 
10  3‐5  (178) 
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Sl   Assay 
(⁰C) 
Morphine 
used 
(route) 
Treatment 
procedure 
Adjusted 
morphine dose* 
(mg/kg or as 
stated) 
Tolerance 
from day 
(time)   
Tolerance: 
as changes 
in 
Animal 
species 
(male, or as 
stated)  
Cut‐
off 
Lat. 
[s] 
Basal 
Lat. 
[s] 
Ref. 
42  TF  M pellets (s.c.) 
Continuous 
delivery until 6th 
day; tested days: 
0.5, 1, 2, 3 and 6. 
75 mg 
1  
(24 h or 
after) 
ED50 
SW mice 
(20‐23 g) 
(both sexes) 
‐  1.1± 0.2 
 
(153) 
 
 
 
43  TF  M pellets (s.c.) 
Continuous 
delivery for 7 days; 
tested days 1 and 
7 with MS s.c.  
25 or 75 mg 
(induction); 0.5, 
1.0, 2.0, 3.0 (test) 
7  ED50  SW mice (22‐44 g)  10  2‐4 
 
(179) 
44  WWTW (48 ⁰C)  M (s.c.)  Once daily for 7 days  5  7  Latency 
C57BL6 
mice (25‐30 
g) 
25  ‐  (180) 
45  PLH   M** (s.c.) 
Twice daily for 10 
days; tested days: 
1,6 and 11 
10  7 (30 min)  MPE%  SD rats  (200‐250 g)  20  ‐  (181) 
46  TF  M** (s.c.) 
Twice daily for 6 
days, tested on 
days: 1, 7. 
10  7 (30 min)  MPE%  SD rats  (200‐250 g)  15  6‐8  (182) 
47  TF, PLH,VFF  M** (i.t.)  Twice daily for 6 days 
10 µg 
(induction); 0.25 
µg (test) 
7 (30 min)  MPE%  SD rats  (200‐250 g)   ‐  ‐  (183) 
48  WWTW (55 ⁰C)  M** (i.p.)  Once daily for 5 days  4  5  MPE% 
C57Bl6 mice 
(25‐28 g)  10  ‐  (184) 
49  VFF  M** (s.c.)  Twice daily for 9 days  10  5 (30 min)  PWT 
Kunming 
mice  
(26‐30 g) 
‐  ‐  (185) 
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Sl   Assay 
(⁰C) 
Morphine 
used 
(route) 
Treatment 
procedure 
Adjusted 
morphine dose* 
(mg/kg or as 
stated) 
Tolerance 
from day 
(time)   
Tolerance: 
as changes 
in 
Animal 
species 
(male, or as 
stated)  
Cut‐
off 
Lat. 
[s] 
Basal 
Lat. 
[s] 
Ref. 
50  WWTW (52 ⁰C), VFF  M** (i.p.) 
Twice daily for 4 
days  10 or 20  4  MPE % 
SD SNL rats 
(250‐300 g)  10 
3.95± 
0.04  (186) 
51  VFF  M** (s.c.) 
Twice daily for 9 
days; tested days: 
0 and 9 
10 (induction), 5 
(test)  9  PWT 
SD rats 
(220±10 g)  ‐  ‐  (187) 
52  HP (52.5⁰C)  M** (vIPAG) 
Twice daily for 2 
days  5 µg   2 (15 min)   
SD rats  
(250‐350 g)  50  <20  (188) 
53  WWTW(52.5⁰C)  M** (i.t.) 
Twice daily for 7 
days and tested 
everyday 
15 µg  4 (30 min)  MPE%  SD rats  (220‐250 g)  10  ‐  (189) 
Notes: *Morphine dose was adjusted as morphine base.  Conversion factor based on their molecular formula: Morphine in M. (base) (100%), in M.HCl (88.67%) and in MS. 
(75.20%). **There is no clear information on types of morphine (base, sulphate or hydrochloride). Only morphine is mentioned in these articles.  
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1.1.4.2. Behavioural effects 
In addition to antinociceptive tolerance as an adverse effect of long-term opioid treatment, the 
discussion also needs to include behavioural side-effects which are observed in the clinic (190). 
Morphine-induced biphasic behavioural effects are well known from preclinical studies and 
include initial motor suppression and subsequent hyper-excitation 
(191,192,193,194,195,196,197). An open-field arena is widely used to assess motor behaviour 
and typically includes horizontal movement, rearing (vertical movement) and turning 
behaviour. Morphine-induced horizontal locomotion, turning and circling behaviours are 
related to the dopaminergic system (194,198,199,200). Morphine treatment induces the 
dopamine receptor-1 (D1) dependent beta-arrestin-2 (βarr2) / phospho-ERK (βarr2/pERK) 
signalling complex, which regulates morphine-induced locomotion (201). Acute morphine 
administration induces phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 
32 kDa (DARPP-32), which activates the D1 receptor in neurons of nucleus accumbens and 
dorsal striatum and alters locomotor activity (201,202,203,204). In contrast, the effects of 
chronic morphine treatment on the cAMP/PKA/DARPP-32 signalling are not fully understood 
at present. However, rearing behaviour can indicate anxiety, exploration or sedation, which are 
related to gama-aminobutyric (GABA) inhibitory neurotransmission (205,206,207). The 
activation of the cAMP-responsive element binding protein (CREB) transcription factor 
regulates anxiety-related behaviours, as CREB-deficient mice showed an increased anxiogenic 
response (208). However, the behavioural changes in response to chronic morphine treatment 
are independent of the MOP receptor, cyclin-dependent kinase 5 (cdk5) or adenylate cyclase 
activities in areas of brain relevant (209). The likely multiple mechanisms that link chronic 
morphine-treatment with its behavioural effects are not completely understood, but are 
probably controlled by a combination of dopaminergic, GABA-ergic, opioidergic and 
additional unknown neuronal signals (86,201,202,203,205,206,207).The combination of 
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multiple independent behavioural measurements is generally regarded as the most reliable 
approach to assess the total motor effects induced by opioids (192,193,210).  
1.1.4.3. Constipation 
Constipation is a very common side-effect of opioids and it is caused by activation of MOP 
receptor in the enteric nervous system (211,212). Opioids bind with MOP receptors in the 
enteric neurons and delay gastrointestinal (GI) transit time, which also stimulates non-
propulsive GI motility, pylorus and ileocecal sphincters. Morphine treatment increases 
expression of aquaporin-3 (AQP3) water channels in the colon by increased secretion of 5-HT 
(serotonin), which increases water absorption from luminal part to the vascular part of the colon 
(213). As a result, constipation develops by increased fluid absorption from the large intestine 
along with less electrolyte secretion by intestinal lumen (212). In contrast, chronic morphine 
treatment does not produce tolerance to reduced gastrointestinal (GI) motility in the lower GI 
tract, while it induces analgesic tolerance and leaves GI motility unaffected in the upper GI 
tract (214). As a result, patients continuously suffer from constipation over a long-term opioid 
treatment. Constipation affects about 40% of patients with chronic oral opioid treatment and 
therefore different laxatives and non-medication approaches (e.g. fibrous diet, hydration) are 
used to provide comfort of the patients (215,216,217,218). In addition, opioids combined with 
a low dose of opioid antagonists like naloxone or methylnaltrexone are effective to reduce 
constipation without affecting pain-relief and inducing less withdrawal symptoms 
(218,219,220,221). 
1.1.4.4. Nausea and vomiting 
Nearly 20% of patients with long-term opioid treatment experience nausea and vomiting (222). 
The actual mechanism for opioid-induced nausea and vomiting is not clear, but the activation 
of opioid receptors (MOP or DOP) present in the chemoreceptor trigger zone, vestibular 
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apparatus (MOP) and GI tract (MOP, DOP or KOP) are probably involved in the induction of 
nausea and vomiting (130). At present, it is thought that these adverse effects are a direct 
consequence of opioid-induced effects in the area postrema of the brainstem, an area rich in 
dopamine, opioid and serotonin receptors (223,224).  In the clinic, 5-HT3 and NK1 receptor 
antagonists are used to prevent opioid-induced emesis, which could indicate that several non-
opioid receptors (e.g. dopamine (D2), 5-HT3 and histamine (H1)) might interact with opioid 
receptors in those brain areas that control nausea and vomiting (130,225,226,227). Although 
patients treated with oral morphine experience chronic nausea and vomiting, opioid rotation or 
changing the route of administration (e.g. oral to subcutaneous) appear helpful to reduce these 
adverse effects (216,228,229).  
1.1.4.5. Respiratory depression 
Respiratory depression occurs less frequently compared to other adverse effects, but it typically 
can have fatal consequences in the clinic (217,230). Similar to the other side effects, opioid-
induced respiratory depression is mediated by the MOP receptor (231,232,233). Neurons of 
the pre-Bötzinger complex, a sub-region of the ventrolateral medulla, are responsible to control 
autonomic neuronal functions including normal respiration (233). The neurons of pre-
Bötzinger complex express a variety of receptors including neurokinin-1, serotonin (5-HT) and 
MOP receptors (233). MOP receptor activation inhibits AC and reduces synthesis of 
intracellular cAMP, which is thought to depress the respiratory neurons as reduced cAMP 
levels in cytoplasm reduces neuronal excitability by an unknown mechanism (130). On the 
other hand, serotonin receptors in this region stimulate respiration (234,235). 5-HT1(a) receptors 
are expressed widely in respiratory neurons and are activated by reduced cAMP levels 
activating the glycine receptor type α3 (GlyRα3) (236). The activated GlyRα3 receptor inhibits 
the inhibitory neurons that cause respiratory depression. This effect is independent of the MOP 
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receptor induced signal transduction pathway (236). Therefore, multiple non-opioid receptors 
together with the MOP receptor are involved in the control of respiration and opioid-induced 
respiratory depression.  Although high dose opioid users are at risk of respiratory depression 
(237), selective opioid receptor antagonist can effectively reduce the incidence of respiratory 
depression without significant withdrawal symptoms (238).  
1.1.4.6. Addiction and physical dependence 
Physical dependence is the craving for a drug either for pleasure or to avoid the occurrence of 
withdrawal symptoms following a reduction of treatment dose or intake of an opioid receptor 
antagonist (217,239). Addiction indicates a loss of control of opioids use, despite adequate 
pain-relief (239). Opioid addiction is mediated by MOP receptors in the ventral tegmental area 
and the nucleus accumbens of the brain (240,241). Physical opioid dependence associated with 
upregulation of cAMP and noradrenergic signalling in the locus coeruleus neurons of dorsal 
pontine tegmentum of the brainstem (240,241,242). In contrast to acute exposure of morphine 
that reduces cAMP levels, chronic morphine administration increases AC levels type I and VII, 
PKA subunits, several phosphoproteins (e.g. CREB) and results in activation of the cAMP 
pathway (241). The actual molecular mechanism that initiates the beginning of physical 
dependence is unknown, but is associated with repeated opioid treatment over longer time 
intervals (240). Clinical guidelines for long-term opioid use propose a “start low and go slow” 
dosing regimen to prevent addiction, physical dependence, overdosing or abuse 
(111,243,244,245,246,247). Therefore, clinical guidelines propose the smallest effective dose 
(248), rather than aiming for adequate long-term pain relief (249). 
1.1.4.7. Other adverse effects  
Drowsiness, lethargy, hyperalgesia and pruritus are also common adverse effects of morphine 
(250,251,252).  Drowsiness and lethargy are caused by a suppression of motor behaviour, 
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however the exact mechanisms for this effect are not known. Morphine is also responsible to 
generate an itching skin sensation by signalling through spinal heteromers of opioid- and itch-
mediating GPCRs (253,254). Withdrawal after chronic morphine exposure also induces 
histamine-induced itching or scratching responses (255). Finally, morphine can induce 
increased pain sensation (hyperalgesia) via the MOP receptor (256). However, the molecular 
mechanism of morphine-induced hyperalgesia are not well-understood but might be related to 
the upregulation of protein kinase C gamma (PKCγ) and the NMDA receptor subtype NR1 in 
the spinal cord (257,258). It is also thought that different MOP receptor isoforms, functional 
interactions with other GPCRs or opioid metabolites such as morphine 3-glucuronide that 
interact with GABA or NMDA receptors  could be responsible for this adverse effect 
(180,252,256).   
1.2. Opioids with selectivity on multiple receptors 
1.2.1. Receptor dimers and heteromers 
Concomitant treatment of an opioid with an opioid receptor antagonist can reduce adverse 
effects, which indicates the interactions of multiple opioid receptors in the same cell 
(218,219,220,221,238). There is significant evidence that opioid receptors and other G-protein 
coupled receptors can form dimers or oligomers by interacting with similar or different types 
of receptors (56,86,259,260,261,262,263). Opioid receptors can exist as homodimers 
(263,264,265) or heteromers (263,266,267,268). Although dimers between the MOP and DOP 
receptors (266,267,269), DOP and KOP receptors (263) and MOP and NOP receptors were 
reported many years ago (270), dimers consisting of MOP and KOP receptors were initially a 
matter of dispute (86,263,265,271) before MOP-KOP receptor dimers were confirmed (272). 
Opioid receptor dimers were identified by crystal structures of opioid receptors in vitro, but the 
presence of these receptor-dimers in live cells have not been demonstrated yet 
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(14,15,16,17,18). It is therefore likely that the opioid receptor system also contains additional, 
so far unknown types of heterodimers, homodimers and/or oligomers. 
1.2.2. Targeting of multiple opioid receptors to avoid opioid-induced adverse effects 
Given the evidence for receptor heterodimers, it is likely that activation of one opioid receptor 
might affect the behaviour of another opioid receptor in the same complex. Different types of 
interactions are present between two or multiple receptors (61,262,273,274), which depend on 
the pharmacological profile of the ligands that interact with these receptors (275,276). The 
current literature suggests that most opioid receptor ligands are not extremely selective and 
could therefore bind to one/more off-target receptors to produce effects and adverse effects. 
For example, morphine at high doses can induce analgesia in MOP receptor knock-out mice 
by activating the KOP receptor (277). Similarly, in DOP receptor knockout mice a DOP-
receptor agonist effectively produced analgesia, while a non-specific opioid antagonist 
(naltrexone) could reverse this effect (59). Although these data could be interpreted as non-
specific interactions of the different DOP receptor agonists and antagonists, the authors 
interpreted it as evidence for the presence of a different DOP receptor subtype (59). However, 
recent studies suggest that opioid receptor subtypes may not actually exist, but these results 
rather reflect the presence of homo- or heteromeric receptor dimers (56). In light of a reduced 
DOP receptor activity in MOP receptor knock-out mice (61), it was hypothesised that the 
specific interaction between MOP and DOP receptors in specific neural pathways could 
modulate pain perception. In line with this hypothesis, co-administration of morphine and a 
DOP receptor antagonist induce analgesia, while surprisingly reducing tolerance in rodent 
models (122,123,124,125,278,279), which suggests that MOP and DOP receptor interactions 
regulate antinociceptive tolerance. It has to be noted, that under these conditions respiratory 
depression was not prevented, which suggests that additional receptor interactions are likely to 
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be involved (124).  
These studies justify the approach to target two opioid receptors simultaneously, not only to 
explore the molecular mechanisms that contribute to tolerance but also to develop alternative 
drug candidates with reduced risk for the development of tolerance. The challenge ahead is to 
develop multi-target specific ligands that are effective as analgesics with a favourable side-
effect profile. Several strategies for the simultaneous targeting of multiple receptors can be 
envisaged: (i) co-administration of two selective drugs, (ii) administration of one non-receptor-
selective drug, or (iii) use of a single drug that specifically targets different receptors (i.e. 
multiple receptors selective ligand) (280). Especially the third strategy promises clinical 
advantages by reducing drug-drug interactions as well as pharmacokinetics and 
pharmacodynamics that will be easier to control (280,281,282). 
Many new opioid receptor ligands have been designed to simultaneously target two or more 
opioid receptors and many of these are effective to produce an analgesic response in vivo (Table 
3-5). Rational drug design and structure-activity relationship studies have evaluated the 
pharmacology of many of those ligands that act simultaneously on two different opioid 
receptors (282,283) or a combination of an opioid receptor with a non-opioid receptor 
(284,285,286). For example, the potent MOP-receptor agonists MDAN-21 is in fact not a 
selective MOP receptor agonist but rather a mixed MOP-receptor agonist/DOP-receptor 
antagonist that is 50-times more potent than morphine and produces less tolerance (287). This 
effect is likely the consequence of reduced internalisation of MOP-DOP receptor heterodimers 
due to a bridging of both receptors (288).  
Studies showed that chronic administration of morphine increased MOP-DOP receptor 
heteromers in rostral ventral medulla in the brainstem, which is responsible for the processing 
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of nociceptive response (128,289). Different opioid ligands have been focussed to target the 
MOP-DOP receptor dimers with the objective that co-expression of MOP and DOP receptor 
might reduce analgesic tolerance (128,266,290,291). Some of these ligands showed selectivity 
for the MOP-DOP receptor dimer as well as the individual opioid MOP or DOP receptors 
(266), but other ligands do not show selectivity towards the individual receptors (291). MOP-
DOP heteromer-biased ligands can activate both opioid-mediated and β-arrestin-mediated 
signalling. Anti-analgesic effect of DOP-MOP heteromers was also observed (292). The 
adverse effects profile of the heteromer-selective ligands is not clearly known (289), but the 
advancement of research related to opioids with selectivity for heteromers and/or individual 
receptors are increasing with time. 
1.2.3. Barriers of characterising novel opioids 
Currently, many new opioid ligands reported in the literature present with a mixed 
pharmacological profile in that they are activating and/or blocking different opioid receptor(s) 
(Table 3-5). Unfortunately, a detailed characterisation for some of these ligands with regards 
to their complete in vitro pharmacological profile is usually unavailable (Table 5). Mostly, the 
analgesic effects of these ligands and their partial in vitro profiles are reported to provide some 
limited information on their molecular activities. In general, the terms bifunctional, bivalent, 
dual or mixed opioids are widely used to describe these ligands without clear definitions for 
any of these terms (150,284,293,294,295,296). For example, MMP-2200 is a full agonist for 
the MOP and DOP receptor but the authors did not report its efficacy value (ED50) towards the 
KOP receptor (Table 4), which makes it difficult to define the ligand as either a bifunctional, 
non-bifunctional or a biased agonist (151). Similarly, the ED50 value for the KOP receptor is 
not available for the ligands [Dmt1]DALDA, MGM-9, MGM-16 and AN-80 (Table 4) which 
makes the classification of these opioids as bifunctional, non-bifunctional or biased ligand 
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currently impossible (171,297,298,299,300). Therefore, the complete description of the in vitro 
pharmacological profiles of all new ligands should be envisaged as standard procedure to not 
only aide the molecular mechanism-based classification of these molecules but also as a 
prerequisite for the rational development of improved ligands with increased analgesic 
potential and a reduced liability for analgesic tolerance.  
In vivo opioid receptor selectivity tests are routinely used to characterise novel ligands, which 
involve their co-administration with the selective antagonist for particular opioid receptors. 
One of the limitations of this approach is that potentially numerous interactions of a specific 
ligand with other relevant GPCRs in the nervous system are ignored. Given that these GPCRs 
have the potential to interact with opioid receptors, these interactions are likely to modulate 
test results. A better approach to test receptor selectivity in vivo is to use knockout animals for 
a particular opioid receptor, which should provide excellent proof of selectivity for new 
ligands. However, this approach is not without its own limitations, as knock out animals is 
known to display altered gene expression of unrelated genes, which could well affect the test 
results (301,302).It has to be acknowledged that only a combination of different approaches 
will realistically characterise the pharmacology of novel ligands compared to any of the 
individual in vivo or in vitro receptor selectivity assays that are currently widely employed.  
1.2.4. Terminologies to characterise ligands targeting multiple receptors 
Due to the obvious advantages to target multiple opioid receptors, the concept of bi-functional 
and bivalent opioids was developed. Ligands that contain two distinct pharmacophores to target 
two different opioid and/or non-opioid receptors are defined as bivalent. Previously, a 
distinction was made between bi-functional and bivalent ligands (282). It was proposed that 
bifunctional ligands can interact with two targets in a monovalent fashion (Fig. 1e, f). In 
contrast, bivalent ligands should contain two pharmacophores linked by a spacer to interact 
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with two different targets simultaneously such as within a receptor heterodimer (282) (Fig. 1a). 
However, bivalent ligands not necessarily bind selectively to two different specific receptors. 
For example, (-)(-) MCL-144, a MOP/KOP receptor bivalent ligand also shows a significant 
affinity towards the DOP receptor (303). Since ligands with two distinct pharmacophores can 
change their 3D confirmation under different physiological conditions, there is a chance of 
non-specific binding to other receptors or therapeutic targets (Fig. 1g-j). Thus, the term 
“bivalent” only explains the chemical structure of the compound, which does not describe their 
specific pharmacological properties.  Therefore, to differentiate the effects of novel opioid 
analgesics based on their pharmacological activities, the terminology of “bifunctional 
analgesic” and “non-bifunctional analgesic” are used in this chapter. 
Bi-functional opioid analgesics are compounds that (i) must produce antinociception, and (ii) 
must activate at least one and inhibit another opioid receptor; or (iii) activates several opioid 
receptors with a very high selectivity towards two specific receptors (Fig. 1a-f).   
Non-bifunctional opioid analgesics are non-selective compounds that (i) also must produce 
antinociception, but (ii) have no specificity for any particular opioid receptor, with (iii) 
pharmacological data reported for at least three different opioid receptors. 
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Figure 1. Possible in vitro interactions of opioid analgesics targeting multiple opioid receptors. 
The blue and  red  receptors  are opioid  receptors  that  are  specific  to  the bifunctional  ligand. 
Therefore the bifunctional ligands can interact with specific hetero‐dimer (a), homodimer (b, c) 
or  single  opioid  receptor  (e,  f),  but  do  not  interact  with  other  opioid  hetero‐dimers  (d).  In 
contrast, non‐bifunctional ligands can interact with all types of opioid receptors and heteromers 
(g, h, i, j). 
 
Following the terminologies described in section 1.2.4, different OLs reported in the literature 
between the period of January 2008 and November 2017 are categorised in the following 
sections.   
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Table 3. In vitro characteristics of bifunctional opioid analgesic ligands. Keys: The values are presented as Mean ± SD. MOP: mu opioid receptor, 
DOP: delta opioid receptor, KOP: kappa opioid receptor, NOP: NO/FQ opioid receptor. i.p. intraperitoneal, s.c.: subcutaneous, ‘+’ sign after a 
receptor symbol indicates an agonist, ‘‐’ sign after a receptor symbol indicates an antagonist, ‘‐’ sign before time means pre‐administration. NLX: 
naloxone, NTX: naltrexone, NTL: naltrindole, nBNI: norBNI, Ki: affinity value, EC50: effective dose 50%, Emax: maximum effect in percentage, Ke: 
antagonist affinity, pA2 = antagonist affinity using Schild plot. n/a: not applicable/available, dns: does not stimulate, MDV: mouse vas difference, 
GPI: guinea pig ileum. The EC50 values were obtained from GTPγ35S binding assays unless otherwise mentioned in parentheses.  
Ligands  Selectivity  Parameters  MOP  DOP  KOP  NOP  Antinociception 
blocked by 
Ref. 
UMB‐
425 
MOP+  
DOP‐ 
Ki,  
EC50,  
Emax 
3.2 ± 0.14 nM; 
35 ± 3.7 nM; 
73 ± 7.3% 
208 ± 18 nM;  
dns; 
n/a 
(pA2= ‐ 0.91) 
 
212 ± 21 
nM; 
dns;  
n/a 
n/a  NLX;  
Not by: nBNI 
(150) 
17d   MOP+  
DOP‐ 
KOP‐ 
Ki,  
EC50,  
Emax 
0.66 ± 0.06 
nM;  
1.74 ± 0.20 
nM; 
72 ± 2 % 
 
1.20 ± 0.12 
nM; 
dns; 
(Ke= 0.091 ± 
0.01 nM) 
 
1.82 ± 0.11 
nM; 
dns;  
(Ke= 1.35 ± 
0.28 nM) 
n/a  n/a  (160) 
SoRI‐
9409  
MOP+  
DOP‐ 
Ki,  
EC50,  
Emax 
51.0 ± 8.0 nM;  
163 ± 22 nM 
(GPI);  n/a 
2.2 ± 0.16 nM; 
N/A;  
21% (MDV), 
(Ke = 0.66 
nM) 
 
20.0 ± 1.04 
nM; 
n/a 
n/a  β‐FNA;  
Not by: NTL,  nBNI 
(155,304,305) 
 4 
(VRP26) 
MOP+  
DOP‐ 
Ki,  
EC50,  
Emax 
1.74 ± 0.2 nM; 
36.9 ± 8.4 nM;  
41.3 ± 2.8% 
2.43 ± 0.34 
nM; 
dns; 
(Ke= 6.1 ± 1.5 
nM) 
420 ± 25; 
dns; 
n/a  NTX   (306) 
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Ligands  Selectivity  Parameters  MOP  DOP  KOP  NOP  Antinociception 
blocked by 
Ref. 
SR16435 
 
NOP+  
MOP+ 
Ki,  
EC50,  
Emax 
2.70 ± 0.1 nM, 
2.73 ± 0.01 
nM, 
29.5 ± 10% 
>1,000 nM, 
n/a 
 
 
31.7 ± 4.8 
nM, 
>10,000 nM, 
n/a 
7.49 ± 1.31 
nM, 
28.7 ± 0.6 
nM,  
45.0 ± 5.1%  
 
NLX,  
Potentiated by: 
SB612111; 
SR16430 (NOP‐)  
 
 
(152,307,308) 
5a  
(AT‐089) 
NOP+  
MOP+ 
Ki,  
EC50,  
Emax 
8.19 ± 0.16 
nM, 
56.9 ± 19.3 
nM, 
52.3 ± 6.7% 
No affinity.  152 ± 25.7 
nM, 
n/a (Ki > 100 
nM) 
3.16 ± 0 
nM, 
21.7 ± 5.6 
nM, 
96.5 ± 
2.45% 
NLX 
Potentiated by: 
SB612111  
 
(309) 
BU08028  MOP+  
NOP+ 
Ki,  
EC50,  
Emax 
2.14 ± 0.79 
nM, 
6.03 ± 2.1 nM, 
21.1 ± 8.7% 
1.59 ± 0.28 
nM, 
n/a*, 
10.8 ± 6.8% 
5.63 ± 1.30 
nM, 
>10,000 nM 
 
 
8.46 ± 1.31 
nM, 
78.6 ± 49 
nM, 
48 ± 13% 
NLX;  
NTX; 
J‐113397 (NOP‐); 
Potentiated by 
SB612111 
(152,310) 
6 (UMB 
246)#### 
MOP+ 
DOP‐ 
Ki 
EC50 
Emax 
17.5 ± 1.1, 
72 ± 11, 
39 ± 1.3 % 
 
14.4 ± 0.65, 
n/a, 
(Ke = 138 ± 24 
nM) 
1067 ± 39, 
n/a 
n/a  n/a  (311) 
*the stimulation on the DOP receptor was very low to accurately determine the EC50 value (152).
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Table 4. In vitro characteristics of non‐bifunctional opioid analgesic ligands. Keys: The values are presented as Mean ± SD. MOP: mu opioid receptor, 
DOP:  delta  opioid  receptor,  KOP:  kappa  opioid  receptor,  NOP:  NO/FQ  opioid  receptor,  KO:  knock‐out,  WT:  wild‐type.  NTL:  naltrindole,  NTX 
naltrexone, nBNI: norBNI, Ki: affinity value, EC50: Effective dose 50%, Emax: Maximum effect in percentage. n/a: not available. dns: does not stimulate, 
Ke:  antagonist  affinity. MDV: mouse  vas  difference, GPI:  guinea  pig  ileum.  The  EC50  values were  obtained  from GTPγ35S  binding  assays  unless 
otherwise mentioned in parentheses. 
Ligands:  Selectivity  
in vitro 
Parameters  MOP  DOP  KOP   NOP  Antinociception 
blocked by  
Ref. 
MMP‐2200  MOP+  
DOP+ 
Ki,  
EC50,  
Emax 
5.0 ± 0.65 nM, 
220 ± 28 M, 
85 ± 2.7 % 
9.2 ± 1.7 nM, 
14 ± 2.4  nM, 
92 ± 2.3 % 
 
42 ± 5.0  nM, 
n/a 
n/a  β‐FNA (Partial); 
NTL  
(151) 
[Dmt1]DALDA  MOP+ 
KOP+ 
Ki,  
EC50,  
Emax 
0.143 ± 0.015 
nM, 
1.41 ± 0.29 nM 
(GPI), 
n/a 
 
2100 ± 310 nM, 
23.1 ± 2.0 nM 
(MDV), 
n/a 
 
22.3 ± 4.2 nM, 
n/a 
n/a 
 
 
 
 
NLX   (297,2
98,29
9) 
MGM‐16  MOP+  
DOP+ 
Ki,  
EC50,  
Emax 
2.1 ± 0.028 nM 
18 ± 0.055 nM, 
94 ± 1.8 % 
7.0 ± 0.23  nM, 
61 ± 3.2  nM, 
105 ± 8.1 % 
29 ± 1.5 nM, 
n/a 
 
n/a  β‐FNA; NTL 
(partial) 
(300) 
 
MGM‐9   MOP+ 
KOP+ 
Ki,  
EC50 
7.3 ± 0.24 nM; 
n/a 
350 ± 28 nM, 
n/a 
18 ± 2.5 nM, 
n/a 
n/a  NLX; β‐FNA; 
norBNI; GNTI;  
 
(171) 
(‐)(‐) MCL144   MOP+ 
KOP+ 
Ki,  
EC50,  
Emax 
0.09 ± 0.004 
nM; 
1.3 ± 0.15 nM; 
50 ± 6.6 %  
4.2 ± 0.44 nM; 
n/a 
0.05 ± 0.001 
nM; 
0.85 ± 0.053 
nM;  
60 ± 0.68 % 
 
 
n/a  nBNI; β‐FNA;  
 
(303) 
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Ligands:  Selectivity  
in vitro 
Parameters  MOP  DOP  KOP   NOP  Antinociception 
blocked by  
Ref. 
AN81  MOP+ 
DOP+ 
Ki,  
EC50,  
Emax 
0.15 ± 0.02nM, 
0.32 ± 0.0nM 
(GPI) 
 
0.60 ± 0.07nM, 
0.42 ± 0.02nM 
(MVD) 
118 ± 12nM, 
n/a 
n/a  n/a  (184) 
1(4R)#  MOP+ 
DOP+ 
KOP+ 
Ki,  
EC50,  
Emax 
0.22 ± 0.02 nM;  
1.6  ±0.3 nM;  
81 ± 2 %  
 
9.8 ± 0.8nM; 
110 ± 6 nM; 
16 ± 2 %  
68 ± 2 nM; 
540 ± 72 nM; 
22 ± 2 %  
n/a  NTX  (312) 
14a  MOP+ 
 
Ki 
EC50 
Emax 
0.04, 
0.93, 
87% 
 
0.02, 
dns 
48, 
dns 
n/a  NTX  (313) 
16 (MP1104)  MOP+ 
DOP+ 
KOP+ 
Ki 
EC50 
Emax 
0.021 ± 0.003, 
0.21 ± 0.03, 
103 ± 2.5 % 
 
0.08 ± 0.019, 
0.41 ± 0.11, 
88 ± 0.38 % 
0.006 ± 0.002, 
0.027 ± 0.002, 
104 ± 2.3 % 
n/a  nBNI, NTL; KOP‐
KO mice 
(314) 
10j  MOP+ 
KOP+ 
Ki 
EC50 
Emax 
0.15 ± 0.08, 
3 ± 1, 
96 ± 4 % 
 
15 ± 5, 
dns 
2 ± 1 
15 ± 9, 
14 ± 2 
n/a  n/a  (315) 
4h   MOP+ 
DOP+ 
 
Ki 
EC50 
Emax 
0.19, 
0.78, 
95 % 
 
0.51, 
14, 
40 % 
29, 
250, 
28 %  
n/a  n/a  (295) 
13a 
(KGNOP1)## 
MOP+ 
DOP+ 
KOP+ 
NOP‐ 
Ki 
EC50 
5.0 ± 1.7, 
6.1 ± 0.1 (GPI) 
 
99 ±4, 
5.3 ± 1.4 (MDV) 
33 ± 15, 
n/a 
42 ± 6, 
>10000 
n/a  (316) 
37 
 
Ligands:  Selectivity  
in vitro 
Parameters  MOP  DOP  KOP   NOP  Antinociception 
blocked by  
Ref. 
4  MOP+ 
DOP+ 
KOP+ 
pIC50 
pEC50 
 
0.25 ± 0.02, 
8.25, 
51.20 ± 3.00, 
7.19, 
1.78 ± 0.15, 
7.38, 
n/a  n/a  (317) 
11  MOP+ 
DOP+ 
KOP+ 
pIC50 
pEC50 
 
0.49 ± 0.06, 
8.78 
11.2 ± 5.2, 
8.06 
0.30 ± 0.05, 
8.87 
n/a  β‐FNA  (318) 
DeNo  MOP+ 
DOP+ 
KOP+ 
NOP+ 
Ki  
pEC50 
9.55 ± 0.10, 
7.77 
8.12 ± 0.11, 
6.78 
7.34 ± 0.13 
5.92 
10.2 ± 0.09, 
9.5 
 
n/a  (319) 
BN‐9###  MOP+ 
DOP+ 
KOP+ 
pEC50  
Emax 
 
6.51±0.15 
92.4±9.7% 
 
 
6.23±0.06 
82.2±3.7% 
6.25±0.25 
105.6±20.7% 
n/a  NLX; nBNI;  
β‐FNA 
(178) 
PPL‐101  MOP+ 
DOP+ 
KOP+ 
Ki 
EC50 
Emax 
0.35 ± 0.04 
0.3 ± 0.1 
12 ± 2.9  
4.0 ± 1.4 
40 ± 6.3 
22 ± 5.8 
0.43 ± 0.1 
15 ± 2.5 
63 ± 0.3 
n/a  JDTic; 
Not by: β‐FNA 
(320) 
                 
#1(4R): a peptide, poor bioavailability (306). 
##13a is an antagonist for NOP receptor (pA2, 6.00 ± 0.05), which is inactive after oral administration.  
###BN‐9: data from cAMP assay (178)  
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Table 5. In vitro characteristics of opioid analgesic ligands with the incomplete pharmacological profile. Keys: The values are presented as Mean ± 
SD. MOP: mu opioid receptor, DOP: delta opioid receptor, KOP: kappa opioid receptor, NOP: NO/FQ opioid receptor, KO: knock‐out, WT: wild‐type. 
NTL: naltrindole, NTX naltrexone, nBNI: norBNI, Ki: affinity value, EC50  : Effective dose 50%, Emax: Maximum effect in percentage. n/a: not available, 
dns: does not stimulate, Ke antagonist affinity. MDV: mouse vas difference, GPI: guinea pig  ileum. The EC50 values were obtained from GTPγ35S 
binding assays unless otherwise mentioned in parentheses. 
 
Ligands:  Selectivity 
in vitro 
Parameters  MOP  DOP  KOP   NOP  Antinocicepti
on blocked 
by  
Ref. 
10  MOP+ 
DOP+ 
Ki,  
EC50,  
Emax 
 0.48 ± 0.06 
nM, 
13 ± 1.1nM, 
47 ± 4 % 
(GPI IC50=  
2.5 ± 0.7 nM) 
 
 0.65 ± 0.35 nM, 
44 ± 5.9 nM, 
56 ± 6 % 
(MVD IC50 = 
9.3 ± 0.4 nM) 
 
n/a  n/a  n/a  (321) 
RV‐Jim‐C3  MOP+  
DOP+ 
Ki  n/a  n/a  n/a  n/a  NTL,  
CTAP  
 
(322) 
1  MOP+  
DOP+ 
Ki,  
EC50,  
Emax 
1.1 nM, 
50 ± 6.5 nM 
(GPI), 
 
 
0.72 nM, 
33 ± 9.4 nM 
(MDV), 
 
n/a  n/a  n/a  (323) 
SR14150#  NOP+ 
MOP+ 
Ki,  
EC50,  
Emax 
29.9 ± 2.1 nM;  
99 ± 12 nM; 
23.4  ± 3.2 % 
n/a  42.7 ± 1.0 nM, 
276 ± 75.8 nM, 
38 % 
 
1.39 ± 0.42 
nM, 
20.8 ± 3.1,  
54.2 ± 10.9 %  
 
NLX  (283,3
08) 
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Ligands:  Selectivity 
in vitro 
Parameters  MOP  DOP  KOP   NOP  Antinocicepti
on blocked 
by  
Ref. 
SR16507## 
 
NOP+ 
MOP+ 
Ki,  
EC50,  
Emax 
1.07 ± 0.17 nM, 
5.2 ± 1.6 nM, 
47 ± 1.5 % 
 
n/a  82.4 ± 16.4 
nM, 
 
5.22 ± 0.65 
nM, 
8.5 ± 0.8 nM, 
95 ± 12 % 
 
NLX  (283,3
07) 
RSA 504  MOP+ 
DOP+ 
 
Ki,  
EC50,  
Emax 
27 nM , 
0.47 nM, 
110 %   
(GPI: 210 ± 52 
nM) 
23 nM, 
5.5 nM, 
81 % 
(MDV: 23 ±  9.7 
nM) 
 
n/a  n/a  n/a  (284) 
(294) 
RSA 601  MOP+ 
DOP+ 
 
Ki,  
EC50 
 
5.7 nM, 
71 nM (GPI) 
0.55 nM, 
24 nM (MVD) 
n/a  n/a  n/a  (294)  
(324) 
TY027  MOP+ 
DOP+  
Ki,  
EC50,  
Emax 
16 nM, 
7.0 nM, 
55 % 
(GPI IC50:  
490 ± 29 nM) 
0.66 nM, 
8.6 nM,  
58 % 
(MDV IC50:  
15 ± 2.0 nM) 
 
n/a  n/a  n/a  (325,3
26) 
TY005  MOP+ 
DOP+ 
 
Ki,  
EC50,  
Emax 
36 nM, 
32 nM, 
42  ± 2 % 
(GPI IC50:  
360 ± 130 nM) 
2.8 nM, 
2.9 nM, 
45 ± 3 % 
(MDV IC50:  
22 ± 1.2 nM) 
 
n/a  n/a  β‐FNA; NTL  (327,3
28) 
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Ligands:  Selectivity 
in vitro 
Parameters  MOP  DOP  KOP   NOP  Antinocicepti
on blocked 
by  
Ref. 
Tapentadol 
### 
MOP+ 
 
Ki  96 ± 9 nM   970 ± 10 nM  910 ± 90 nM  n/a  NLX   (329) 
13  MOP+ 
DOP+ 
Ki 
EC50 
1.82, 
13.0 (GPI) 
11.2, 
12.6 (MDV) 
 
n/a  n/a  n/a  (330) 
5 (AKG127)  MOP+ 
DOP+ 
Ki 
EC50 
 
1,  
42 ± 9.7 (GPI), 
59 ± 23 (cAMP) 
 
1, 
2 ± 0.68 (MDV) 
21 ± 14 (cAMP) 
n/a  n/a  n/a  (331) 
26  MOP+ 
DOP+ 
KOP+ 
Ki  8 ± 2.3  0.7 ± 0.3  67 ± 23   n/a  NTI (WT); 
MOP‐KO, 
KOP‐KO mice 
  
(332) 
22  MOP+ 
DOP+ 
Ki 
EC50 
0.08,  
1.86 (GPI) 
0.28, 
2.16 (MDV) 
 
n/a  n/a  n/a  (293) 
11a  MOP+ 
KOP+ 
pIC50  1.61  n/a  2.73  n/a  n/a  (333) 
6 (UMB 246)  MOP+ 
DOP‐ 
Ki 
EC50 
Emax 
17.5 ± 1.1, 
72 ± 11, 
39 ± 1.3 % 
 
14.4 ± 0.65 
n/a 
1067 ± 39 
n/a 
n/a  n/a  (311) 
#SR14150 (30 mg/kg s.c.): Animals were not moving and tried to stay curled up at 30 min post‐injection (283).  Values are shown as, Mean ± SD.  
##SR16507 (3 mg/kg s.c.): Animals treated with SR16507 were preferred to be still (283). Values are shown as Mean ± SD. 
 ###Tapentadol: Data was obtained from rat opioid binding assay (329) 
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1.2.5. Bifunctional opioid analgesics 
1.2.5.1. Pharmacological profiles of bi-functional opioid analgesics 
Over the period of January 2008 to November 2017, eight ligands with multiple selectivity and 
complete in vitro pharmacological profile for at least three of the major opioid receptors (MOP, 
DOP, KOP) have been described (UMB-425, 17d, SoRI-9404, VRP26, SR16435, 5a, UMB 
246 and BU08028) (150,152,160,304,307,309,310), with three of these (SR16435, 5a and 
BU08028) also showing NOP receptor affinity (Table 3).  All of these ligands showed better 
MOP selectivity than towards other ORs. In addition, five of these compounds acted as DOP 
receptor antagonist, while three other ligands did not show any selectivity for this receptor. In 
addition to their agonistic effects towards the MOP receptor, SR16435, AT-089 and BU08028 
showed similar agonism towards the NOP receptor. Overall, UMB-425, 17d, SoRI-9409, UMB 
246 and VRP26 are MOP receptor agonists and at the same time DOP receptor antagonists, 
while SR16435, AT-089, BU08028are MOP and NOP receptor antagonists, without affecting 
the DOP and KOP receptors (Table 3). Apart from their in vitro characterisation, these 
bifunctional compounds were mostly tested for their antinociceptive effects in mice to 
investigate the capacity of these ligands to penetrate to the central nervous system.  
1.2.5.2. Antinociceptive effects of bifunctional opioid analgesics 
Among the eight reported bi-functional ligands, six (UMB-425, 17d, SoRI-9409, SR16435, 5a 
and BU08028) were tested for antinociception in male mice, sex-related information was 
missing for animals tested with UMB 246, while VRP26 was tested using both male and female 
mice (Table 6). This is a significant experimental limitation as sex-specific differential opioid 
effects have been reported for rodents (334,335), and female animals have been used 
comparatively less than males to avoid the interference of hormonal effects (336). Since most 
of these OLs were not tested in female animals, differential gender-specific antinociceptive 
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effects are so far unknown for these compounds. Overall, antinociception induced by these 
OLs was tested using tail-flick test by radiant heat or warm water (50-55 ⁰C) tail-withdrawal 
assay with cut-off times ranging from 10-20 seconds, whereas baseline latency was 
approximately 5 seconds (Table 6). Apart from experimental variations, all antinociception 
results were consistently expressed as Maximum Possible Effect (MPE) based on their 
respective latencies, which allows a superficial level of comparison. The reported MPE varied 
between 40 - 100 % for these ligands at the maximal tested dose, while peak antinociception 
ranged between 30 - 120 min post administration times. Antinociception (median effective 
doses (ED50 or MPEs) compared to morphine were reported for six of these ligands (UMB-
425, 17d, SoRI-9409, 5a, VRP26 and BU08028), while SR16435 and UMB-246 were not 
compared to morphine (Table 6). 
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Table 6. Antinociceptive effects of bifunctional opioid analgesic ligands using tail flick assay. Keys: MPE: maximum possible effect, ED50: effective 
dose 50%, ‘~’ shows an approximate value, other values are Mean ± SEM (standard error mean), CL: cut‐off latency, SW: Swiss Webster, SD: Sprague 
Dawley, WWTW: warm water tail withdrawal assay, TF: tail flick assay by radiant heat, TFL: tail‐flick latency, FEN: fentanyl, s.c.: subcutaneous, i.c.v.: 
intracerebroventricular, i.p.: intraperitoneal, ‘‐’ sign before time means pre‐administration. n/a: not applicable/available. 
 
Ligands 
(route of 
administration) 
 
Animal, assay, 
Cut‐off Latency, 
baseline 
latency, %MPE 
 %MPE of Ligand 
(dose, post‐admin 
time) 
%MPE of 
Morphine (or 
other) (dose, 
post‐admin time) 
 
ED50 of Ligand  ED50 of Morphine 
(or other) 
Ref. 
Tail flick (TF) / Warm water tail withdrawal (WWTW) assay 
UMB‐425  
(s.c.) 
Male SW mice (21‐
30g), TF, 
10s, 2‐4s, %CL 
~90% (20 mg/kg, 30 
min)  
~100% (20 
mg/kg, 30 min) 
8.83 mg/kg   6.85 mg/kg  (150) 
17d  
(i.c.v.)  
Male ICR mice, 
WWTW 55°C,  
10s, no BL, %CL 
 
75% (1 nmol, 45 min)  100% (10 nmol)   0.35 nmol  0.43 nmol  (160) 
SoRI‐9409  
(i.c.v.) 
Male ICR mice (20‐
30g), 
WWTW 55°C, 
15s, ≤5s, %CL 
 
40.3% (100 nmol, 20 
min) 
~90% (10 nmol, 
30 min)  
> 100 nmol  2.94 nmol  (155,3
04) 
 4 (VRP26) 
(i.p.)  
Male & female 
C57BL/6 mice (20‐35g), 
WWTW 50°C, 
20s,  3‐6s, %CL 
~100% (20s) 
(32 mg/kg, 45 min) 
~100% (10 
mg/kg, 30 min) 
(312) 
n/a  n/a  (306) 
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Ligands 
(route of 
administration) 
 
Animal, assay, 
Cut‐off Latency, 
baseline 
latency, %MPE 
 %MPE of Ligand 
(dose, post‐admin 
time) 
%MPE of 
Morphine (or 
other) (dose, 
post‐admin time) 
 
ED50 of Ligand  ED50 of Morphine 
(or other) 
Ref. 
VRP26 
(i.p.; s.c.) 
Male & female 
C57BL/6 mice (20‐35g), 
WWTW 50°C, 
20s,  ~5s, %CL 
~100% (20s, 10 
mg/kg, 30 min) 
FEN:~100% (0.3 
mg/kg, 30 min) 
5.44±0.10 
mg/kg (i.p.); 
5.08±0.23 
mg/kg (s.c.) 
FEN: 0.17±0.013 
mg/kg (i.p.); 
0.20±0.001 
mg/kg (s.c.)   
 
(337) 
SR16435  
(s.c.) 
Male ICR mice (25‐
30g), TF, 
15s, 5.03±0.3s, %CL 
 
~90% (30 mg/kg, 30 
min) 
n/a   n/a  n/a  (307) 
5a 
(s.c.) 
 
Male ICR mice (25‐
30g), TF, 
15s, 5.5±0.16s, 
%CL 
~40% (10 mg/kg s.c., 
60 min) 
~100% (10 mg/kg 
s.c., 60 min) 
n/a  n/a  (309) 
 
BU08028 
(s.c.) 
Male ICR mice (25‐
30g), TF, 15s, 
4.32±0.12s, %CL 
~95% (30 mg/kg, 120 
min) ~90% (10 
mg/kg, 240 min) 
~100% (10 
mg/kg, 30 min) 
n/a  n/a  (152) 
BU08028* 
(s.c.) 
Male and female 
rhesus monkeys (10‐17 
y), WWTW 50°C, 20s,  
~100% (0.01 mg/kg, 
1‐24 h)  
n/a  n/a  n/a  (310) 
UMB 246  Mice, no info  ~60% (60 mg/kg s.c., 
30 min)  
n/a  n/a  n/a  (311) 
     *BU08028: Animals were reported with no reinforcing effects and no respiratory depression (310) 
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Apart from the universally used tail flick assay, antinociception by UMB-425 and UMB-246 1 
was also quantified using the hot plate assay, while SR16435 prevented mechanical allodynia, 2 
and SoRI-9404 produced antinociception in an acetic acid-induced inflammation pain assay. 3 
Although the ED50 values of UMB-425 and SoRI-9404 in the hot plate or inflammation pain 4 
assay were higher than morphine, their MPE values were similar to morphine at the highest 5 
dose tested (Table 7). Overall, seven ligands produced relatively similar antinociception levels 6 
to morphine after acute administration, while UMB-246 was not directly compared against any 7 
other OL. 8 
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Table 7. Effects of bifunctional opioid analgesic ligands using different antinociception tests. Keys: MPE: maximum possible effect, ED50: effective 
dose 50%, ‘~’ shows an approximate value, other values are Mean ± SEM (standard error mean), CL: cut‐off latency, SW: Swiss Webster, SD: Sprague 
Dawley, HP: hot plate, FEN: fentanyl, s.c.: subcutaneous, i.c.v.: intracerebroventricular, i.p.: intraperitoneal, i.t.: intrathecal, AAW: acetic acid writhing.  
n/a: not applicable/available. 
 
Ligands 
 
Animal, assay, 
Cut‐off Latency, 
baseline latency, 
%MPE 
 %MPE of Ligand  
(dose, post‐admin time) 
%MPE of Morphine  
(dose, post‐admin time) 
ED50 of 
Ligand 
ED50 of 
Morphine 
Ref. 
Hot‐plate (HP) assay 
UMB‐425   Male SW mice, HP 
(53°C), 
30s, 8‐10s, %CL 
 
~90% (20mg/kg s.c., 30 min); 
~100% (10mg/kg s.c., 50 min) 
~100% (20mg/kg s.c.,  
30 min) 
4.30 mg/kg 
s.c. (30 min) 
2.73 mg/kg 
s.c. (30 min) 
 
(150) 
UMB‐246  Mice  ~40% (60 mg/kg s.c., 50 min)  
 
n/a  n/a  n/a  (311) 
Mechanical allodynia test 
Ligands:  Animal (SNL), 
baseline 
threshold  
Peak threshold of Ligand 
(dose, post‐admin time) 
Peak threshold of 
Morphine (dose, post‐
admin time) 
ED50 of 
Ligand  
ED50 of 
Morphine 
Ref. 
SR16435  Male ICR mice  
(25–30 g), 
0.09± 0.01 g 
  
92±6% (~1.8g)  
(3µg i.t., 30 min) 
 
89±6% (~1.7g) (10µg i.t., 
30 min);  
(SCH221510: 91±2%, 
~1.9 g; 10µg i.t., 30 min) 
 
n/a  n/a  (338) 
SR16435  Male SD rats  
(250‐300g),  
4.3 ± 0.9 g 
 
~12 g (10 mg/kg i.p., 60 min)  ~10 g (10 mg/kg i.p., 60 
min) 
n/a  n/a  (308) 
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Acetic acid writhing assay 
Ligands:  Animal, assay, 
%MPE 
 %MPE of Ligand (route of 
administration)  
%MPE of Morphine  
(route of administration) 
ED50 of 
Ligand 
ED50 of 
Morphine 
Ref. 
SoRI‐9409  Male ICR mice  
(20‐30 g), 
%MPE 
~80% (i.c.v.)  
~100% (i.p.) 
   
~90% (i.c.v.)  
~100% (i.p.) 
7.5 nmol 
(i.c.v) 
11.5 mg/kg 
(i.p.) 
0.004 nmol 
(i.c.v.)  
2.3 mg/kg 
(i.p.) 
(155) 
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Similar to the in vitro selectivity tests, the involvement of specific OR for the antinociceptive 
effects was also investigated using co-administration of non-selective (naloxone) or selective 
OR antagonists (β-FNA, naltrindole, nor-BNI for MOP, DOP and KOP receptors respectively) 
in vivo. Overall the receptor selectivity of the eight bifunctional ligands for antinociceptive 
effects in vivo reflected their in vitro receptor selectivity and thus confirmed the involvement 
of specific opioid receptors for each ligand that are responsible for their antinociceptive effects 
and likely also their effect on tolerance (Table 3).  To investigate whether these bifunctional 
OLs can avoid antinociceptive tolerance that is a major drawback of all clinically used opioids, 
their efficacy over several days of repeated administration has been typically compared against 
morphine or fentanyl.  
1.2.5.3. Effects of bi-functional opioid analgesics on antinociceptive tolerance  
Previous studies suggest that simultaneous activation of the MOP receptor and inhibition of 
the DOP receptor can prevent tolerance. One of the first studies reported that coadministration 
of morphine with the DOP receptor antagonist naltrindole can reduce morphine tolerance 
(122). This hypothesis was supported by the observation that DOP receptor knockdown (339) 
and DOP receptor knockout mice (59) showed reduced levels of drug-induced tolerance. In the 
later study, daily administration of morphine over 5 days produced tolerance in wild-type 
animals, whereas no tolerance was observed over 8 days in DOP receptor knockout animals 
(59). These studies strongly support the hypothesis that targeting multiple OR, especially the 
MOP and DOP receptors, has the potential to reduce antinociceptive tolerance. 
Out of eight bifunctional opioid analgesics (Table 3), antinociceptive tolerance was tested for 
only five ligands (Table 8), using repeated administration of 1 to 3 doses daily over a period of 
3 to 9 days. Antinociceptive effects were measured as reduction of MPE (%) or fold-shifts of 
antinociceptive ED50. All five ligands were compared with morphine or fentanyl at their 
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equivalent analgesic doses. Thus, differences compared to morphine or fentanyl provided 
insight towards understanding the potency of these ligands. Four ligands (UMB-425, 17d, 
VRP26 and BU08028) were tested for tolerance by measuring spinal antinociception (e.g. tail-
flick test, warm-water tail withdrawal assay), while for SoRI-9409 the inflammatory 
antinociception assay (AAW) was employed. Overall, MOP receptor agonist / DOP receptor 
antagonist ligands showed less tolerance, while the MOP / NOP receptor agonist BU08028 
induced slightly more tolerance than morphine (Table 8). However, BU08028 showed fewer 
adverse-effects (less respiratory depression and dependence) than morphine in primates (310). 
Therefore, bifunctional opioid analgesics showed overall a trend towards reduced 
antinociceptive tolerance and/or other adverse effects.  
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Table 8. The effects of bifunctional opioid analgesic ligands on sub‐chronic administration and antinociceptive tolerance. Keys: MPE: maximum 
possible effect, ED50: effective dose 50%, ‘~’ shows an approximate value, WWTW: warm water tail withdrawal assay, TF: tail flick assay by radiant 
heat, HP: hot plate, FEN: fentanyl, s.c.: subcutaneous, i.p.: intraperitoneal. AAW: acetic acid writhing.  n/a: not applicable/available. MOR: morphine, 
b.i.d.: twice daily, t.i.d.: three times daily. Note: Same experimental conditions/animals apply for the TF or WWTW assay with acute administration.  
 
Ligand 
 
Procedure summary 
 
Result  %MPE of 
ligand 
% MPE of 
morphine 
Tolerance 
ED50 shift 
of Ligand  
Tolerance 
ED50 shift of 
Morphine 
Ref. 
UMB‐425  UMB‐425 (15 mg/kg s.c.) or 
MOR (15 mg/kg s.c.) were 
administered twice daily for 5 
days. Antinociception was 
assessed in tail flick and hot 
plate assays at 30 min post 
admin time. Tolerance ED50 
was measured on Day 6. 
 
Reduced 
tolerance: Less 
ED50 shifts  
than MOR 
Day 1: ~100 % 
(both) 
Day 4:  
~85% (HP) 
~90% (TF) 
Day 1: 
~100% 
(both) 
Day 4:  
~60% (HP) 
~75% (TF) 
TF: 1.3 
fold 
HP: 3 fold 
TF: 6.4 fold 
HP: 7.8 fold 
(150) 
17d   17d and MOR were 
administered at their ED90 dose 
twice daily for 3 days. The 
tolerance ED50 was determined 
on Day 4 using WWTW (55°C) 
assay. (Note: ED50 of 17d: 0.35 
nmol and MOR: 0.43  nmol)  
 
Reduced 
tolerance: Less 
ED50 shift than 
MOR 
Day 1: ~75%  Day 1: 
~100% 
7.9 fold  44 fold  (160) 
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Ligand 
 
Procedure summary 
 
Result  %MPE of 
ligand 
% MPE of 
morphine 
Tolerance 
ED50 shift 
of Ligand  
Tolerance 
ED50 shift of 
Morphine 
Ref. 
SoRI‐
9409 
Antinociception was measured 
in AAW at ED90 doses of 
morphine (6mg/kg i.p.) and 
SoRI‐9409 (30mg/kg i.p.) twice 
or thrice daily for 3 days. 
Tolerance ED50 was measured 
on Day 4. 
 
Reduced 
tolerance: Less 
ED50 shift than 
MOR 
Day 1: ~80% 
Day 4: ~85% 
(b.i.d.) 
~70% (t.i.d.) 
Day 1:  ~95% 
Day 4: ~ 
~90% (b.i.d.) 
~85% (t.i.d.) 
 
0.6 fold 
(b.i.d.) 
1.1 fold 
(t.i.d.) 
2.4 fold 
(b.i.d.)  
5.1 fold  
(t.i.d.) 
(155) 
 
VRP26  FEN (0.3 mg/kg s.c) or VRP 26 
(10 mg/kg s.c.) were 
administered daily 
continuously via osmotic 
pumps for 7 days. Tolerance 
ED50 was measured on Day 8 in  
WWTW (50°C assay) 
Reduced 
tolerance: Less 
ED50 shift than 
FEN. No 
difference in 
latencies on 
Day 1 and Day 
8. 
 
Latency:  
Day 1 ~20 s 
Day 8: ~20 s 
Latency: 
FEN: 
Day 1 ~20 s 
Day 8: ~20 s 
No shift  FEN:  
3 fold 
(337) 
BU08028  MOR  (10  mg/kg  s.c.)  and 
BU08028  (10 mg/kg  s.c.) were 
injected  once  daily  for  9  days 
and tested on days 1,2,4 and 9 
at  1‐hour  post  injection  in    TF 
assay. 
Morphine 
tolerance: Day 
9 
BU08028 
tolerance:  
Day 4 
Day 1: ~85% 
Day 4: ~50% 
Day 9: ~15% 
Day 1: ~90% 
Day 4: ~70% 
Day 9: ~15% 
n/a  n/a  (152) 
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1.2.6. Non-bifunctional opioid analgesics 
1.2.6.1. Pharmacological profiles of non-bifunctional ligands 
In addition to bifunctional OLs, several non-bifunctional OLs with antinociceptive effects have 
been reported over the same time-period and were categorised following our terminologies.  
Noticeably, all of these ligands are MOP, DOP and KOP receptor agonists (Table 4), but their 
selectivity profiles towards different ORs were similar and not specific to any particular OR. 
For eleven of these OLs, the specific opioid receptors responsible for their antinociceptive 
effects were also identified by co-administration of a non-selective or selective antagonist of 
the MOP, DOP and KOP receptors (Table 4). In addition, antinociception induced by ligand 
16 (MP1104) reportedly involve the KOP receptor as its antinociceptive effect was abolished 
in KOP receptor knock out mice (314). To my knowledge, similar studies have not been 
reported for other sixteen OLs, which is a source of uncertainty regarding the actual mode of 
action of these ligands (Table 4).  
1.2.6.2. Antinociceptive effects of non-bifunctional ligands 
The antinociception characteristics for these non-bifunctional OLs were assessed by either 
using thermal (e.g. tail-flick; hot plate) or mechanical (e.g. von Frey filament) assays in mice 
or rats (Table 9, 10 and 11). From these, fourteen ligands (82 %) were reported for 
antinociceptive effects using tail flick assay (Table 9). Noticeably, only BN-9 was tested using 
three different routes of administration, another three ligands (AN81, MGM-9 and MGM-16) 
were tested using two different routes of administration and the rest of the compounds were 
tested using a single route of administration. Subcutaneous (5), intraperitoneal (4) or 
intravenous (3) were commonly used routes of administration in these preclinical studies. 
Noticeably, only two ligands (MGM-9 and MGM-16) produced antinociceptive response, 
when the compounds were administered orally (Table 9). There are variations in the 
53 
 
experimental settings of tail-flick assay, such as cut-off latency was varied from 7 to 20 seconds 
with a baseline latency was used between 2 to 6 seconds (Table 9). In most cases, 
antinociception was determined as MPE (%). Antinociception (MPE) produced by eight (57%) 
of these ligands were similar to morphine (Table 9).   
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Table 9. The antinociceptive effects of non‐bifunctional analgesic ligands using tail flick assay. Keys: MPE: maximum possible effect, ED50: effective 
dose 50%, ‘~’ shows an approximate value, other values are Mean (± SEM (standard error mean)), CL: cut‐off latency, SW: Swiss Webster, SD: Sprague 
Dawley, WWTW: warm water tail withdrawal assay, TF: tail  flick assay by radiant heat, HP: hot plate, TFL: tail flick latency, FEN: fentanyl, MOR: 
morphine, s.c.: subcutaneous,  i.c.v.:  intracerebroventricular,  i.p.:  intraperitoneal,  i.t.:  intrathecal, admin. route: route of administration, n/a: not 
applicable/available, BL: baseline latency. 
 
Ligands 
(admin. route) 
Animal, assay, Cut‐
off latency, baseline 
latency, %MPE 
 %MPE of Ligand (dose, 
post‐admin time) 
%MPE of Morphine 
(dose, post‐admin 
time) 
 
ED50 of 
Ligand 
ED50 of 
Morphine 
Ref. 
MMP‐2200 (s.c.)  Male ICR mice (25‐35 
g), WWTW 55° C, 10s, 
<5s, %CL  
 
~90% (20 mg/kg, 30 
min) 
~100% (20 mg/kg, 
30 min)  
8.90 µmol/kg  23.80 µmol/kg  (151) 
MGM‐16 (s.c.)  Male ddY mice, TF, 
10s, no BL, %CL 
 
~95% (0.2 mg/kg, 15 
min) 
n/a  0.064 mg/kg  
 
4.57 mg/kg  (300) 
MGM‐16 (p.o.)  Male ddY mice, TF, 
10s, no BL, %CL 
 
~98% (1 mg/kg, 15 min)  n/a  0.263 mg/kg   63.0 mg/kg  (300) 
AN81 (i.v.) 
 
 
Male C57Bl6 mice 
(25‐28 g) 
10 s, WWTW 55° C, 
10s, %CL 
 
100% (4 mg/kg, 30 min) 
95 ± 2.89%  (1 mg/kg, 
30 min) 
95.08 ± 1.67%  (4  
mg/kg, 15 min) 
n/a  n/a  (184) 
AN81 (s.c.) 
 
 
Male CD1 mice (27‐
33 g), TF, 10 s, no 
info, %CL 
 
~85% ( 1 mg/kg, 60 
min) 
~95% (5 mg/kg, 30 
min) 
n/a  n/a  (184) 
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Ligands 
(admin. route) 
Animal, assay, Cut‐
off latency, baseline 
latency, %MPE 
 %MPE of Ligand (dose, 
post‐admin time) 
%MPE of Morphine 
(dose, post‐admin 
time) 
 
ED50 of 
Ligand 
ED50 of 
Morphine 
Ref. 
1(4R) (i.p.)  Male C57BL/6 mice 
(20‐30g),WWTW 50° 
C, 20s, 3‐6s, %CL 
 
 100% (10 mg/kg, 15 
min) 
100% (10 mg/kg, 
30 min) 
3 mg/kg  n/a  (312) 
(‐)(‐)MCL144  
(icv.) 
Male, ICR mice (20–
30 g), WWTW 55°C, 
15s, <5s, %CL 
 
95% (10 nmol, 20 min)  n/a  30 nmol   n/a  (303) 
MGM‐9 (s.c.)  Male ddY mice(25‐33 
g),  TF, 10s, no BL, 
%CL  
 
95% (2 mg/kg, 15 min)  90% (8mg/kg, 30 
min) 
0.57 mg/kg   4.57 mg/kg   (171) 
MGM‐9 (p.o.)  Male ddY mice (25‐33 
g), TF, 10s, no BL, 
%CL  
 
85% (8mg/kg, 15 min)  75% (100 mg/kg, 
60 min) 
2.84 mg/kg  63.0 mg/kg  (171) 
[Dmt1]DALDA 
(i.t.) 
Male SD rats (300‐
350g), TF, 
7s, 2.5‐3.5s, 
%CL 
 
~100% (7s) (3.18 pmol, 
60 min) 
(~3000 times more 
potent than morphine) 
~93% (~6.5s) (9990 
pmol, 60 min) 
1.06 pmol  3330 pmol  (298) 
 
 
 
14a (i.p.)  Male C57BL/6 mice 
(20‐30g), WWTW, 50° 
C, 20s, 3‐6s, latency 
~20s (10 mg/kg)  n/a  4.73±0.08 
mg/kg 
n/a  (313) 
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Ligands 
(admin. route) 
Animal, assay, Cut‐
off latency, baseline 
latency, %MPE 
 %MPE of Ligand (dose, 
post‐admin time) 
%MPE of Morphine 
(dose, post‐admin 
time) 
 
ED50 of 
Ligand 
ED50 of 
Morphine 
Ref. 
16 (MP1104) 
(s.c.) 
Male CD1 mice (20‐
32 g), TF, 10 s, 2‐3s, 
%CL 
 
~95% (1 mg/kg, 30 min)  n/a  0.33±0.09 
mg/kg  
n/a  (314) 
10j (i.p.)  Male C57BL/6 mice 
(20‐30 g), WWTW, 
50° C, 20s, 3‐6s, 
latency 
 
20s (10 mg/kg, 30 min)  n/a  n/a  n/a  (315) 
4h (i.p.)  Male C57BL/6 mice 
(20‐30 g), WWTW 50° 
C, 20s, ~5s, latency 
 
~20 s (10 mg/kg, 30 
min) 
n/a  n/a  n/a  (295) 
13a (i.v.)  MaleC57BL6 (20‐25 
g), TF, 10s 
 
100% (31 nmol, 60 min)  100% (390 nmol, 
30 min) 
n/a  n/a  (316) 
BN‐9 (i.c.v.)  Male Kunming mice, 
TF, 10s, 3‐5s 
 
~95% (2 nmol, 15 min)  ~90% (4nmol, 30 
min) 
0.39 nmol  1.02 nmol  (178) 
BN‐9 (i.t.)  Male Kunming mice, 
TF, 10s, 3‐5s 
 
~100% (2 nmol, 10 min)  ~95% (4nmol, 10 
min) 
0.29 nmol  0.35 nmol  (178) 
BN‐9 (i.v.)  Male Kunming mice, 
TF, 10s, 3‐5s 
 
~90% (224 nmol)  ~90%   58.6 nmol  46.2 nmol  (178) 
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Ligands 
(admin. route) 
Animal, assay, Cut‐
off latency, baseline 
latency, %MPE 
 %MPE of Ligand (dose, 
post‐admin time) 
%MPE of Morphine 
(dose, post‐admin 
time) 
 
ED50 of 
Ligand 
ED50 of 
Morphine 
Ref. 
PPL‐101  Male ICR mice, TF, 
15s, 4.83s 
 
~90% (3 mg/kg, 60 min)  ~100% (15 mg/kg)   n/a  n/a  (320) 
KGNOP1 (13a)  Male Wister rats 
(250‐350 g), TF, 9s 
~100% (5 nmol, i.t., 30 
min)  
~85% (3.5 nmol, 
i.t., 30 min) 
n/a  n/a  (340) 
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Apart from using the tail-flick assay, four non-bifunctional OLs were tested in male mice for 
their antinociceptive effects using the hot plate test. While the non-bifunctional ligands 4 and 
11 showed 80 to 100 % MPE, ligand 13a showed only 30 % MPE (Table 10). Noticeably, the 
cut-off latency used in these studies varied between 25 to 240 seconds, which indicate very 
significant variations with regards to the antinociceptive responses of the ligands (Table 10). 
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Table 10. Antinociceptive effects of non‐bifunctional analgesic ligands using hot plate assay. Keys: MPE: maximum possible effect, ED50: effective 
dose 50%, ‘~’ shows an approximate value, other values are Mean (± SEM (standard error mean)), CL: cut‐off latency, HP: hot plate, FEN: fentanyl, 
s.c.: subcutaneous, i.c.v.: intracerebroventricular, i.p.: intraperitoneal, n/a: not applicable/available.  
 
Ligands 
(admin 
route) 
Animal, assay, Cut‐off latency, 
baseline latency, 
%MPE  
 %MPE of Ligand 
(dose, post admin 
time) 
%MPE of 
Morphine (dose, 
post admin time) 
ED50 of Ligand   ED50 of Morphine   Ref. 
MGM‐9 
(s.c.) 
Male ddY mice (25‐33 g), 
55±0.2° C, 30s, no info, %CL 
 
~95% (2.0mg/kg, 7.5 
min) 
~90% (8mg/kg,  
30 min) 
0.70  mg/kg  4.08 mg/kg  (171) 
MGM‐9 
(p.o.) 
Male ddY mice (25‐33 g), 
55±0.2° C, 30s, no info, %CL 
 
~90% (8mg/kg, 7.5 
min) 
~80% (100mg/kg, 
30 min) 
2.98 mg/kg   48.2 mg/kg  (171) 
4 (i.c.v.)  Male Albino mice (20‐26 g), 
55±0.5° C, 240s, no info, %CL 
 
~100% (0.1µg, 10µl, 
10 min) 
n/a  0.06µg  n/a  (317) 
4 (i.p.)  Male Albino mice (20‐26 g), 
55±0.5° C, 240s, no info, %CL 
 
82% (10 mg/kg, 15 
min) 
n/a  1.160 mg/kg  n/a  (317) 
11 (i.c.v.)  Male albino (CD1) mice (20‐26 
g), 55±0.5° C, 240 s, no info, 
%CL  
 
~90% (0.1µg, 10µl, 
10 min) 
n/a  n/a  n/a  (318) 
11 (i.p.)  Male albino (CD1) mice (20‐26 
g), 55±0.5° C, 240s, no info, 
%CL 
 
~84% (10  mg/kg, 15 
min) 
n/a  n/a  n/a  (318) 
KGNOP1 
(13a) 
Male SD rats (250‐350 g), 
52±0.2° C, 60s, %CL 
~30% (0.34 µmol/kg, 
180 min) 
~90% (17.52 
µmol/kg, 180 min) 
0.41 µmol/kg  14.7 µmol/kg  (341) 
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The antinociception of four non-bifunctional ligands was further tested using spinal nerve 
ligated animals. In these studies, antinociceptive latency or threshold were measured using 
Hargreaves’ method or von-Frey filaments respectively (Table 11), which assess peripheral 
antinociception (342). In this setting, [Dmt1]DALDA produced paw withdrawal latencies and 
mechanical allodynia comparable to morphine, while similar effects were reported with 13a 
and DeNo using mechanical allodynia. Therefore, these non-bifunctional OLs appear to be 
effective against neuropathic pain (Table 11).  
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Table 11. Antinociceptive effects of non‐bifunctional opioid analgesic ligands using paw withdrawal latency and paw withdrawal threshold assays. 
Keys: MPE: maximum possible effect, ED50: effective dose 50 %, ‘~’ shows an approximate value, other values are Mean (± SEM (standard error 
mean)), SD: Sprague Dawley, s.c.: subcutaneous, i.t.: intrathecal. n/a: not applicable/available. SNL: spinal nerve ligated, CPIP: Chronic Postischemia 
Pain, MOR: morphine, GAB: gabapentin, DRM: dermorphin, VE: vehicle. 
 
Ligands: 
(admin route) 
Animal, assay, Cut‐off 
latency, baseline latency, 
%MPE  
 %MPE or latency of Ligand 
(dose, post admin time) 
%MPE or latency of Reference  
(dose, post admin time) 
ED50 of 
Ligand  
ED50 of 
Reference 
ligand 
Ref. 
Paw withdrawal latency assay (SNL rats) 
[Dmt1]DALDA   Male SD rats, R/H, 20s, 
8.01 ±0.17s   
15s (0.71 mg/kg, 120 min)  MOR: 12s (5.4 mg/kg, 30 min)  n/a  n/a  (297) 
Mechanical allodynia assay (SNL rats) 
Ligands: 
(admin route) 
Animal, assay, baseline 
threshold 
 Peak threshold  of Ligand  Threshold  of Reference   ED50 of 
Ligand 
ED50 of 
Reference 
ligand  
Ref. 
MGM‐16 (s.c.)  Male ddY mice, no info  ~1.4 g (0.4mg/kg, 30 min) 
 
VE: ~0.75 g (30 min)  n/a  n/a  (300) 
MGM‐16 (p.o.)  Male ddY mice, no info  ~1.3g (2.0mg/kg, 30 min)  GAB: ~0.4g (100mg/kg, 30 min) 
VE: ~0.65g (30 min) 
n/a  n/a  (300) 
[Dmt1]DALDA 
(s.c.) 
Male Long Evans rats 
(250‐450g), 0.25g ‐ 15g, 
CPIP model 
 
~15 g (0.5 mg/kg in 0.5 
ml,180 min )  
MOR: ~15 g (2 mg/kg, 40 min)  0.10±0.05 
mg/kg  
1.55±0.66 
mg/kg 
(343) 
DeNo (i.t.)  Male SD rats (280‐300 g), 
40‐150 g, ~ 60 g 
 
~100 g (1nmol, 10 µl, 60 min)  DRM: ~130 g (1nmol, 10 µl, 45 
min) 
n/a  n/a  (319) 
13a (i.t.)  Male CD1 mice (30‐35 g), 
0.6 g ‐ 6 g, 6 g, CCI model 
~6 g (0.05 nmol, 30 min)  MOR: ~4.5 g (35 nmol, 30 min)  0.003 nmol  7 nmol  (316) 
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1.2.6.3. Effects of non-bifunctional ligands on antinociceptive tolerance development 
Apart from testing acute antinociception, some limited testing for antinociceptive tolerance 
was performed. Four different non-bifunctional analgesics were assessed in mice using 
repeated administration over 3 to 8 days using spinal antinociceptive assays (Table 12). In 
addition, tolerance to antinociceptive effects was measured as ED50 shifts compared to the first 
treatment day. Overall, these four non-bifunctional ligands showed reduced tolerance to 
morphine, which is similar to the results obtained with the bifunctional opioid analgesics (Table 
12). 
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Table 12. The effects of non‐bifunctional opioid analgesic ligands on sub‐chronic administration and antinociceptive tolerance. Keys: ED50: effective 
dose  50%,  ‘~’  shows  an  approximate  value,  other  values  are  shown  as  Mean.  TF:  tail  flick  assay  by  radiant  heat,  TFL:  tail‐flick  latency,  s.c.: 
subcutaneous,  i.c.v.:  intracerebroventricular,  i.p.:  intraperitoneal,  i.t.:  intrathecal,  n/a:  not  applicable/available,  MOR:  morphine.  (Note:  Same 
experimental conditions/animals apply for the TF or WWTW assay with acute administration. 
 
Ligand 
 
Procedure summary 
 
Result  %MPE of ligand  % MPE of 
morphine 
Tolerance 
ED50 shift 
of Ligand  
Tolerance 
ED50 shift of 
Morphine 
Ref. 
MMP‐
2200  
MOR  or  MMP‐2200  were 
administered at ED90 doses (b.i.d.) 
for  3  days  and  tested  on  day  4. 
Antinociceptive  tolerance  was 
measured using WWTW (55° C). 
 
Less ED50 shifts  
than MOR 
(less tolerance 
than MOR) 
Day 1: ~90%  Day 1: ~100%  4.8 fold  12.8 fold 
 
(151) 
AN81  
 
 
AN81  (4 mg/kg  i.v.)  and MOR  (4 
mg/kg  i.p.)  once  daily  were 
administered  for 5 days. TFL was 
measured days 1 and 5. 
Morphine 
tolerance: Day 5 
AN81  
tolerance:  Day 5 
 
Day 1:  ~100%,  
Day 5: 34.99% 
Day 1: ~80% 
Day 5: ~0% 
n/a  n/a  (184) 
MGM‐9   MGM‐9  (1  mg/kg  s.c.)  and MOR 
(8mg/kg  s.c.)  were  administered 
twice  daily  for  5  days.  TFL  was 
measured on days 1, 3 and 5. 
Morphine 
tolerance:  Day 3 
MGM‐9 
tolerance: Day 5 
  
Day 1: ~85% 
Day 3: ~70% 
Day 5: ~50% 
Day 1: ~90% 
Day 3: ~55% 
Day 5: ~35% 
n/a  n/a  (171) 
BN‐9  MOR (4 nmol i.c.v. and 2 nmol i.t.) 
and BN‐9 (0.5, 1 and 2 nmol i.c.v. 
and  i.t.) were  administered  once 
daily  8  days.  TFL  was  measured 
daily. 
Morphine 
tolerance: Day 4 
BN‐9 tolerance:  
No tolerance 
Day 1: ~95% 
(i.c.v.), ~90% (i.t.)  
Day 4 to 8:  
no change 
Day 1: ~90% 
(i.c.v.), ~95% (i.t.)  
Day 4:~50% 
(i.c.v.), ~80% (i.t.) 
n/a  n/a  (178) 
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1.2.7. Opioid analgesics with an incomplete pharmacological profile 
1.2.7.1. Pharmacological effects of opioid ligands with an incomplete profile 
Apart from bifunctional and non-bifunctional opioid analgesics, some other OLs were reported 
over the described time-period, but only with incomplete pharmacological profiles. All of these 
sixteen OLs are described as MOP receptor agonists with some effects on other opioid 
receptors (Table 5). While these compounds were reported for their antinociceptive effects, no 
antinociceptive tolerance profiles have been reported for these ligands so far. 
1.2.7.2. Antinociceptive effects of opioids with an incomplete pharmacological profile 
Among the sixteen OLs with an incomplete pharmacological profile, ten compounds (62%) 
showed antinociceptive effects in three different animal species (Table 13). These compounds 
showed efficacy using intrathecal (5) and intravenous (3) administration, while none of these 
compounds was orally active. However, most of these ligands produced similar or better 
antinociception compared to morphine (Table 13). In addition to the tail-flick test, compounds 
1 (323) and 11a (333) were also tested using the hot-plate assay where ligand 11a produced 
antinociception levels similar morphine. Ligand 1 reportedly produced full antinociception 
after intracerebroventricular (i.c.v.) administration, whereas it achieved only 50% 
antinociception after intravenous (i.v.) injection. In contrast, morphine produced more 
antinociception using i.v. administration compared to i.c.v. administration (Table 14).  
Therefore, it is important to note that opioid-induced antinociception can be significantly 
influenced by its route of administration.  
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Table 13. The antinociceptive effects using tail‐flick assay of opioids with an incomplete pharmacological profile. Keys: MPE: maximum possible 
effect, ED50: effective dose 50%, ‘~’ shows an approximate value, other values are Mean, CL: cut‐off latency, WWTW: warm water tail withdrawal 
assay, TF: tail flick assay by radiant heat, TFL: tail‐flick latency, s.c.: subcutaneous, i.c.v.: intracerebroventricular, i.t.: intrathecal, i.v. intravenous. n/a: 
not applicable/available.  
 
Ligands 
(admin 
route) 
Animal, assay, Cut‐off 
latency, baseline 
latency, %MPE 
 %MPE of Ligand (dose, 
post‐admin time) 
%MPE of 
Morphine (dose, 
post‐admin time) 
ED50 of 
Ligand 
ED50 of 
Morphine 
Ref. 
10 (i.t.)  Male Whister rats (200‐
250 g), no info, % 
biphalin i.t., latency  
 
99‐100% (8.40 nmol, 30 
min) 
~40% (7.80 nmol, 
20 min) 
n/a  n/a  (321) 
RV‐Jim‐C3 
(i.t.) 
Male ICR mice (20‐25g), 
WWTW 52°C , 15 s, <7 s, 
%CL 
 
~80% (10μg, 15 min)  n/a  3.92µg  n/a  (322) 
1(i.c.v.)  Male CD‐1 mice (25‐30 
g), TF, 15 s, no info, %CL 
 
~85% (0.6 nmol, 30 
min) 
~25% (0.6 nmol, 30 
min) 
n/a  n/a  (323) 
1(i.v.)  Male CD‐1 mice (25‐30 
g), TF, 15 s, no info, %CL 
 
51.3±7.3% (3 μmol, 30 
min)  
~90% (3 μmol, 30 
min) 
n/a  n/a  (323) 
SR14150 
(s.c.) 
Male CD1 mice, TF, 15 s, 
6.25 s, %CL 
 
~75% (30 mg/kg, 60 
min) 
~95% (15 mg/kg, 
60 min) 
n/a  n/a  (344) 
SR14150 
(s.c.) 
Male ICR SNL mice (20‐
25 g), 15 s, 4.17 s, 
latency  
80% (10 mg/kg, 30 min)  93% (10 mg/kg, 30 
min) 
n/a  n/a  (296) 
SR14150 
(s.c.) 
Male ICR mice (20‐
25g),TF, 15 s, 4.1 s, % CL 
~100% (30 mg/kg, 60 
min) 
~90% (10 mg/kg, 
30 min) 
n/a  n/a  (283) 
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Ligands 
(admin 
route) 
Animal, assay, Cut‐off 
latency, baseline 
latency, %MPE 
 %MPE of Ligand (dose, 
post‐admin time) 
%MPE of 
Morphine (dose, 
post‐admin time) 
ED50 of 
Ligand 
ED50 of 
Morphine 
Ref. 
SR16507 
(s.c.)  
Male ICR mice (20‐
25g),TF, 15 s, 
4.11 s, % CL 
 
~95% (3 mg/kg, 30 min)   ~85% (10 mg/kg, 
30 min) 
n/a  n/a  (283) 
Tapentadol 
(i.v.) 
Beagle dogs, 
TF, 12 s, 3‐5 s, 
%CL 
 
~100% (6.81mg/kg, 10 
min)  
~100% (1.0mg/kg, 
10 min)  
4.3 mg/kg   0.71 mg/kg  (345) 
13 (i.t.) 
 
Male Wistar rats (300‐
350g), TF, 9 s, 1.4 s, 
latency 
 
Max latency: ~8.5s 
(10nmol, 5µl, 30 min) 
Max latency: ~7.5s 
(35nmol, 5µl, 30 
min) 
n/a  n/a  (330) 
5 (AKG127)  ICR mice (15‐20g), 
WWTW 52° C, 10 s, 3‐6 s, 
%CL 
 
68.4±14% (0.1µg, 5µl, 
60 min) 
n/a  n/a  n/a  (331) 
26 (i.c.v.) 
 
Male C57BL/6 mice, 
WWTW 55° C, 15 s, %CL  
 
~90 % (30 nmol, 5 µl, 
20 min ) 
~95% (10 nmol, 5 
µl, 30 min ) 
1.98 nmol   2.35 nmol   (332) 
22 (i.t.)  Male Wistar rats (250‐
300 g), TF, 9 s, 2 s, %CL 
~95% (11 nmol, 30 min)  ~85% (35 nmol, 30 
min) 
2.78 nmol   0.49 nmol   (293) 
22 (i.v.)  Male C57BL6 mice (25‐
28 g), TF, 7s, 2s, % CL 
~90% (10.8 µmol/kg, 30 
min) 
~30% 
(12.5µmol/kg, 30 
min) 
n/a  n/a  (293) 
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Table 14. Antinociceptive effects using hot‐plate assay of opioids with an incomplete pharmacological profile. Keys: MPE: maximum possible effect, 
ED50: effective dose 50%, ‘~’ shows an approximate value, other values are Mean ± SEM (standard error mean), CL: cut‐off latency, HP: hot plate, 
FEN: fentanyl, i.c.v.: intracerebroventricular, i.p.: intraperitoneal, i.v.: intravenous.  
 
Ligands 
(admin route) 
Animal, assay, Cut‐off latency, baseline latency, 
%MPE  
 %MPE of Ligand (dose, post 
admin time) 
%MPE of Morphine (dose, 
post admin time) 
Ref. 
1 (i.c.v.)  Male CD‐1 mice (25‐30 g), 55.0 ± 0.1° C, 60s, no 
info, %CL 
 
~100% (30 min)  ~30% (30 min)   (323) 
1 (i.v.)  Male CD‐1 mice (25‐30 g), 55.0 ± 0.1° C, 60s, no 
info, %CL  
 
52.4±8.5% (30 min)   ~80% (30 min)  (323) 
11a (i.p.)  Albino Balb/c mice (25‐30 g) (no info of sex),  
55° C, 25 s, 7.8 s,  %CL 
~85% (40 mg/kg, 15 min)  ~90% (10 mg/kg, 15 min)  (333) 
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1.3. Novel UTAS-derived opioids 
Previously, the potential of combined bifunctional MOP receptor agonist / DOP receptor 
antagonist to reduce antinociceptive tolerance was highlighted (282,306,346). One of the most 
widely discussed ligands of this class is UFP-505 (H-Dmt-Tic-Gly-NH-Bzl) (306) (Fig. 2). It 
is believed that ‘Dmt-Tic’ peptides are required for DOP receptor antagonism and the spacer 
(Gly-NH) and third aromatic ring (Bzl) of UFP-505 is required for MOP receptor agonist 
activity (347,348). This compound was synthesised and characterised as compound 6 as part 
of a drug optimisation study to develop a DOP receptor antagonist and MOP receptor agonist 
(348). Later it was renamed to “University of Ferrara Peptide 505” (UPF-505) (349). In a recent 
study, Dietis and colleagues characterised that UFP-505 displays a variable expression-
dependent efficacy (antagonist or partial agonist) at the DOP receptor (chapter 6) (350). Several 
previous studies reported the effects of opioids with mixed selectivity profile on multiple 
receptors based on the “Dmt-Tic” pharmacophore (348,351,352,353). After repeated 
intrathecal (i.t.) administration over a period of 3 days, UFP-505 produces less antinociceptive 
tolerance compared to morphine (354). On the other hand, UFP-505 increases antinociceptive 
tolerance and produces toxicity after intracerebroventricular (i.c.v.) administration (306). 
Moreover, UFP-505 was not an effective antinociceptive agent after systemic (subcutaneous or 
intravenous) administration (354). Novel analogues of UFP-505 with better bioavailability via 
clinically relevant routes of administration (e.g. subcutaneous, oral or intravenous) appear as 
attractive molecules for further development. 
 
69 
 
 
 
Figure  2.  Chemical  structure  of UFP‐505  (H‐Dmt‐Tic‐Gly‐NH‐Bzl). Key:  Dmt:  2‘,6‘‐dimethyl‐l‐
tyrosine, Tic: 1,2,3,4‐tetrahydroisoquinoline‐3‐carboxylic acid, Gly: Glycine, Bzl: Benzyl. 
 
So far, it was assumed that the Dmt-tic (benzyloxy-methylene group) pharmacophore of UFP-
505 is essential for the agonistic effect on the MOP receptor and the antagonistic effect on the 
DOP receptor. To improve our understanding of the structure-activity relationship of UFP-505, 
six analogues of UFP-505 were synthesised by A/Prof Jason Smith (Division of Chemistry, 
University of Tasmania). These analogues included modifications of the “Tic” and 
hydrocarbon chain between the “NH” and “Bnz” groups, without any modification on the 
“Dmt” structure. Apart from providing a better understanding around the structure-activity 
relationship of this compound, these changes were intended to assess the suitability to alter the 
chemical structure of UFP-505 from a peptide to a peptidomimetic that might be effective via 
an oral route of administration.  
1.4. Role of opioids in insulin homeostasis 
In addition to the effects of morphine and other opioids on pain on antinociception, tolerance 
and behaviour, opioids are also used to mitigate pain in different metabolic disorders. However, 
the connection between the opioidergic system and the pancreatic metabolic system (e.g. 
glucose homeostasis) is important for diabetes patients. Diabetes mellitus is a metabolic disease 
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characterised by hyperglycemia, caused by either decreased pancreatic insulin secretion or an 
imbalance of insulin and glucose levels (355,356,357,358).  
Globally, an ageing population is responsible for the highest opioid use, while this population 
is also increasingly susceptible to diabetes mellitus (359,360). Nearly one-third of diabetes 
patients experience neuropathic pain due to diabetes-induced nerve injury and nearly one-fifth 
of these patients suffer from chronic pain (361,362). Clinically used opioids like morphine or 
fentanyl are effective for the management of chronic or surgical pain, however, their effects in 
diabetic neuropathy are not fully understood (363). Opioid combinations (e.g. hydrocodone 
combinations, oxycodone, propoxyphene), topical preparations (e.g. lidocaine patches), 
anticonvulsants (e.g. gabapentin, pregabalin), antidepressants (e.g. amitriptyline, nortriptyline, 
venlafaxine, sertraline), ion-channel blockers, skeletal muscle relaxants (e.g. cyclobenzaprine) 
and different NSAIDs are also used to treat the patients with diabetic neuropathy (DPN) 
(364,365). Pregabalin, duloxetine and tapentadol are also known to be effective to manage 
neuropathic pain in patients experiencing DPN (366,367,368,369,370).  
Different preclinical studies showed opioid-induced hypoglycaemia (reduction of blood 
glucose) in non-diabetic and diabetic animals (371,372,373,374,375), whereas several other 
animal studies showed opioid-induced hyperglycaemia (increase in blood glucose) 
(376,377,378,379,380). Studies show that MOP or KOP receptor agonist opioids induce 
hypoglycaemic effect (371,372,373,374,375) but DOP receptor agonist opioids can produce 
hyperglycaemia (380). In contrast, in healthy individuals as well as in non-diabetic patients 
opioids have only been reported to induce hypoglycaemia in the clinic 
(381,382,383,384,385,386). The opioid antagonist naloxone can help to prevent this 
hypoglycaemic response in healthy individuals as well as in diabetic patients (387,388). The 
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exact mechanism how opioids regulate glucose homeostasis is not clear but it might be related 
to a direct effect on insulin secretion as reported in a clinical case report (381) where 
unintentional exposure of methadone increased insulin secretion in an 11-month-old individual. 
Opioids therefore might have a short-term impact on the reduction of blood glucose levels in 
T2DM patients but the long-term effects of opioids on blood glucose levels are not clearly 
understood (389). Overall, opioids produce hypoglycaemic effects in either diabetic and non-
diabetic patients or healthy people.  
Activation of peripheral MOP receptors (by endogenous (e.g. β-endorphin) and exogenous 
opioids (e.g. loperamide) may increase glucose utilisation in the insulin-secreting pancreatic 
cells through the phospholipase C and protein kinase C (PLC-PKC) pathway (390). Similarly, 
activation of DOP or KOP receptor can reduce hyperglycaemia through increased glucose 
utilisation (372,391). Since insulin secretion can be blocked by an opioid antagonist like 
naloxone, it is likely that insulin secretion is affected by opioid receptors (392). Therefore, 
opioid receptors contribute to insulin-glucose homeostasis. However, while some studies 
showed stimulating effects of opioid agonists on insulin release from pancreatic cells 
(392,393,394,395,396,397,398), other studies reported opioid-dependent inhibition of insulin 
secretion (399,400,401,402,403,404). The discrepancy is likely a consequence of different 
methodologies or tools used in these studies, such as primary cell lines (e.g. β-cells) perfused 
organs, tissues or live animals. Therefore, understanding the specific roles of opioid receptors 
on insulin homeostasis is important to predict the effect of specific OLs on diabetic neuropathy. 
Therefore, the present study investigated the effects of different selective OLs on opioid-
mediated insulin release in a pancreatic β-cell line. 
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1.5. Age-dependent antinociception and behavioural effects of opioids 
Similar to diabetes and neuropathy, the prevalence of surgical and chronic pain is high among 
individuals over 60 years of age and therefore this population represent the largest cohort of 
opioid users (405). Since most preclinical studies are using adult animals to measure 
antinociceptive and behavioural effects of opioids, there is a consistent lack of available data 
from aged animals. This lack of data is particularly important for this high opioid-user age-
cohort as it could inform the clinical use of opioids in older individuals. Morphine is a widely 
used opioid with different psychological and behavioural adverse effects but also with a very 
narrow therapeutic index (406,407,408). The pharmacokinetics of opioids significantly impact 
the balance between adequate pain-relief and minimal adverse effects (409,410,411). In the 
clinic, pharmacological pain management is approached by adjusting drug dose using different 
subjective calculations, but these are inconsistent and subjective to the specific clinical setting 
(i.e. hospital or clinic) (409,410,411,412,413). Some clinical studies observed differences in 
physiology, drug-receptor interactions and opioid kinetics between older and younger patients 
(414,415,416). Similar to those clinical studies, differential effects of morphine have also been 
described between older and younger animals, but these results are inconclusive 
(417,418,419,420,421,422). Most studies reported lower antinociception in older animals after 
administration of the same mg/kg doses of morphine (417,418,419,420,421), while one study 
showed no differences between aged and young animals (422). The reported variations are 
likely the consequence of experimental differences with regards to the use of animal species, 
age of animals, testing methods and other experimental conditions (417,418,419,420,421,422). 
In addition, in most preclinical studies, there is only sporadic evidence for simultaneous 
measurements of antinociception, behavioural effects and its connection to morphine 
pharmacokinetics. However, in the clinic, differential body composition and altered ADME 
parameters of elderly patients may result in different response to morphine compared to 
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younger patients. Drug-drug interactions are also prevalent among the elderly, as they are 
typically using multiple drugs simultaneously (423,424). In addition, age-dependent 
cytochrome P450 (CYP) enzyme activities and/or impaired renal function in older patients may 
contribute to opioid toxicity (424,425,426,427,428). Therefore, the evidence-based dosing of 
opioids in the elderly population is an urgent need to achieve effective pain-control while 
ensuring the safety of these patients.  
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CHAPTER TWO 
 
Morphine dosing strategy plays a key role in the 
generation and duration of the produced 
antinociceptive tolerance   
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Preface to chapter two 
 
Long-term use of morphine and other opioids in the clinic is limited due to its analgesic 
tolerance and other adverse effects, as described in chapter one. The role of morphine dosing 
in the manifestation of analgesic tolerance is not known over a period of long-term treatment, 
as most of the preclinical studies were conducted over a few days (chapter one, Table 2). The 
object of this study (chapter two) was to design an optimised dosing strategy (starting dose, 
follow-up dose after tolerance, the frequency of daily dosing and duration of treatment) to delay 
morphine-induced antinociceptive tolerance after chronic treatment.   
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2. Morphine dosing strategy plays a key role in the generation and duration of the 
produced antinociceptive tolerance 
 
Abstract  
Antinociceptive tolerance after repetitive administration of morphine severely limits its clinical 
use. Despite an increased mechanistic understanding of morphine tolerance, little is known 
about the influence of dosing regimens in its development. I hypothesised that the starting dose 
of morphine, dosing frequency and dose increments, influence antinociception and the 
manifestation of antinociceptive tolerance in rats.  Male rats were randomly divided into four 
groups with different intermittent starting-doses of daily morphine (b.i.d.) followed by different 
increments of single-dose morphine upon development of antinociceptive tolerance, for 2-3 
weeks: 2.5 (b.i.d.)  5  10  15 mg/kg/day, 5 (b.i.d.)  10 mg/kg/day, 5 (b.i.d.)  15 
mg/kg/day, 10 (b.i.d.)  20 mg/kg/day. Antinociception was assessed daily pre-treatment and 
at several time-points over two hours post-administration, using tail-flick and hot-plate assays. 
Tolerance was defined as significant antinociceptive desensitisation and was presented as a 
significant reduction of the maximum and total antinociceptive efficacy upon morphine 
administration. Rats commenced on 2.5 mg/kg/day (b.i.d.) morphine developed tolerance faster 
than those started on 5 or 10 mg/kg/day (b.i.d.). Higher starting and maintenance doses of 
morphine compared to the previous dosing regimen produced prolonged antinociception and 
delayed tolerance. In contrast, lower starting and maintenance doses of morphine produced less 
total antinociception during the course of treatment and did not delay the onset of tolerance, 
but require smaller dose-increments to reach antinociception after the development of 
antinociceptive tolerance. These results suggest that morphine starting dose, dosing frequency, 
increments and timing determine the manifestation of antinociceptive tolerance and extent of 
antinociception. In addition, these results also highlight the need for generally standardised and 
validated assay protocols and procedures to compare different studies, as a prerequisite to 
translate pre-clinical results into the clinic. 
 
Keywords: morphine; dosing regimen; antinociceptive tolerance; antinociception. 
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2.1. Introduction 
Morphine is one of the most effective and widely prescribed drugs against chronic pain (22). 
The efficacy of long-term opioid treatment of chronic pain is debated in clinical practice due 
to the risk of unwanted side effects such as respiratory depression, sedation, chronic 
constipation, fluid retention, addiction, hyperalgesia, compromised immune function and 
antinociceptive tolerance (111,112). Tolerance manifests as decreased drug efficacy following 
repeated administration of the same drug (113). It necessitates increased dosing in order to 
maintain efficacy and represents the biggest problem for long-term pain management. To 
understand the factors influencing antinociceptive tolerance several distinct molecular 
mechanisms have been proposed, such as receptor trafficking and regulation, molecular 
desensitisation as well as receptor dimerisation (68,126,127,128,129,429). In addition, 
morphine can be administered in three different chemical forms, at different frequencies, using 
different routes of administration, all of which reportedly modify the extent of tolerance 
(140,154,180,183,429).  
Nevertheless, there is very little information if and how morphine dosing itself can influence 
the development of its tolerance or its extent after long-term administration. One study that 
reported a clear link between morphine dosing (magnitude of starting dose and increment dose) 
and tolerance was (179), where Duttaroy and colleagues showed that a lower increment dose 
produced a higher shift in morphine’s ED50 after 7 days of morphine’s administration. They 
concluded that increment of the dose was a stronger predictor of tolerance than starting dose. 
In later studies the same group explored the effect of opioid efficacy in the development of 
tolerance and reported that high efficacy agonists produce less tolerance than lower efficacy 
agonists at equi-effective doses (430), whereas Madia and colleagues (431) and Dighe and 
associates (148) reported that the dosing method also plays a role in the development of 
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tolerance, with continuous administration (infusions/pellets) producing more tolerance than 
intermittent dosing. Although these reports insinuate the existence of an inverse relationship 
between dosing increment and opioid efficacy with tolerance development, the short-term 
administration protocols used in these studies do not reflect the molecular complexity of 
tolerance in long-term opioid exposure.  
One major drawback of most pre-clinical studies that investigate the development of 
antinociceptive tolerance in rodents, is the methodology used for describing tolerance. One 
traditional method that has been widely used in the past is the cumulative administration of an 
opioid after pre-exposure to opioids and the description of a shift in the ED50 value of the 
generated dose-response curves. However, since the continuous exposure to opioids is known 
to be tightly related with molecular changes in opioid receptor behaviour, expression and 
desensitisation, it is highly likely that this traditional method of describing antinociceptive 
tolerance influences the outcome of the response that it is meant to describe. Although this 
method for describing antinociceptive tolerance might be acceptable in the area of basic 
pharmacology for the purpose of pharmacological profiling of an opioid, it does not reflect the 
way we understand and manage tolerance in a clinic. In a clinical setting, tolerance to opioids 
is detected as a reduction of the patient’s analgesic response (efficacy) to non-analgesic levels 
after long-term administration of opioids (usually intermittent). The extent and grade of the 
patient’s manifested tolerance is complete only after the patient returns to sufficient analgesia 
following the administration of a higher dose of the same opioid or the administration of a 
different opioid with higher efficacy. In an effort to bypass the above limitations in the 
exploration of tolerance, I designed a study that uses a method that reflects more accurately the 
way we understand and manage tolerance in the clinic, by using the significant drop of efficacy 
(response) and the overall analgesia experienced over a set period of time after repetitive 
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administration of opioids, as the two main markers of tolerance-development rather than the 
shift of the opioid’s potency at a specific end-point. I believe that this method reflects more 
accurately the method we use today in the clinic to detect and manage opioid tolerance, and 
therefore the conclusions from this study might help us understand better the existing 
relationship between opioid dosing regimen and opioid tolerance.  
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2.2. Methods 
2.2.1. Animal maintenance and care 
Twenty-four male Sprague-Dawley (SD) rats (238.0 ± 6.2 g, 8 weeks), supplied by the animal 
services of the University of Tasmania were housed as three littermates per cage at 22 ºC with 
50-60 % humidity under an automated 12 hour day/night cycle (lights on at 7:00 am) with free 
access to food (Barastoc rodent cubes, Ridley Corporation, Melbourne, Australia) and water. 
Only male rats were used to avoid any possible effects of the oestrous cycle of female rats 
(336). Measurement of nociception was performed according to the ethical guidelines for 
investigations of experimental pain in conscious animals (432,433). Moreover, all procedures 
and handling were approved by the University of Tasmania Animal Ethics Committee 
(A0013864) and were conducted according to The Australian Code for the Care and Use of 
Animals for Scientific Purposes (434). The experiments were also in compliance with the 
ARRIVE guidelines (435).  
2.2.2. Treatment protocol 
Weights were recorded daily immediately prior to experiments in order to determine the dosage 
for each rat and it was calculated based on their body weights from a commercially available 
30 mg/ml morphine sulphate solution (Hameln Pharmaceuticals GmbH, Germany). The drug 
was administered by daily subcutaneous injections between the space between left thigh and 
the spine. All rats were randomly divided into four subgroups and different sub-groups received 
different dosing-regimes of morphine (Fig. 3). 
Group 1 (n = 5): Morphine sulphate 2.5 mg/kg/day (twice daily, b.i.d.) for 5 days, followed by 
a single dose of 5 mg/kg/day from day 6 to 10, 10 mg/kg/day from day 11 to 18, and 15 
mg/kg/day from day 19 to 23.  
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Group 2 (n = 5): Morphine sulphate 5 mg/kg/day (b.i.d.) for 5 days, followed by a single dose 
of 10 mg/kg/day from day 6 to 14. 
Group 3 (n = 8): Morphine sulphate 5 mg/kg/day (b.i.d.) for 5 days, followed by a single dose 
of 15 mg/kg/day from day 6 to 14. 
Group 4 (n = 6): Morphine sulphate 10 mg/kg/day (b.i.d.) for 10 days, followed by a single 
dose of 20 mg/kg/day from day 11 to 14.  
 
Figure 3. Schematic diagram of morphine dosing strategy. Twenty‐four Sprague Dawley rats 
were randomly divided into four groups (A, B, C and D). All of these animals were treated with 
morphine at multiple escalating doses: 2.5 (b.i.d.)  5  10  15 mg/kg/day (group A), 5 (b.i.d.) 
 10 mg/kg/day (group B), 5 (b.i.d.)  15 mg/kg/day (group C) and 10 (b.i.d.)  20 mg/kg/day 
(group D) over 14 to 23 days, as described in Methods. 
 
The intensity of laboratory illumination was reduced prior and during experiments to minimise 
any potential discomfort to the animals. At the end of the observation period, animals were 
anesthetised with 5% (w/v) isoflurane in oxygen at a flow rate of 1 L/min, until the animal was 
unconscious (usually 5-7 min), before decapitated.  
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2.2.3. Assessment of antinociception  
Nociceptive thresholds were determined by two independent assays performed (tail-flick & hot 
plate) using commercially available tail-flick and hot/cold plate assay equipment (Ugo Basile, 
Comerio, Italy). The maximum exposure to the nociceptive thermal stimulus was 15 sec for the 
tail-flick (basal latency: 3.93 ±0.18 sec) and 30 sec for the hot-plate assay (basal latency: 5.69 
±0.15 sec). The infrared intensity of the tail-flick photocell was set at 30, whereas the plate 
temperature of the hot-plate was set at 54 ±0.5 °C. Every rat was tested immediately prior to 
morphine administration to obtain the basal measurement and at 15, 30, 60 and 120 min post-
administration in both assays on the first and the last treatment day for every morphine dose. 
On all other days, the rats were tested pre- (basal) and 30 min post-administration of morphine. 
Nociception measurements were conducted in a blinded manner and the mean of three 
independent measurements for each time-point with a 1 min interval between measurements 
was recorded to minimise the ‘handling’ effects. The maximum possible effect (MPE) was 
defined as MPE % or antinociception = 100 X [(test latency – baseline latency)/(cut-off time – 
baseline latency)] as previously described (436). Where “baseline latency” is the basal 
measurements prior to injections of that particular test-day or test-time. Basal latencies (in 
seconds) from day 1 to day 14 of all group of rats were not significantly different from day 1 
(Fig.4). Typically, antinociceptive tolerance is described either as the percentage of the 
maximum possible antinociceptive effect (MPE %), area under the curve (AUC) of the 
antinociceptive effect, a shift of its dose-response curve to the right, or the fold-shift of its 
median effective dose (ED50) from naive to tolerant animals (140,149,429).  Here, the 
antinociceptive effect was measured by two different methods (MPE % and AUC) in order to 
express changes in time-dependent and total efficacy over the course of treatment.   
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Figure 4. Basal antinociception of rats. Antinociceptive latencies of morphine in male Sprague 
Dawley rats at pre‐administration (basal) were measured using the tail‐flick (A) and hot‐plate (B) 
assays.  The  antinociception  is  represented  as  latency  in  seconds  (sec).  Group A,  B,  C  and D 
represent different morphine‐treated rats as described in Methods. All data are represented as 
Mean ± SEM derived from n = 5 ‐ 8 rats. No statistically significant differences were observed 
against day 1 using one‐way ANOVA with Dunnett’s multiple comparisons tests. 
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2.2.4. Statistical analysis 
Data are expressed as mean ± SEM and analysed by one-way ANOVA with Dunnett’s or 
Tukey’s multiple comparisons (post hoc) test or unpaired t-test with Welch’s correction, using 
GraphPad Prism V6 software (GraphPad Software Inc., La Jolla, CA, USA). Multiple 
comparisons tests were employed when F was achieved p < 0.05 and there was no significant 
variance in homogeneity. A ‘p’ value less than 0.05 was considered statistically significant.  
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2.3. Results 
2.3.1. Morphine-induced tolerance is delayed by higher morphine doses 
To gain a basic understanding of morphine-induced tolerance in my experimental setting, rats 
were treated with two daily morphine doses of up to 10 mg/kg/day and the resulting 
antinociception was assessed daily over a period of 5 days. Before morphine administration, 
no significant differences in basal antinociception (day 0) were observed in the three dosing 
groups (Fig. 5 A-C), in both the tail-flick (circles) and hot-plate assays (squares). Upon 
morphine administration on day 1, all animals produced a significant antinociceptive response 
within 30 min of injection. However, only animals treated with 5 mg/kg/day (b.i.d.) (Fig. 5 B) 
or 10 mg/kg/day (b.i.d.) (Fig. 5 C) reached 100 % antinociception, while in the dose-group of 
2.5 mg/kg/day (b.i.d.), morphine produced only 43.6 ± 7.4 % and 30.6 ± 2.4 % antinociception 
in the tail flick and hot plate assays respectively on day 1 (Fig. 5 A).  
Overall, there was a trend that antinociception in the tail-flick assay measured higher 
antinociception levels compared to the hot plate assay. These differences were significant for 
the 5 mg/kg/day dose group on days 1, 2, 3 and 5 (e.g. on day 5: unpaired t-test; p < 0.05; t 
(9.65) = 2.62; Fig. 5 B) and in the 10 mg/kg/day dose group on day 3 (unpaired t-test; p < 0.05; 
t (5.00) = 2.74; Fig. 5 C), while for the 2.5 mg/kg/day dose group no significant differences 
were observed (Fig. 5 A). The development of antinociceptive tolerance in this system was 
defined as a significant reduction of antinociception compared to the response on day 1. For 
the lowest morphine dose, significant tolerance already manifested from day 2 and day 3 
onwards in the tail flick and hot plate assays respectively (Fig. 5 A).  
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Figure 5. Morphine‐induced tolerance. 
Antinociceptive effects of twice daily (8 
am,  5  pm)  s.c.  injections  of  morphine 
sulphate  were  tested  in  tail‐flick  (TF, 
circles)  and  hot‐plate  (HP,  squares) 
assays  in  male  Sprague  Dawley  rats. 
Antinociception  was  calculated  as 
maximum  possible  effect,  %  MPE,  as 
described  in Methods.  Antinociception 
was measured every morning (8‐10 am) 
over 5 days, 30 min post‐administration 
of  different  morphine  doses:  2.5 
mg/kg/day b.i.d. (A), 5 mg/kg/day b.i.d. 
(B),  and  10  mg/kg/day  b.i.d.  (C).  The 
areas under the curves (AUC) from A‐C 
were plotted against the corresponding 
morphine doses for each assay used (D), 
presenting  the  dose‐dependent 
increase of total antinociception from 5 
treatment days. All data are represented 
as mean ±SEM derived from n = 5 (A), n= 
13  (B),  n=  6  (D)  rats  per  group. 
Statistically  significant  differences 
compared  to  day  1  were  calculated 
using  one‐way  ANOVA  with  Dunnett’s 
multiple  comparisons  test  (*p  <  0.05, 
**p < 0.01  and ****p < 0.0001). Error 
bars  are  present  in  all  graphs  but  are 
sometimes too small to be visible. 
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In the 5 mg/kg/day (b.i.d.) morphine group tolerance was delayed by one day from day 3 in the 
tail flick and day 4 in the hot plate assay (Fig. 5 B). In contrast, 10 mg/kg/day (b.i.d.) morphine 
produced full antinociception (100 %) over the entire 5-day period with no significant tolerance 
observed (Fig. 5 C). To correlate morphine dose with antinociception, the areas under the 
curves (AUC) of Fig. 5 A-C were plotted against the respective morphine doses and good 
correlations between antinociception and morphine dose were observed for both the hot plate 
(R2 = 0.984) and tail flick assay (R2 = 0.821) (Fig. 5 D). 
2.3.2. Higher starting-doses and larger dosing-increments delay antinociceptive tolerance 
and produce higher total antinociception levels 
 
To further investigate the effect of morphine-dosing on the development of tolerance during 
the whole treatment period of 14 days, increasing concentrations of morphine were tested 
sequentially over a period of 2 weeks, while antinociception was measured by the tail flick 
assay. As described before (Fig. 5 A), 2.5 mg/kg/day (b.i.d.) daily morphine doses produced 
tolerance from day 3 onwards (Fig. 5 A). Under these conditions, a single morphine dose of 5 
mg/kg/day at day 6 restored antinociception to previous maximum levels (Fig. 6 A) as shown 
by the lack of significant difference in the levels of antinociception between days 1 and 6. With 
this reduced injection-frequency of the same daily morphine dose, tolerance reappeared 
immediately from day 7 and this effect could be again reverted by increasing the morphine 
dose to a single 10 mg/kg/day injection. Comparable to the previous lower doses, tolerance 
immediately reappeared one day later on day 12 (Fig. 6 A).  
The same paradigm was followed in the higher starting-dose group of 5 mg/kg/day (b.i.d.) 
morphine, which produced 100 % antinociception on day 1 (Fig. 6 B). Consistent with our 
previous results (Fig. 5 B), tolerance developed at day 4 and was overcome by a single 
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morphine dose of 10 mg/kg/day from day 6. Using this reduced frequency of administration by 
keeping the same daily dose, tolerance developed from day 9 until the end of the observation 
period (Fig. 6 B). Interestingly, under these conditions, antinociception (latencies in seconds) 
on day 14 was still significantly higher than the basal antinociception on day 0 (unpaired t-test; 
p < 0.05; t (3.57)  = 3.20).   
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Figure 6. Dose‐dependent morphine tolerance 
using tail flick assay. Antinociceptive effects of 
morphine  were  measured  in  male  Sprague 
Dawley  rats  30 min  post‐administration  (s.c.) 
using  the  tail‐flick  assay. Antinociception was 
calculated  as  percentage  of  the  maximum 
possible effect. Morphine was administered at 
multiple escalating doses: 2.5 (b.i.d.)  5  10 
mg/kg/day (A), 5 (b.i.d.)  10 mg/kg/day (B), 5 
(b.i.d.)  15 mg/kg/day (C) and 10 (b.i.d.)  20 
mg/kg/day  (D)  over  14  days,  as  described  in 
Methods. (E) The areas under the curves (AUC) 
of  the  antinociceptive  effects  of  (A)‐(D) were 
compared. All data are represented as Mean ± 
SEM  derived  from  n  =  5‐6  rats  per  group. 
Statistically  significant  differences  compared 
against day 1 (*p < 0.05, **p < 0.01 and ****p 
< 0.0001), against day 6 (#p < 0.05, ##p < 0.01, 
###p < 0.001 and ####p < 0.0001) or against 
day  11  (+p  <  0.05,  ++p  <  0.01  and  ++++p  < 
0.0001) are shown for the respective groups, as 
produced  from  one‐way  ANOVA  with 
Dunnett’s  multiple  comparisons  tests. 
Additionally,  significant  differences  between 
AUCs  of  different  groups  (A,  B,  C  and D)  are 
shown as **p < 0.01 and were calculated using 
one‐way  ANOVA  with  Tukey’s  multiple 
comparisons test. Error bars are present in all 
graphs  but  are  sometimes  too  small  to  be 
visible. 
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Since increasing the morphine dose after the first occurrence of tolerance appeared to produce 
increased levels of antinociception, I increased the second morphine dose of the next group 
even further, to 15 mg/kg/day (Fig. 6 C) from day 6, in order to evaluate whether a higher 
increment would produce higher antinociception. As seen before (Fig. 6 B), tolerance only 
occurred from day 6 in this treatment regime, manifesting a delayed tolerance and a higher total 
antinociception. Nevertheless, when 15 mg/kg/day morphine was administered from day 6 
onwards, the animals only became tolerant at day 12 (Fig. 6 C) and antinociception (latencies 
in seconds) on day 14 was still significantly higher than the basal response of day 0 (unpaired 
t-test; p < 0.05; t (2.30) = 7.18) (Fig. 6 C). In this paradigm, antinociception on day 14 (38.4 ± 
5.2%) was not significantly different from the antinociception on day 1 (43.6 ± 7.4 %) of the 
lowest starting-dose group (2.5 mg/kg/day b.i.d.). 
For the last group, a starting dose of morphine 10 mg/kg/day (b.i.d.) produced significant 
antinociception for 8 days, until significant tolerance developed on day 9. At day 10, 
antinociception was not statistically different from the basal value on day 0 (Fig. 6 D). 
Following the manifestation of tolerance, a single morphine dose of 20 mg/kg/day on day 11 
was able to produce a maximum antinociception (100 %) (Fig. 6 D). However, a subsequent 
morphine dose was unable to sustain antinociception and tolerance quickly developed at day 
12, which was sustained until the end of the test. Nevertheless, the antinociception level 
(latencies in seconds) at day 14 was still significantly higher than the basal at day 0 (unpaired 
t-test; p < 0.05; t (2.87) = 4.00) (Fig. 6 D), which demonstrates that a 14-day high-dose 
morphine treatment can manifest not only higher total antinociception but also delayed 
tolerance compared to low-dose treatments.     
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The total morphine-induced antinociception of the entire 2-week period from all four different 
dosing groups was calculated as AUC values and compared (Fig. 6 E), with significant 
differences observed between groups (Fig. 6; Group A vs. Group B, Group B vs. Group C, or 
Group A vs. Group C; One way ANOVA with Tukey’s multiple comparisons test; p < 0.01; F 
(3, 15) = 24.64). The corresponding latencies (in seconds) of Fig. 6 are shown in Fig. 7. 
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Figure  7.  Dose‐dependent  morphine 
tolerance  using  tail‐flick  assay. 
Antinociceptive  latencies  of  morphine 
in  male  Sprague  Dawley  rats  30  min 
post‐administration  (s.c.)  were 
measured using the tail‐flick assay. The 
antinociception  is  represented  as 
latency in seconds (sec). Morphine was 
administered  at  multiple  escalating 
doses: 2.5 (b.i.d.)  5  10 mg/kg/day 
(A),  5  (b.i.d.)   10  mg/kg/day  (B),  5 
(b.i.d.)    15  mg/kg/day  (C)  and  10 
(b.i.d.)   20  mg/kg/day  (D)  over  14 
days, as described in Methods. All data 
represent Mean ± SEM derived from n = 
5‐6  rats  per  group.  Statistically 
significant  differences  compared 
against day 1 are  shown as *p < 0.05, 
**p  <  0.01  and  ****p  <  0.0001  or 
against day 6 as #p < 0.05, ##p < 0.01 
and ####p < 0.0001 or against day 11 as 
+p < 0.05 and ++++p < 0.0001 using one‐
way  ANOVA  with  Dunnett’s  multiple 
comparisons test. Error bars are present 
in  all  graphs  but  are  sometimes  too 
small to be visible. 
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In contrast to the tail flick assay, which is largely a measure of spinal-mediated pain perception 
(135), the hot plate assay is reflective of supra-spinal-mediated pain perception (136). To see 
if the observed dose-dependency of tolerance initiation could also be replicated using the hot 
plate assay, morphine-induced antinociception was measured in the 4 different dosing 
paradigms utilised in the previous experiment (Fig. 8 A-D). Comparable to the results from the 
tail flick assay, 2.5 mg/kg/day (b.i.d.) morphine induced a short period of antinociception on 
day 1 (30.6 ± 2.4 %), while tolerance was observed from day 2 to day 5 (Fig. 8 A). A 
subsequently reduced administration frequency of the same daily morphine dose (5 mg/kg/day) 
from day 6 was unable to overcome the induced tolerance. Only when the morphine dose was 
doubled to 10 mg/kg/day on day 11, was limited antinociception induced (21.9 ± 5.8 %). 
However, tolerance reappeared from day 13 (Fig. 8 A).  
At the higher starting dose of 5 mg/kg/day morphine (b.i.d.), tolerance developed from day 3 
and was reversed on day 6 by decreasing the administration frequency of the same daily dose 
to 10 mg/kg/day, which produced similar antinociception levels (p = 0.696) compared to day 1 
(Fig. 8 B). Using this stage, tolerance developed after 2 days and persisted for the residual 
observation period. However, under these conditions, antinociception on day 14 (latencies in 
seconds) was still significantly higher than basal antinociception on day 0 (unpaired t-test; p < 
0.05; t (2.52) = 4.46) (Fig. 8 B). Analogous to the tail flick experiment (Fig. 8 C) the second 
dose in the hot plate experiments was increased to a single dose of 15 mg/kg/day (Fig. 8 C). In 
contrast to the tail flick experiments, this increase did not delay the re-appearance of tolerance 
compared to the lower dose of 10 mg/kg/day (Fig. 8 C). Instead, the development of tolerance 
was remarkably similar to between the 10 and 15 mg/kg/day dose regimes (Fig. 8 B, C). Similar 
to the lower morphine dose (Fig. 8 B), 15 mg/kg/day on day 14 produced a trend towards 
slightly increased antinociception (14.6 ± 5.9 %) compared to day 0, which however did not 
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reach statistical significance. 
When the dosing regimen was increased to a starting dose of 10 mg/kg/day morphine (b.i.d.), 
significant levels of antinociception were observed until day 5. While tolerance increased 
gradually from day 6 to day 10, antinociception on days 9 and 10 was statistically not different 
to the basal antinociception on day 0 (Fig. 8 D). With the reduction of the administration-
frequency of the same daily morphine dose to 20 mg/kg/day from day 11 onwards, a 
significantly lower level of antinociception (78.1 ± 7.7 %; unpaired t-test; p < 0.05; t (2.85) = 
4.00) compared to day 1 was only observed on day 11 before tolerance was evident from day 
12 onwards (Fig. 8 D). However, under these conditions, antinociception on day 14 (latencies 
in seconds) remained significantly higher compared to basal antinociception on day 0 (unpaired 
t-test; p < 0.001; t (4.93) = 22.66).   
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Figure  8.  Dose‐dependent  morphine 
tolerance  using  hot‐plate  assay. 
Antinociceptive  effects  of  morphine  were 
measured  in male Sprague Dawley rats 30 
min post‐administration (s.c.) using the hot 
plate assay. Antinociception was calculated 
as  percentage  of  the  maximum  possible 
effect.  Morphine  was  administered  at 
multiple escalating doses: 2.5 (b.i.d.)  5  
10 mg/kg/day (A), 5 (b.i.d.)  10 mg/kg/day 
(B),  5  (b.i.d.)   15 mg/kg/day  (C)  and  10 
(b.i.d.)  20 mg/kg/day (D) over 14 days, as 
described in Methods. (E) The areas under 
the  curves  (AUC)  of  the  antinociceptive 
effects of  (A)‐(D) were compared. All  data 
are  represented  as  Mean  ±  SEM  derived 
from  n  =  5‐8  rats  per  group.  Statistically 
significant  differences  compared  against 
day 1 (****p < 0.0001), against day 6 (#p < 
0.05,  ##p  <  0.01,  ###p  <  0.001  and  ####p  < 
0.0001) or against day 11 (++p < 0.01 and ++++ 
p  <  0.0001)  are  shown  for  the  respective 
groups, as produced from one‐way ANOVA 
with  Dunnett’s multiple  comparisons  test. 
Additionally,  significant  differences 
between AUCs of different groups (A, B, C 
and D) are shown as ****p < 0.0001 and were 
calculated  using  one  way  ANOVA  with 
Tukey’s  multiple  comparisons  test.  Error 
bars  are  present  in  all  graphs  but  are 
sometimes too small to be visible. 
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When the four dosing groups were compared regarding the total morphine-induced 
antinociception for each animal over the entire observation period, significant differences in 
antinociception were observed between the first and the second dosing group (Fig. 8 E; A 
versus B; using one way ANOVA with Tukey’s multiple comparisons test; p < 0.0001; F (3, 
13) = 108.3), as well as the third and fourth group (Fig. 8 E; C versus D, using one way ANOVA 
with Tukey’s multiple comparisons test; p < 0.0001; F (3, 13) = 108.3). No statistical difference 
was detected between the AUCs of the second and third group (Fig. 6 E; B versus C). The 
corresponding latencies (in seconds) of Fig. 8 are presented in Fig. 9. 
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Figure 9. Dose‐dependent morphine 
tolerance  using  hot‐plate  assay. 
Antinociceptive  latencies  of 
morphine  in  male  Sprague  Dawley 
rats 30 min post‐administration (s.c.) 
were measured  using  the  hot‐plate 
assay.  The  antinociception  is 
represented  as  latency  in  seconds 
(sec). Morphine was administered at 
multiple escalating doses: 2.5 (b.i.d.) 
 5  10 mg/kg/day (A), 5 (b.i.d.)  
10  mg/kg/day  (B),  5  (b.i.d.)   15 
mg/kg/day  (C)  and 10  (b.i.d.)   20 
mg/kg/day  (D)  over  14  days,  as 
described  in  Methods.  All  data 
represent Mean ± SEM derived from 
n  =  5‐8  rats  per  group.  Statistically 
significant  differences  compared 
against  day  1  are  shown  as  **p  < 
0.01,  ***p  <  0.001  and  ****p  < 
0.0001 or against day 6 as #p < 0.05, 
###p  <  0.001  and  ####p  <  0.0001  or 
against day 11 as ++++p < 0.0001 using 
one‐way  ANOVA  with  Dunnett’s 
multiple comparisons test. Error bars 
are  present  in  all  graphs  but  are 
sometimes too small to be visible. 
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2.3.3. Time-resolved antinociception by a single morphine dose in tolerant and non-tolerant 
animals 
The observed dosing-dependent manifestation of antinociceptive tolerance throughout the 
treatment period of two weeks (Fig. 5, 6 and 8), was calculated from measurements of 
nociception taken at 30 min post-administration of morphine since the maximum efficacy of 
antinociception was observed during this time mark. This does not exclude the possibility that 
compensatory mechanisms developed during the treatment period could have altered 
morphine’s pharmacokinetics and opioid receptor regulation, which might have led to 
antinociception and tolerance at different time-points post-injection. In order to examine this 
possibility, a time-resolved analysis of antinociception response to each morphine injection 
over a 2-hour post-administration period was used to compare the first day of treatment (non-
tolerant) to the last day of the tolerant phase (day 5 for the 2.5 and 5 mg/kg/day groups; day 10 
for the 10 mg/kg/day group). My results indicate that maximal antinociception was achieved at 
30 min post-morphine administration on all days tested throughout the 2-week test period (Fig. 
10), which therefore represents a precise and appropriate time-point to measure maximal 
antinociception after a single subcutaneous injection. This time-resolved analysis on the non-
tolerant vs the tolerant treatment day in each group revealed that all three morphine starting-
doses (2.5, 5 and 10 mg/kg/day b.i.d.) induced a dose-dependent antinociception in the pre-
tolerance phase (Fig. 10). Consistent with the previous results, tolerance was evident on day 5 
for the first two dose-groups, although the total antinociception of day 5 at the 5 mg/kg/day 
dose group was significantly higher than that of 2.5 mg/kg/day. Interestingly, although 
tolerance was developed 5 days later in the 10 mg/kg/day group (day 10), the total 
antinociception produced from a single-dose at day 10 was similar to the other groups. Rats 
showed no residual antinociception after 24 h of morphine administration as evidenced by the 
lack of difference between their basal antinociception levels at day 1 and day 5 or 10 (Fig. 10 
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A-C, E-G). The significant differences detected in antinociception were also evident by the 
comparison of the AUC of total antinociception among groups in both assays (Fig. 10 D, H).  
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Figure 10. Time‐resolved morphine tolerance. Antinociceptive measurements of a single‐dose 
morphine from the first treatment day (day 1) and last treatment day (day 5 or 10) of each dosing 
group  in  both  assays  used:  2.5 mg/kg/day  (b.i.d.)  (A  &  E),  5  mg/kg/day  (b.i.d.)  (B  &  F),  10 
mg/kg/day (b.i.d.) (C & G), where A‐B‐C from tail‐flick and E‐F‐G from hot‐plate. Antinociception 
was calculated as % of maximum possible effect, as described in Methods. The area under the 
curve analysis (AUC) is shown in D and H for tail‐flick and hot‐plate assays respectively.  All data 
are represented as Mean ± SEM derived from n = 5‐13 rats per group. Statistically significant 
differences between values of similar time‐points within each graph, are shown as *p < 0.05, **p 
<  0.01,  ***p  <  0.001  and  ****p  <  0.0001,  produced  from  unpaired  t‐test  with  a  Welch’s 
correction. Additionally, significant differences between AUCs of day 1 and day 5 (or day 10) of 
the same morphine‐treated group are shown as *p < 0.05, **p < 0.01 and ****p < 0.0001 and 
were calculated using unpaired t‐test with a Welch’s correction.   
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2.3.4. Overall dosing strategy affects tolerance development  
The results up to this point suggested that the morphine dose determines the induction of 
antinociceptive tolerance. In addition, the data was interrogated to reveal if the time in a 
treatment paradigm when a specific dose is used, can also affect tolerance manifestation. 
Therefore, total antinociception (depicted as the area under the curve, AUC) over 5 consecutive 
days produced by the same morphine dose at 4 different treatment phases were compared using 
the tail flick (Fig. 11 A) and the hot plate assays (Fig. 11 B). The different time periods analysed 
were Phase 1 (1-5 days), Phase 2 (6-10 days), Phase 3 (11-15 days), Phase 4 (19-23 days) (For 
the 15 mg/kg/day dose the treatment range was extended to 23 days to compare the effects of 
15 mg/kg/day morphine-treated animals in phase 2 (day 6-10); Fig. 12). The AUCs produced 
by the same dose of morphine was significantly different when this dose was used at different 
phases of the treatment protocol (Fig. 11 A, B). My results show that if the same dose was used 
at a later stage of the treatment paradigm, it resulted in less antinociception (Fig. 11 A, B). 
Thus, apart from the morphine dose itself, antinociceptive tolerance appears to depend on the 
overall dosing strategy. 
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Figure 11. Effect of timing within a morphine dosing regimen on antinociceptive tolerance. The 
area under the curves (AUCs) of the antinociceptive effects of morphine in male Sprague Dawley 
rats 30 min post‐administration (s.c.) were measured using the tail flick (A) and the hot plate (B) 
assays. Phases 1, 2, 3, 4 represent the treatment periods of 5 days as days 1‐5, 6‐10, 11‐15 and 
19‐23 respectively with different repeated daily morphine administrations. AUCs of the same 
dose are compared against different phases of the treatment protocols. All data represent Mean 
± SEM derived from n = 5‐13 animals as described in Methods. Statistically significant differences 
between AUCs of different phases of treatment are shown as *p < 0.05, ***p < 0.001 and ****p 
< 0.0001 and were calculated using unpaired t‐test with a Welch’s correction.  
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Figure 12. Long‐term treatment with morphine: dose‐dependent tolerance using tail‐flick and 
hot plate assay. Antinociceptive effects of morphine were measured in male Sprague Dawley 
rats  30 min  post‐administration  (s.c.)  using  the  tail‐flick (A) and  hot  plate (B) assays. 
Antinociception  was  calculated  as  the  percentage  of  the  maximum  possible  effect  (MPE). 
Morphine was administered at multiple escalating doses: 2.5 (b.i.d.) → 5 → 10 → 15 mg/kg/day 
over 23 days, as described in Methods. All data are represented as Mean ± SEM derived from 
n = 5  rats.  Statistically  significant  differences  are  shown  as  compared  to  day  1  (*p < 0.05, 
**p < 0.01  and  ****p < 0.0001),  against  day  6  (#p < 0.05, ##p < 0.01, ###p < 0.001 
and ####p < 0.0001), against day 11 (+p < 0.05, ++p < 0.01 and ++++p < 0.0001) or against day 
19 (ϕϕϕϕp < 0.0001), as produced from one‐way ANOVA with Dunnett's multiple comparisons 
tests. 
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2.4. Discussion 
The development of tolerance represents one of the major hurdles for effective clinical pain 
control using opioids. A vast number of studies since the ‘70s have investigated analgesic 
tolerance in rodents in terms of opioid exposure, molecular mechanisms involved, receptor 
expression and trafficking, neurophysiological parameters that are involved, etc. Nevertheless, 
the opioid tolerance issue is still a major concern in the clinic. Clinicians detect opioid tolerance 
by recording a significant drop of analgesia after repetitive administration to opioids, and a 
major part of their management strategy is to increase the dosing of the opioid to levels that 
will reconstitute sufficient analgesia or change the opioid drug to a more efficacious one. In the 
present study, I used two clinically-related markers of antinociceptive tolerance (the drop of 
antinociceptive efficacy and total antinociception) to investigate the effect of morphine’s 
dosing regimen in the manifestation of morphine tolerance. 
Although different studies consistently reported the development of antinociceptive morphine 
tolerance within 3-8 days of repeated morphine administration (146,149,170,171,178,429), it 
is typically difficult to compare studies in the field due to different experimental set ups. In 
particular, choice of the assay and specific assay conditions (such as cut-off times), type of 
morphine (base, sulphate or hydrochloride salt), treatment protocols (dose, dosing frequency, 
continuous infusion, bolus injections), routes of administration, animal species and strains 
likely influence the experimental outcomes. Previous reports typically utilised only one test-
method to assess morphine-induced tolerance. In contrast, two different thermal testing 
paradigms were employed in this study and distinct differences between the two assays with 
regards to the levels of antinociception and the timing of tolerance induction were observed. 
Since this approach allows to validate tolerance-induction in much more detail and reduces 
misinterpretation of antinociceptive responses. In this study, only recent and commercially 
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available equipment that can be accurately validated was utilised for the commonly employed 
radiant heat tail flick assay as well as the hot plate assay with widely used conditions 
(152,429,437,438). Tolerance was presented by two different methods to increase the 
robustness of my results: reduced efficacy of antinociception as % MPE and reduced total 
antinociception as AUCs. Using these indicators of tolerance, my results consistently suggest 
that morphine dosing (dose, frequency and increment) directly influences the development of 
tolerance. Under my experimental conditions, higher morphine starting doses or lower 
frequency not only delayed tolerance development but also reversed tolerance that was initiated 
with a lower starting dose or higher dosing frequency.  
 My results are supported by similar antinociceptive responses and tolerance profiles reported 
in earlier studies. Similar levels of morphine-induced antinociception (MPE%) were reported 
previously (167) and 10 mg/kg (b.i.d.) daily injections of morphine sulphate (s.c.) have been 
previously shown to result in a similar degree of tolerance in mice (140,141). Nevertheless, the 
data presented here indicate that a combination of factors such as treatment duration and general 
dosing strategy (e.g. dose, dosing frequency and dose increments) directly affects tolerance 
development and its manifestation. This is a finding which, to the best of my knowledge, has 
not been clearly reported in the literature to date, even though hints of evidence either supported 
or opposed this hypothesis. Previous studies provided some suggestions that dosing and 
frequency of dosing could affect the expression of tolerance. In one study a constant starting 
dose (0.5 mg/kg s.c.) was combined sequentially with different dose increments (+0.5 to 3 
mg/kg s.c.) after mitigation of antinociception of the initial dose (179). This study also assessed 
the combination of different starting doses (0.5 to 3 mg/kg s.c.) with constant increments of 
dose (+1 mg/kg s.c.). In line with my results, in this short-term study higher starting doses and 
higher dose increments of morphine sulphate produced less tolerance in mice (179). Although 
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this was an acute study, it raised the question whether the same findings could be seen under 
chronic treatment conditions.  A small number of studies that used 10 mg/kg/day (b.i.d.) 
morphine sulphate dosing reported earlier manifestation of antinociceptive tolerance (by a 
couple of days) compared to studies utilising a single-dose of 10 mg/kg/day morphine sulphate 
in rodents, but these differences may have easily occurred due to the large extent of differences 
in the protocols applied and species used (140,145,429). However, one single, recent and 
thorough study that contradicts my results associated mRNA changes of mu-opioid receptor 
splice variants with the induction of tolerance after long-term exposure to morphine (149). The 
authors provided ED50 data from a probit analysis of antinociception using assessed by a tail-
flick assay in mice, using different dose-groups, and reported a lower tolerance manifestation 
in animals receiving low doses. Although the Xu et al. 2015 paper offers data with high power 
(high animal numbers and clinically-relevant long treatment periods), there are particular 
methodological disadvantages when using changes of ED50 values and shifts of dose-response 
curves in probit analysis as indicators of tolerance expression, that render these data difficult 
to interpret. Utilising an incremental exposure of morphine in already morphine-exposed 
animals of different treatment dose in order to produce a dose-response curve, produces an 
inevitable bias in response. For example, an animal that has been treated regularly with 40 
mg/kg/day morphine, twice a day, for 21 consecutive days, is naturally expected to produce a 
reduced response when exposed to a much lower dose-screening range of morphine (1 to 10 
mg/kg). In addition, the probit analysis used by a number of studies including the Xu et al. 
2015 paper, is a less appropriate method than sigmoidal curves, due to their basic requirement 
of a binary outcome instead of the grading response offered by the tail-flick assay. 
Transforming grading responses to binary outcomes involves loss of information and therefore 
the analysis becomes suboptimal (439).  
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In summary, my data are consistent with all previous studies that antinociceptive tolerance to 
morphine is not a phenomenon where its expression and profile solely depends on the 
pharmacodynamics of the drug, but also on the dosing regimen employed. My study 
strengthened and expanded this hypothesis by providing solid evidence that higher doses of 
morphine not only lead to improved antinociceptive short-term relief (as total antinociception 
from a single-dose) and long-term relief (as total antinociception per treatment period) but also 
significantly delayed the induction of tolerance in terms of significant reduction in efficacy. 
Equally importantly, the results of this study on incremental strategies in the post-tolerant phase 
suggest that the higher the ‘jump’ of the second dosing level, the longer it takes the animal to 
develop those compensatory mechanisms needed for a low antinociceptive efficacy (tolerance). 
I acknowledge to the difficulty in discussing the clinical implications of these results given the 
strong adverse-effects associated with morphine use. I believe I provide substantial evidence 
in this study to support the hypothesis that the relationship between antinociceptive tolerance 
development and morphine is not just dependent on pharmacodynamics and receptor 
behaviour, but also on the magnitude of the starting dose and the frequency of exposure to 
morphine; two factors that have been largely underestimated in most pre-clinical studies 
investigating antinociceptive tolerance to date. 
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CHAPTER THREE 
 
Profiling the effects of morphine dosing on motor 
behaviour   
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Preface to chapter three  
Chapter two described how an adequate dosing strategy can delay antinociceptive tolerance 
and maintain effect antinociception during long-term treatment. In chapter two, I observed that 
a high starting and follow-up dose of morphine can maintain effective antinociception and 
reduce antinociceptive tolerance after chronic administration over a period of 2-3 weeks. The 
current study (chapter three) was designed to measure detailed locomotor activities, rearing 
and turning behaviours of morphine-treated animals in order to identify a possible connection 
between motor behaviour and antinociceptive tolerance.  
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3.  Profiling the effects of morphine dosing on motor behaviour 
 
Abstract 
 
Efficient repetitive clinical use of morphine is limited by its numerous side effects, whereas 
analgesic tolerance necessitates subsequent increases in morphine dose to achieve adequate 
levels of analgesia. Although analgesic tolerance has been the focus of many studies, the effect 
of morphine dosing on non-analgesic effects has been overlooked. This study aimed to 
characterise development and progression of morphine-induced motor behaviour in relation to 
the development of antinociceptive tolerance. Adult male Sprague-Dawley rats were 
repetitively treated with subcutaneous morphine for 14 days in two dose groups (A: 5 
mg/kg/day (b.i.d.) → 10 mg/kg/day; B: 10 mg/kg/day (b.i.d.) → 20 mg/kg/day). Motor 
behaviour was assessed daily (distance travelled, speed, moving-time, rearing, rotation) in an 
open-field arena, prior to and 30 min post-injections. Antinociception was measured using tail-
flick and hot-plate assays. In both dosing groups, all measured parameters were highly 
suppressed on the first treatment day, followed by a gradual manifestation of behavioural 
tolerance as the treatment progressed. The kinetics of morphine-induced suppression of motor 
behaviour and subsequent behavioural tolerance were similar to those of antinociception and 
antinociceptive-tolerance. Animals of the high-dose group showed increased locomotor 
activity after 10 days of morphine treatment that paralleled antinociceptive tolerance. This 
excitatory phase converted to an inhibition of behaviour when a higher morphine dose was 
introduced. My results indicate that repetitive morphine dosing leads to broad tolerance against 
morphine-induced locomotor suppression in parallel with antinociceptive tolerance. I suggest 
that the excitatory locomotor effects of repetitive high-dose morphine exposure represent a 
signature of its antinociceptive tolerance. 
 
Keywords: morphine dosing; behaviour; locomotor activity; antinociception; tolerance. 
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3.1. Introduction 
Long-term clinical use of opioids such as morphine is limited due to its significant side-effects 
such drowsiness, itching, respiratory depression, constipation, addiction and dependence 
(111,112). Although predicting the appearance of morphine-induced side effects is important 
for effective pain-relief, the relationship between opioid dosing and the appearance of drug-
induced side effects is currently not well established.  In the clinic, pain-relief and side effects 
are different responses to morphine, which appear to correlate poorly (190). Behavioural side-
effects of morphine in different clinical studies are both described as dose-dependent such as 
pruritus (250,440), as well as dose-independent, such as nausea and vomiting (251,440). In this 
context, it becomes important to understand how the dosing regimen can affect both morphine-
induced antinociception, as well as the appearance of behavioural effects. Antinociceptive 
tolerance largely depends on treatment dose and dosing-protocol of morphine. One of our 
recent studies showed that a higher starting dose or larger increases of a testing dose of 
morphine produced overall less antinociceptive tolerance in rats (137).  
The current literature shows inconsistent effects of morphine on animal behaviour. These 
inconsistencies are likely due to the use of different species/strains, routes of administration, 
types or formulations of morphine and differing treatment protocol (dose, frequency or duration 
of treatment) (192,194,441,442). Locomotor activity has been widely assessed to characterise 
behavioural effects of morphine-treated animals. While lower morphine-doses largely left 
locomotor activities unaffected, higher doses produced stimulatory or biphasic effects when 
morphine was administered acutely (191,193,441). Similarly, long-term morphine treatment 
with lower doses (1.25 to 5 mg/kg i.p.) showed no effects on locomotion, while higher doses 
(10 to 40 mg/kg i.p.) produced a biphasic effect with initial suppressive and subsequent 
increased locomotor activities (191).  In addition, locomotor activity alone cannot reflect the 
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total behavioural side-effects profile of morphine, while concomitant measurement of 
locomotor activities together with other behavioural parameters is better suited to model the 
behavioural side-effects of morphine (193). In this study, 20 mg/kg of intraperitoneal morphine 
increased, while 10 mg/kg of morphine decreased horizontal movements in female mice, while 
both doses decreased rearing and grooming activities (193). In contrast, no dose-dependent 
differences in locomotion or rearing were detected in male rats in response to 0.5-50 µg 
intracerebroventricular morphine injections (441). These discrepancies illustrate that 
morphine-induced behavioural activities are, among other parameters such as route of 
administration and species, influenced by the gender of animals, which is not surprising as it is 
well described that female animals are more sensitive to morphine treatment (443,444). As 
such, female mice showed increased distance and rearing duration compared to male mice in 
response to morphine treatment (444). Moreover, different environmental settings have been 
used for behavioural tests. Especially changes to the illumination conditions, such as brightly 
illuminated (444,445,446), moderately illuminated (192,193), or low illuminated (191) have 
been reported. Since rodents are more active in the dark or under conditions of low illumination, 
brightly lit open-field arenas can distract the animals, which is likely to alter the results from 
experiments performed under conditions of low illumination intensity. In addition, most studies 
only tested the animal responses 30 min after acute treatment of morphine (192,193,441), 
which completely disregarded the known biphasic behavioural pattern of morphine exposure 
(191,447).  
Although some studies combined several behavioural activities such as distance travelled, 
rearing, immobility or grooming after acute treatment of morphine (192,193,441), any possible 
connections between locomotion and other behavioural effects have not been established for 
repetitive long-term morphine treatment. Therefore, a significant gap of knowledge is evident 
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regarding the relationship between antinociceptive and behavioural effects of morphine, but 
also regarding its long-term effect on behaviour and antinociceptive tolerance. In this study, I 
measured multiple behavioural effects before, during and after long-term morphine treatment 
in rats. Animals were treated with two different morphine dosing-regimens to establish the 
influence of dosing regimen on behaviour and antinociceptive tolerance. Seven behavioural 
parameters were measured automatically in an open-field arena, which has been rarely done 
before (441).  I aimed to generate a very detailed behavioural profile of long-term morphine 
treatment, behavioural tolerance and the influence of different morphine dosage-regimens, to 
accurately reflect existing relationships between behavioural and antinociceptive tolerance. 
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3.2. Methods 
3.2.1. Animal maintenance and care 
Twelve male Sprague-Dawley (SD) rats (233.6 ± 5.96 g, 8 weeks), supplied by the animal 
services of the University of Tasmania were housed as three littermates per cage at 22 ºC with 
50-60 % humidity under an automated 12-hour day/night cycle (lights on at 7:00 am) with free 
access to food (Barastoc rodent cubes, Ridley Corporation, Melbourne, Australia) and water. 
Male rats were used to avoid any possible effects of the oestrous cycle of female rats (336). 
Moreover, all procedures and handling were approved by the University of Tasmania Animal 
Ethics Committee (A0013864) and were conducted according to The Australian Code for the 
Care and Use of Animals for Scientific Purposes (434). The experiments were also in 
compliance with the ARRIVE guidelines (435). F10SC veterinary disinfectant solution (Health 
and Hygiene Pty Ltd, Florida Hills, South Africa) was used for cleaning and hygiene purposes 
as a diluted solution (1:250 in water). Animals were handled for 5-6 days before the 
experiments were conducted. On the morning of behavioural tests, animals were transported to 
the testing room in their home cages and acclimatised to the test environment for 2 hours. 
3.2.2. Treatment protocol 
Body weight was recorded daily immediately prior to experiments in order to determine the 
accurate dosing for each rat. Commercially available 30 mg/ml morphine sulphate solution 
(Hameln Pharmaceuticals GmbH, Germany) was administered by daily subcutaneous 
injections between left thigh and the spinal cord. All animals were divided into two subgroups 
using a completely randomised design as previously described (448). Two sub-groups of 
animals received different morphine dosing-regimes. Group A (n = 6): morphine sulphate 5 
mg/kg (twice daily) for 5 days, followed by a single dose (once daily) of 10 mg/kg from day 6 
to 14. Group B (n = 6): morphine sulphate 10 mg/kg (twice daily) for 10 days, followed by a 
115 
 
 
single dose (once daily) of 20 mg/kg from day 11 to 14. Volumes of morphine solution for 
injection were ranged between 60 to 180 µl depending on the dose and body weights of the 
animals. For injection volumes of less than 60 µl, the volume was adjusted with sterile 0.9 % 
sodium chloride solution to fit into the volume range. Thesubcutaneous administration was 
previously shown to be an effective and quick route of morphine administration (449), with 
minimal discomfort to the animals. Different morphine doses and timing of injections were 
selected, based on our previous results (137). Morphine doses were doubled after the 
manifestation of antinociceptive tolerance induced by a starting dose. All doses were assessed 
for long-term safety in pilot trials before use in the present study. The illumination intensity of 
the laboratory was reduced prior to and during experiments to minimise discomfort to the 
animals. At the end of each study, animals were anesthetised with 5 % (w/v) isoflurane in 
oxygen at a flow rate of 1 L/min before decapitation. 
3.2.3. Locomotor activity and other behavioural measurements  
Behaviour was tested in an open-field arena in an automated Multi-Conditioning System 
(MCS) (TSE GmbH, Homburg, Germany) 2 min after nociception testing at pre-, post- (15, 30, 
60, 120 and 180 min) administration of morphine over a period of 5 min on the 1st and the last 
treatment day of the same dose, since a 5 min observation period is widely used for open field 
measurements (192,193,446,450). On all other treatment days, the rats were tested only for 
baseline behaviour (pre-) and 30 min post-administration of morphine, which represents the 
time-point of morphine-induced maximal behavioural suppression on day 1. Baseline 
behaviour was defined as the basal behavioural measurements prior to morphine injection on 
each particular test-day. Rats were returned to their home cages after antinociceptive testing 
and kept there for 2 min before the start of behavioural measurements. Behavioural testing 
included seven different parameters (moving time, total distance travelled, speed, rotation 
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numbers, rearing numbers, rotation time and rearing time). Speed (m/s) was calculated as 
distance travelled (m) divided by the corresponding moving time (s) obtained from the system 
(MCS). Rotation numbers were calculated as the sum of clock-wise and counter-clockwise 
rotations obtained directly from the MCS. The area under the curves (AUC) was calculated by 
the trapezoid method using GraphPad Prism V6 software (GraphPad Software Inc., La Jolla, 
CA, USA). 
The MCS included an internal noise/light/temperature insulation system and a 3D infrared-
beam frame that provided fast and accurate animal movement detection (100Hz), combined 
with a high-resolution video monitoring and automated movement tracking. Quantification and 
visualisation of the MCS data were processed by the integrated system software (TSE 
ActiMot). The open-field arena was fully cleaned and dried between each animal. A 
background white noise (20 dB) generator was used during all experiments to cancel out any 
unexpected laboratory sounds.  
3.2.4. Assessment of antinociception  
Nociceptive thresholds were determined by two independent assays (tail-flick & hot plate) 
using commercially available tail-flick and hot/cold plate assay equipment (Ugo Basile, 
Comerio, Italy). Two independent assays were used to determine whether antinociceptive 
tolerance is dependent on the method of antinociception measurement. Animals were tested 
randomly to avoid any bias effects to due to multiple repeated measurements. The maximum 
exposure to the nociceptive thermal stimulus was 15 sec for the tail-flick (basal latency: 4.26 ± 
0.22 sec) and 30 sec for the hot-plate assay (basal latency: 5.72 ± 0.29 sec). The infrared 
intensity of the tail-flick photocell was set at 30, whereas the plate temperature of the hot-plate 
was set at 54 ± 0.5 °C. The experimental settings for antinociceptive measurements used in this 
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study were previously described (137,152,437,438). Every rat was tested immediately prior to 
morphine administration as well as 15, 30, 60 and 120 min post-administration using both 
assays on the first and the last treatment day. Nociception measurements were conducted in a 
blinded manner and the mean of three independent measurements for each time-point with a 1 
min interval between measurements was recorded to minimise ‘handling’ effects. The 
maximum possible effect (MPE) was defined as MPE % = 100 X [(test latency – baseline 
latency)/(cut-off time – baseline latency)] as previously described (436). Baseline latency was 
defined as the basal antinociceptive measurement prior to morphine injection on each particular 
test-day. The area under the curves (AUC) was calculated by the trapezoid method using 
GraphPad Prism V6 software (GraphPad Software Inc., La Jolla, CA, USA).3.2.5. Statistical 
analysis 
Data are expressed as mean ± SEM and analysed by one-way ANOVA with Dunnett’s multiple 
comparisons test or unpaired t-test, using GraphPad Prism v6 software (GraphPad Software 
Inc., La Jolla, CA, USA). Multiple comparisons (Dunnett’s test) were employed when F 
achieved p < 0.05 and there was no significant variance in homogeneity. A ‘p’ value less than 
0.05 was considered statistically significant.   
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3.3. Results 
3.3.1. Time-resolved efficacy of a single dose of morphine to locomotor behaviours: 
hypoactivity vs hyperactivity  
To acquire a basic understanding of how repeated administration of morphine affects rat 
behaviours such as moving, rearing and rotation, rats were treated daily with 10 mg/kg (b.i.d.) 
morphine over a period of 10 days and their activities were recorded and assessed daily at 
regular intervals, for a total of 180 min after administration. The basal levels of activity (t = 0 
min) at every day for the duration of treatment were similar with no significant differences, 
therefore no residual effects of morphine on the examined behaviour were observed at the 
beginning of every daily experiment from previous administrations. Behavioural scoring at 
every time-point was compared between days 1 and 10 for the recorded behaviours and their 
parameters (general locomotion Fig. 13; rearing and rotation Fig. 15).  For general locomotion, 
at day 1 of morphine administration, suppression of locomotor activities was observed after 30 
min at all parameters analysed (one-way ANOVA; F (11, 46) = 12.43; p < 0.01(distance); F 
(11, 54) = 8.96; p < 0.0001 (moving time); F (11, 57) = 22.12; p < 0.001 (speed)), which 
persisted until 60 min after administration (Fig. 13 A-C). The repression of all examined 
parameters of locomotion returned to their basal levels within 180 min after administration. 
However, after 10 days of daily repetitive administration of morphine (day 10), general 
locomotion is manifested as hyperactivity, as shown by significant increases in travelled 
distance (one-way ANOVA; F (11, 46) = 12.43; p < 0.0001) and moving speed (one-way 
ANOVA; F (11, 57) = 22.12; p < 0.0001), along with non-significant differences in moving 
time from basal levels. This change in the activity profile towards hyperactivity was 
accompanied by a shift of its time-peak at 15 min after morphine administration and a faster 
recovery to basal within 180 min of treatment (Fig. 13 A-C). Relevant behavioural activities 
induced by morphine 5 mg/kg (b.i.d.) for 5 days repeated treatment are shown in Fig. 14. 
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Figure  13.  Time‐resolved 
locomotor  activities  after 
repeated  morphine  treatment. 
Locomotor parameters recorded in 
an  open‐field  arena  after  a  single 
subcutaneous  injection  of 
morphine (10 mg/kg, b.i.d. over 10 
days)  on  day  1  or  day  10  in male 
Sprague  Dawley  rats.  Motor 
behaviour  of  treated  animals  was 
assessed by quantification of total 
distance travelled (A), total moving 
duration  (B) or average speed  (C), 
for  a  period  of  180  min  post‐
administration.  Statistically 
significance  (p  <  0.05)  against  the 
basal effects of day 1 is shown as *p 
< 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001 and was calculated 
using  one‐way  ANOVA  with 
Dunnett’s  multiple  comparisons 
test. Values are presented as mean 
±  SEM  (n  =  6  animals  per  group). 
Error bars are present in all graphs 
but are sometimes too small to be 
visible. 
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Figure  14.  Time‐resolved 
locomotor activities after repeated 
morphine  treatment.  Open‐field 
locomotor  activities  after  a  single 
subcutaneous  injection  of 
morphine  (5  mg/kg,  b.i.d.  over  5 
days)  on  day  1  or  day  5  were 
measured in male Sprague Dawley 
rats.  Activities  of  treated  animals 
were  measured  as  distance 
travelled  (A),  moving  time  (B),  or 
speed  of  movement  (C)  over  a 
period  of  180  min.  Statistically 
significance  (p  <  0.05)  against  the 
basal effects of day 1 is shown as *p 
< 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001 and was calculated 
using  one‐way  ANOVA  with 
Dunnett’s  multiple  comparisons 
test. Values are presented as mean 
±  SEM  (n  =  6  animals  per  group). 
Error bars are present in all graphs 
but are sometimes too small to be 
visible. 
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The specific locomotor behaviours of rotation and rearing were also analysed in a similar time-
resolved manner in terms of total score (numbers; Fig. 15 A & B) and duration (time; Fig. 15 
C & D). Rotational behaviour was suppressed by morphine at day 1 at a similar fashion as 
general locomotion in terms of peak and recovery timing (one-way ANOVA; F (11, 42) = 
31.56; p < 0.05) (Fig. 15 A, C). As in the case of general locomotion, the rotational behaviour 
was also observed to be significantly increased at day 10 of treatment compared to basal (one-
way ANOVA; F (11, 42) = 31.56; p < 0.01) (Fig. 15 A, C). Interestingly, although rearing 
showed to be significantly suppressed by morphine at day 1 similarly to general locomotion 
(one-way ANOVA; F (11, 39) = 45.85; p < 0.0001), this behaviour remained suppressed at day 
10 of treatment without contributing to the hyperactivity profile usually seen in the previously 
recorded parameters at day 10 (Fig. 15 B & D). The corresponding behavioural activities 
induced by morphine 5 mg/kg (b.i.d.) for 5 days repeated treatment are shown in Fig. 16. 
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Figure 15. Time‐resolved rotation and rearing activities after repeated morphine treatment. 
Open‐field turning and rearing activities after a single subcutaneous injection of morphine (10 
mg/kg, b.i.d. over 10 days) on day 1 or day 10 were measured  in male Sprague Dawley rats. 
Activities of treated animals were measured as rotation no (A), rearing no (B), rotation time (C) 
and rearing time (D) over a period of 180 min. Statistically significance (p < 0.05) against the basal 
effects of day 1 is shown as *p < 0.05, **p < 0.01 and ****p < 0.0001 and was calculated using 
one‐way ANOVA with Dunnett’s multiple comparisons test. Values are presented as mean ± SEM 
(n = 6 animals per group). Error bars are present in all graphs but are sometimes too small to be 
visible. 
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To evaluate the overall behavioural effects of repeated morphine administration over a period 
of 10 days, the overall scores of Fig. 13 and Fig. 15 were quantified as area under the curves 
(AUC) and presented in Table 15. From this analysis, it is evident that morphine significantly 
stimulates locomotion after 10 days of repetitive administration, compared to day 1 where it 
significantly suppresses locomotion, with the notable exception of rearing behaviour that 
persists to be suppressed at day 10 (Table 15).                                  .   
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Figure 16. Time‐resolved rotation and rearing activities after repeated morphine treatment. 
Open‐field turning and rearing activities after a single subcutaneous  injection of morphine (5 
mg/kg,  b.i.d.  over  5  days)  on  day  1  or  day  5 were measured  in male  Sprague  Dawley  rats. 
Activities of treated animals were measured as rotation no (A), rearing no (B), rotation time (C) 
and rearing time (D) over a period of 180 min. Statistically significance (p < 0.05) against the basal 
effects of day 1 is shown as *p < 0.05, **p < 0.01 and ****p < 0.0001 and was calculated using 
one‐way ANOVA with Dunnett’s multiple comparisons test. Values are presented as mean ± SEM 
(n = 6 animals per group). Error bars are present in all graphs but are sometimes too small to be 
visible.
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Table 15. Overall comparison of motor‐behaviours from day 1 after repeated morphine treatment. Total scoring of motor‐behaviours recorded 
over 180 min after subcutaneous administration of morphine 10 mg/kg (b.i.d.) over 10 days repeated treatment. Parameters (presented as area 
under curve; AUC) were calculated from the behavioural curves  in Figures 13 and 14. Statistically significant differences between AUCs of each 
behaviour were assessed using an unpaired t‐test.   
 
Behavioural 
Parameter 
AUC units  Day 1 
(Dose‐group B) 
Day 10 
(Dose‐group B) 
Significant difference 
 
Distance  min * days  8958 ± 995  19492 ± 1562  t (10) = 5.688; p <0.001 
Moving time  % of recorded time * days  8349 ± 643  11715 ± 643  t (9) = 3.668; p < 0.01 
Speed  (metre/sec) * days  60.22 ± 1.25  99.51 ± 3.34  t (10) = 11.02; p < 0.0001 
Rotation numbers  incidences * days  8374 ± 550  25423 ± 1761  t (10) = 9.24; p < 0.0001 
Rotation time  % of recorded time * days  2464 ± 240  3704 ± 199  t (10) = 3.979; p < 0.01 
Rearing numbers  incidences * days  3018 ± 308  3717 ± 206  t (8) = 1.887; p = 0.096 
Rearing time  % of recorded time * days  2116 ± 171  2803 ± 458  t (9) = 1.297; p = 0.2269 
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3.3.2. Dose-dependent efficacy of repetitive morphine administration and incremental 
changes of dosing on locomotor behaviour: hypoactivity vs hyperactivity  
To investigate the effect of morphine dosing regimens on locomotion and related behaviour, 
the animals were treated with two dosing regimens that differ in morphine’s dose and duration 
of treatment (5 mg/kg/day b.i.d. or 10 mg/kg/day b.i.d.), followed by a subsequent change in 
administration of morphine (double dosing in single daily injections) until day 14 of treatment 
(Fig. 17). Noticeably, no differences between the basal locomotion, rotation or rearing activities 
over the total treatment-period of 14 days were observed, which were recorded daily (every 
morning) immediately before morphine injections (Fig. 18 and 19).  
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Figure  17.  Dose‐dependent  locomotor  activities  after  long‐term  morphine  treatment.  
Locomotor parameters recorded in an open‐field arena after daily subcutaneous injections of 
morphine in male Sprague Dawley rats, at a daily 30 min mark post‐administration during a 5 
min recording period. The motor behaviour of treated animals was assessed by quantification of 
distance travelled (A, D), moving duration (B, E) or average speed (C, F). Two morphine regimens 
were used in two different groups of animals respectively: 5 (b.i.d.)  10 mg/kg (A, B, C) and 10 
(b.i.d.)  20 mg/kg (D, E, F) over a total period 14 days, as described in Methods. Values are 
presented as mean ± SEM (n = 6 animals per group). Statistically significant (p < 0.05) differences 
compared against day 0 are shown as *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 
and were calculated using one‐way ANOVA with Dunnett’s multiple comparisons test.  Error bars 
are present in all graphs but are sometimes too small to be visible. 
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In the ‘low’ starting dose treatment group (5 mg/kg b.i.d. → 10 mg/kg/day; Fig. 17 A), a 
significantly reduced moving distance was observed at days 1 and 2 (one-way ANOVA; F (14, 
48) = 4.26; p < 0.05), with a slow but steady recovery till day 5. The subsequent change in the 
method of administration of morphine (from twice daily 5mg/kg to once daily 10mg/kg) on day 
6 onwards somewhat increased the suppressive effect of morphine on moving distance 
returning the difference from basal back to significant levels (one-way ANOVA; F (14, 48) = 
4.26; p < 0.001). No behavioural recovery was observed from day 6 to the end of treatment 
period (day 14). The parameter of moving time (Fig.  17 B) and moving speed (Fig. 17 C) 
expressed very similar responses to morphine treatment and changes in administration, as in 
the case of total distance.  
In the second group of ‘high’ morphine dosing (10mg/kg/day b.i.d. till day 10 → 20 mg/kg/day 
till day 14), the same locomotive parameters were assessed, with a marked change in the overall 
profile manifested (Fig. 17 D-F). In these animals, the 10 mg/kg/day b.i.d. morphine 
significantly reduced moving distance at day 1 compared to basal (one-way ANOVA; F (14, 
47) = 19.20; p < 0.01), however, the recovery to basal values was not only at a fast and steady 
rate despite repetitive morphine administration, but also progressed to a significant increase in 
travelled distance scoring compared to basal, from day 6 (one-way ANOVA; F (14, 47) = 19.20; 
p < 0.05) until it reached a hyperactivity plateau at day 10. When morphine administration 
changed to a single dose of 20 mg/kg/day from day 11 (Fig. 17 D), the suppressive effect of 
morphine returned to the observed levels of day 1 (one-way ANOVA; F (14, 47) = 19.20; p < 
0.05) and remained suppressed until the end of treatment period (day 14). This pattern of 
morphine-induced changes observed for travelled distance was also replicated to the rest of 
observed parameters of general locomotion (moving time; Fig. 17 E and speed of movement; 
Fig. 17 F), as well as rotational behaviour (Fig. 20 A & 20 C). 
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Figure  18.  Basal  locomotor 
activities  of  rats.  Open‐field 
locomotor  activities  at  pre‐
administration  (basal)  in  male 
Sprague Dawley rats over a period 
of  14  days.  Activities  of  animals 
were  measured  as  distance 
travelled  (A), moving  time  (B),  or 
speed of movement (C). Values are 
presented  as mean  ±  SEM  (n  =  6 
animals per group). No statistically 
significant  differences  were 
observed against day 1 using one‐
way  ANOVA  with  Dunnett’s 
multiple  comparisons  tests.  Error 
bars are present  in all  graphs but 
are  sometimes  too  small  to  be 
visible. 
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Figure 19. Basal rotation and rearing activities of rats. Open‐field rotation and rearing activities 
at pre‐administration (basal) in male Sprague Dawley rats over a period of 14 days. Activities of 
animals were measured as rotation no (A), rearing no (B), rotation time (C) and rearing time (D). 
Values  are  presented  as mean  ±  SEM  (n  =  6  animals  per  group).  No  statistically  significant 
differences  were  observed  against  day  1  using  one‐way  ANOVA  with  Dunnett’s  multiple 
comparisons tests. Error bars are present in all graphs but are sometimes too small to be visible. 
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Figure  20.  Dose‐dependent  rotation  and  rearing  activities  after  long‐term  morphine 
treatment.  Rotation  and  rearing  behaviours  recorded  in  an  open‐field  arena  after  daily 
subcutaneous injections of morphine in male Sprague Dawley rats, at a daily 30 min mark post‐
administration during a 5 min recording period. Activities of treated animals were measured as 
rotation numbers (A, C), and rearing numbers (B, D). Two morphine regimens were used in two 
different groups of animals respectively: 5 (b.i.d.)  10 mg/kg (A, B) and 10 (b.i.d.)  20 mg/kg 
(C, D) over a total period 14 days, as described in Methods.  Values are presented as mean ± SEM 
(n = 6 animals per group). Statistically significant (p < 0.05) differences compared against day 0 
are shown as *p < 0.05 and ****p < 0.0001 and were calculated using one‐way ANOVA with 
Dunnett’s multiple comparisons test. Error bars are present in all graphs but are sometimes too 
small to be visible. 
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In the case of rearing behaviour, data showed a similar profile in morphine’s effect during 
repetitive administration for both ‘low’ and ‘high’ dose groups (Fig. 20 B & 20 D). Morphine 
significantly suppressed rearing from day 1 until day 14 (one-way ANOVA; F (14, 53) = 35.57; 
p < 0.0001) without any recovery or observed increase in recorded activity, even when a change 
in morphine’s administration from twice daily to single double-dose daily (5mg/kg/day b.i.d. 
→ 10m/kg/day; Fig. 20 B, 10 mg/kg/day b.i.d. → 20 mg/kg/day; Fig. 20 D), essentially staying 
suppressed until the entire treatment period.  
The regimen-dependent behavioural changes were also calculated as area under the curves  
(AUCs) over the whole treatment period of 14 days and comparison between groups is shown 
in Table 16. The AUCs of behavioural parameters of the higher dosing paradigm (10 mg/kg/day 
b.i.d. → 20 mg/kg/day), were significantly higher than the AUCs of the lower treatment 
paradigm (5 mg/kg/day b.i.d. → 10 mg/kg/day), with the exception of rearing numbers and 
rearing time (Table 16). Thus morphine 10 mg/kg (b.i.d.) → 20 mg/kg/day treated animals 
showed more locomotor and rotational behavioural changes (hyperactivity) than morphine 5 
mg/kg (b.i.d.) → 10 mg/kg/day group (Table 16). 
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Table 16.  Overall comparison of motor behaviours between different dosing groups. Total scoring of recorded motor behaviours (presented as 
area under the curve; AUC) were calculated from the behavioural curves in Figures 17 and 20. Statistically significant differences between AUCs of 
each behaviour were assessed using an unpaired t‐test.   
 
Behavioural 
Parameter 
AUC units  Dose group A: Morphine 
5 mg/kg (b.i.d.) → 10 mg/kg/day 
Dose group B: Morphine 
10 mg/kg (b.i.d.) → 20 
mg/kg/day 
Significant difference 
Distance  min * days  369.6 ± 71.6  982.3 ± 134.3  t (9) = 3.785; p < 0.01 
Moving time  % of recorded time * days  305.5 ± 32.6 
 
700.2 ± 51.4  t (9) = 6.169; p < 0.001 
Speed  (metre/sec) * days  3.80 ± 0.23 
 
5.69 ± 0.42  t (9) = 3.702; p < 0.01 
Rotation 
numbers 
incidences * days  255.8 ± 48.4 
 
1200 ± 124.2 
 
t (9) = 6.552; p < 0.001 
Rotation time  % of recorded time * days  103.1 ± 12.6 
 
233.4 ± 22.2 
 
t (9) = 4.821; p < 0.001 
Rearing numbers  incidences * days  48.0 ± 15.5 
 
97.4 ± 30.1 
 
t (10) = 1.462; p = 0.174 
Rearing time  % of recorded time * days  19.4 ± 2.86 
 
40.6 ± 9.9 
 
t (8) = 1.690; p = 0.130 
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3.3.3. The relationship between antinociceptive tolerance and locomotor activities 
To better understanding of the clinical significance of morphine’s biphasic behavioural effect 
on locomotor behaviour between different dosing regimens, I aimed to compare these effects 
with morphine’s major pharmacological drawbacks, antinociceptive tolerance. Antinociception 
was measured using two major assays (tail-flick and hot-plate) and tolerance was defined as a 
significant reduction of antinociceptive efficacy, whereas distance travelled was measured 
using open-field test over a period of 180 minutes after injections at day 5 or day 10 as described 
in Methods. The area under the curves (AUC) of the first treatment day (day 1) and day 5 for 
Group A (5 mg/kg/day b.i.d.) or day 10 for Group B (10 mg/kg/day b.i.d.) were compared using 
unpaired t-test (Fig. 21). Animals in the first morphine dose group (5 mg/kg b.i.d.) showed no 
difference in distance travelled between days 1 and 5, although they exhibited significant 
antinociceptive tolerance  in both assays used (tail-flick; unpaired t-test; t (10) = 8.48; p < 
0.0001 and hot-plate; unpaired t-test; t (10) = 9.80; p < 0.0001, as shown in (Fig. 21 A)). 
However, animals in the larger morphine dose group (10 mg/kg b.i.d.), presented hyperactivity 
(e.g. significantly higher locomotion) at day 10 when antinociceptive tolerance was first 
manifested in these animals, compared to day 1 (unpaired t-test; t (7) = 7.04; p < 0.001) as 
shown in Fig. 21 B. These data show collectively that antinociceptive tolerance due to repetitive 
morphine administration is an independent effect of morphine’s effects on locomotor 
behaviour, which profile is largely dependent on the dosage regimen used.  
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Figure  21.  Overall  behavioural  and  antinociceptive  effects  after  long‐term  morphine 
treatment. The area under the curves (AUC) of distance travelled and antinociception in male 
Sprague Dawley rats over a period of 180 min post‐administration of subcutaneous morphine at 
different days through a treatment period. The curves used to calculate these AUC values are 
shown in the Fig. 13 A, Fig. 15 A and Fig. 22. Morphine was administered daily as 5 mg/kg (b.i.d.) 
(A) over 5 days or 10 mg/kg b.i.d. (B) over 10 days. D1, D5 or D10 represents day 1, day 5 or day 
10 respectively. Antinociception was assessed by two assays, tail‐flick assay (TF) and hot‐plate 
assay (HP). Values are presented as mean ± SEM (n = 6 animals per group). Statistically significant 
(p < 0.05) differences from day 1 of every treatment groups are shown as ****p < 0.0001 and 
were calculated using unpaired t‐test. Error bars are present in all graphs but are sometimes too 
small to be visible. 
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Figure 22. Antinociceptive effects of daily morphine‐treated rats. Antinociceptive effects of 5 
mg/kg (b.i.d.) and 10 mg/kg (b.i.d.) morphine‐treated Sprague Dawley rats (n = 6 per group) over 
the course of 5 to 10 days (groups A and B). The antinociceptive effects were measured using 
tail‐flick (A, C) and hot‐plate (B, D) assays. The area under the curves are shown in Fig. 21. Error 
bars are present in all graphs but are sometimes too small to be visible. 
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3.4. Discussion 
Morphine is the gold-standard for the treatment of chronic or cancer pain. Nevertheless, long-
term use of morphine is severely limited by its biphasic effects on motor behaviour (inhibitory 
or excitatory) and the manifestation of analgesic tolerance (e.g. reduced analgesic efficacy). 
Despite an increased knowledge about morphine’s activities, little is known how its dosing 
regimens affect the manifestation of motor effects and analgesic tolerance.  
Euphoria, lethargy or drowsiness are very common clinical side-effects of morphine 
(451,452,453) and are mirrored by the hypoactivity reported in rodents administered with 
morphine (454). The connection between morphine dosing and the appearance of these 
behavioural effects has been investigated over several decades with different experimental 
setups and paradigms. In contrast to the present report, a previous study measured horizontal 
movement using male Holtzman albino rats after intraperitoneal morphine injections over a 1 
or 2 hour observation period in their home cages over a total period of up to 4-8 hours (191). 
However, animal behaviour is largely governed by an interest in their surroundings. Therefore, 
if animals are tested in a familiar environment, such as their home cage, as opposed to an open 
filed arena, the reduced novelty will result in reduced exploratory behaviour and therefore 
locomotion (455). In addition, since this study did not measure detailed time points over the 
first hour after morphine injection that coincides with its maximum antinociceptive effect, the 
results of this study cannot be directly compared to the present study and are also unable to 
connect the behavioural effects of morphine with its antinociceptive effects, which was the aim 
of the present study  (191).  
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The relationship between the behavioural effects of morphine, antinociceptive tolerance and 
morphine dosing has been elusive, mainly due to reported inconsistencies in experimental 
results, which are likely the consequence of different experimental approaches with regards to 
route of administration, type or formulation of morphine, type of animals used as well as 
treatment protocols (dose, frequency or duration of treatment) (192,194,441,442). All these 
experimental variables are likely to influence the effect of morphine on motor behaviour and 
therefore highlight the need for a study that examined the relationship between morphine’s 
behavioural effects and dosing in a unified model. Understanding how morphine’s dosing 
contributes to behaviour is crucial for future clinical strategies to reduce morphine’s side-
effects.  
I assessed hypoactivity by monitoring the major parameters of locomotor activity (distance, 
speed, moving-time, rotational behaviour and rearing), which can be seen as surrogate markers 
for morphine-induced motor side-effects. Locomotor activity was previously used to assess 
behavioural side-effects after acute or chronic treatment of morphine (191,193,194). However, 
locomotion alone cannot represent all facets of drug-induced behavioural changes, while 
combining it with additional behavioural parameters is a much more promising approach (193). 
The current study describes drug-induced changes in seven different motor parameters using a 
computerised behavioural monitoring system. My study aimed to explore the association of 
morphine dosage-regimens, biphasic motor behaviour and antinociceptive tolerance over a 
period of 14 days of repeated morphine administration in rats administered with different doses 
of morphine. Mapping the relationship of the presented behavioural effects of morphine with 
its dosing regimen (e.g. starting dose and increment of dosing), will help to reduce these effects 
by manipulating morphine administration protocols in the future.  
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In this study, I confirmed that subcutaneous administration of morphine produces locomotor 
suppression in rats after acute administration (day 1; Fig.13 and Fig. 15), which is in agreement 
with previous studies showing that even lower doses of morphine can decrease motor behaviour 
after acute or short-term treatment in rodents (191,193,195,441,456). However, I also showed 
that repetitive morphine administration (twice a day) resulted in locomotor tolerance 
(morphine-induced reduction of locomotion ) after 5 days, the extent of which depended on the 
dose administered (partial tolerance at 5 mg/kg b.i.d. and full tolerance at 10 mg/kg b.i.d.). The 
tolerance profile for the behavioural effect of morphine seemed to manifest in parallel to the 
manifestation of antinociceptive tolerance, as I recently showed (137). However, one 
significant distinction between the motor effects of the two doses in my study was that the 
effects of the lower dose plateaued after 2 days that were non-significantly different from basal 
levels until 5 days after treatment. The larger dose resulted in the manifestation of the excitatory 
phase of morphine-induced motor effects shown by the resulted hyperactivity after 5 days of 
treatment, which plateaued at 10 days after repetitive treatment (Fig. 17). In fact, I was able to 
show that this excitatory effect of high morphine dosing occurred in parallel to the expression 
of antinociceptive tolerance (Fig. 21). Similar to the basal antinociceptive effects reported 
previously (137), basal locomotor activities (locomotor, rotation and rearing activities) were 
also not affected by repeated morphine dosing over the two week period, which supports 
previous reports (443). Therefore, morphine showed no residual effects on behaviour or 
antinociception after repeated dosing over 2 weeks.  
Biphasic motor effect of morphine is known for quite a while but has been mainly described in 
acute and short-term morphine administration protocols with contradicts the role of morphine 
dosing in this biphasic profile (191,192,193,194,195,196,197).  I was able to show a detailed 
description of the manifestation profile of this excitatory state (i.e. rate of increase and timing 
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of expression), which is key to understand the underlying mechanisms. Moreover, and perhaps 
more interesting, is the exposure of the role of morphine dosing regimen in the expression of 
morphine-induced hyperactivity. This study showed that when the morphine regimen changes 
after the occurrence of hyperactivity, such that the total morphine amount administered remains 
the same, but the dosing frequency is reduced (e.g. 10 mg/kg b.i.d.  20 mg/kg/day). Then, 
the strong suppressive effect of morphine returns to the pro-hyperactivity levels and results in 
the manifestation of morphine-induced hypoactivity (Fig. 17). These data also show that the 
morphine-induced excitatory effect is the result of morphine-induced tolerance on motor 
behaviour, which can be reversed by an increased dose, similarly to the way antinociceptive 
tolerance can be reversed by a dose increase (137).  
Morphine-induced hyperactivity can be reduced by blocking dopaminergic receptors, but these 
are not specific to the dopaminergic system (194,198). The higher AUC of behavioural 
activities of animals treated with morphine over a few days indicates clearly that the locomotion 
related behavioural effects changed over this time using a specific dose. In the present study, 
the effects of morphine were dependent on the dose administered or dosage regimen, as the 
AUCs of locomotor activities were statistically lower (over the total 14 days) with lower doses 
compared to the higher dose group.  
Opioid-induced turning, circling or rotation is mediated by the dopaminergic system (199,200), 
but not by the µ-opioid receptor (457). Circling or rotating behaviour is thought to be regulated 
by dopaminergic mechanisms, and circling animals models have been used to assess anti-
Parkinson’s disease drugs (458). Nevertheless, the rotating or turning behaviour in this study 
was suppressed in line with general locomotion after acute treatment of morphine and with a 
similar time kinetic. This agrees with early studies showing a similar suppression of rotation 
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by morphine in rats (459,460). I also showed that the rotational behaviour is subjected to effects 
of morphine-induced tolerance, similarly to locomotion and antinociception (Fig. 14), 
suggesting a strong link of this behaviour to the opioidergic system.  
Rearing activity is an exploratory behaviour of rodents and is related to information gathering 
or cognitive behaviour (205). Little or no rearing in the open-field may indicate motor 
impairment (206). Therefore not surprising, changes in rearing behaviour are also influenced 
by benzodiazepine treatment (461), which suggests that other neuronal systems might be more 
important for this behaviour. Recent studies have related rearing to gamma-aminobutyric 
(GABA) inhibitory neurotransmission controlled by the GABAA receptor in the hippocampus 
(207). Locomotion and rearing are positively correlated and are very reliable factors in terms 
of exploratory behaviour in untreated animals (192,210). Here, I show that morphine reduces 
rearing activities due to repetitive treatment with both low and high doses of morphine, in-line 
with previous studies (462). However, the morphine-induced suppression of rearing was not 
associated with tolerance, irrespectively of the morphine dose used, the changes in dosing 
regimen and the length of treatment (Fig. 14). The difference of rearing behaviour compared to 
the rest of motor behaviours tested (free moving and rotation) could indicate the involvement 
of additional non-opioidergic systems that affect brain areas that are involved in the motor 
control of this behaviour, which either alleviates or delays the manifestation of tolerance in 
rearing.  
In summary, the results of this study illustrated that a lower morphine dose reduced the motor 
behaviour, which was subject to behavioural tolerance after repetitive administration but did 
not lead to subsequent behavioural hyperexcitation. In contrast, animals treated with a higher 
morphine dose developed acute motor-suppressive behaviour that quickly desensitised to basal 
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levels and progressed to an excitatory phase after 10 days, which was in parallel to the 
development of antinociceptive tolerance. Therefore, morphine dosing plays a crucial role in 
the manifestation of changed motor behaviour similar to antinociception and motor behavioural 
tolerance follows a similar pattern to antinociceptive tolerance. In contrast, rearing shows a 
distinctive resistance to tolerance and dosing changes. My results suggest that morphine dosing 
determines the expression profile of behavioural effects by morphine and that antinociceptive 
tolerance is linked to the morphine-induced hyperexcitatory phase of behaviour. 
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CHAPTER FOUR 
 
Age-dependent antinociception and behavioural 
inhibition by morphine  
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Preface to chapter four  
I described the role of morphine dosing on antinociceptive tolerance and motor behaviour of 8-
week old animals in Chapter two and three. Clinical studies show that morphine has differential 
antinociceptive effects in older compared to younger individuals. Since the published results 
are largely inconclusive, further studies are needed to investigate this observation in more 
detail. This chapter (chapter four) aimed to investigate the effects of morphine on 
antinociception and motor behaviour in older and younger animals and connect the results to 
residual morphine levels in post-mortem tissues. In summary, this chapter was designed to 
increase our understanding of the age-dependent effects of morphine. 
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4. Age-dependent antinociception and behavioural inhibition by morphine 
 
Abstract 
 
In current clinical practice, morphine is dosed in older patients based on patient-weight, with 
different calculations for adjustment. However, at present, neither clinical experience nor the 
literature offers a clear evidence base for the relationship between antinociception, behavioural 
effects and morphine administration in older patients. In this study, I compared the nociceptive 
response of 8 and 24-week old rats after subcutaneous administration of morphine per body 
weight and analysed their behaviour using an advanced multi-conditioning system. Residual 
morphine in all major tissues was determined. I observed prolonged morphine-induced 
antinociception in older rats compared to younger rats. Moreover, morphine significantly 
stimulated locomotor and rearing behaviour 180 min after injection, which was significantly 
higher in the 8-week compared to 24-week old rats. Tissue analysis from animals extracted 
during the stimulatory phase revealed a significantly higher concentration of residual morphine 
in the brain of older versus younger animals when standardised on tissue weight. However, this 
effect was not observed when residual morphine was standardised on protein content. 
Collectively, the present data suggest that in older rats morphine exhibits higher antinociception 
and increased behavioural inhibition compared to younger animals. This effect is likely due to 
a significantly higher accumulation of morphine in the brain of older animals. 
 
Key Words:  Morphine; motor behaviour; ageing; antinociception; open-field; locomotion. 
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4.1. Introduction  
The proportion and number of older people are increasing globally with an expected 20% of 
the total population above 60 years of age by 2050 (463). These individuals experience pain 
comparatively more than younger people, which affects their daily activities and total quality 
of life. Noticeably, due to the high prevalence of pain, individuals over 60 years of age are the 
highest users of analgesics and especially of opioids (405). Therefore, the effective 
management and safe use of opioids are particularly important for this cohort. Morphine, one 
of the most frequently used opiates worldwide, is considered a high-risk medication due to its 
narrow therapeutic index and a plethora of neuropsychological and behavioural effects 
(406,407,408). Therefore, different calculative dose-adjustments are often clinically used to 
ensure drug safety but do not always provide effective pain relief (409,410,411,412,413).  
Although the prevalence of pain in the ageing population is high, these patients are often not 
properly assessed regarding their pain relief (464,465,466,467,468), which severely reduces 
treatment efficacy (469,470,471). A striking lack of data for the ageing population regarding 
the effects of opioid dosing on patient behaviour is especially evident for patients with cognitive 
impairment (472,473,474,475). Furthermore, compared to younger patients, aged patients show 
a higher incidence of adverse events, which are especially associated with long-term opioid 
treatment (412,476). Therefore, the selection of effective and safe morphine doses in aged 
individuals is one of the most frequently faced challenges in the clinic. The difficulty to achieve 
adequate pain relief and at the same time to avert the manifestation of side effects in aged 
patients has fuelled concerns that factors such as altered drug pharmacokinetics, metabolism or 
behavioural changes could contribute to this challenge (409,410,411). 
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Therefore, there is an urgent need to identify a possible correlation between the antinociceptive 
and behavioural effects of morphine in aged individuals. At present, a limited number of studies 
suggest a physiological and/or molecular basis for the differences observed in opioid 
pharmacology when comparing aged and younger individuals (414,415). However, the evident 
lack of established knowledge regarding the behavioural effects of opioids in aged subjects and 
the potential differences compared to young individuals hinders the legitimate and appropriate 
use of opioids in aged individuals.   
In this study, I connected the antinociceptive and behavioural activities of morphine with 
residual morphine concentrations in post-mortem tissues of test animals, to shed some light on 
the age-dependent pharmacokinetic and behavioural differences of morphine administration.  
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4.2. Materials and Methods  
4.2.1. Materials 
Morphine sulphate solution for injection (30 mg/ml) was purchased from Hameln 
Pharmaceuticals GmbH, Germany. The drug was kept at room temperature in a secured safe in 
accordance with Australian regulations around schedule 8 drugs. For the low dose group (5 
mg/kg), morphine sulphate was diluted to 15 mg/ml with sterile 0.9 % sodium chloride solution 
immediately prior to subcutaneous (s.c.) injection.   The injection volumes for both 5 and 10 
mg/kg morphine groups were the same according to volume/weight and within each group 
differed by not more than 8 % when adjusted for individual animal weights. F10SC veterinary 
disinfectant solution (Health and Hygiene Pty Ltd, Florida Hills, South Africa) was used for 
cleaning and hygiene purpose as a diluted solution (1:250 in water). 
4.2.2. Animals 
Male Sprague Dawley (SD) rats (total 20; 4 x n=5) were used in this study. Half of those (n=10) 
aged for 24 weeks using normal diet (6 % crude fat, Barastoc rodent cubes, Ridley Corporation, 
Melbourne, Australia) and water, while the other animals (n=10) aged for only 8 weeks on the 
same diet. During the experimental phase, all animals were single-housed under standard 
laboratory conditions and kept on an automated 12:12 hours day/night cycle (lights on at 7:00 
am). The treated animals were single-housed after administration of morphine and throughout 
the experiments in order to facilitate behavioural health-monitoring and avert the manifestation 
of potential morphine-induced behavioural aggression towards cage-mates. Animals were 
handled for 5-6 days before the experiments were conducted. On the morning of behavioural 
tests, animals were transported to the testing room in their home case and acclimatised to the 
test environment for 1 hour. All procedures and animal handling were performed according to 
the guidelines of the University of Tasmania Animal Ethics Committee (approval no. A13864) 
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and The Australian Code for the Care and Use of Animals for Scientific Purposes (434). 
Animals of each group (8 and 24 weeks of age) were divided into two subgroups using a 
completely randomised design as previously described (448). Each group received a different 
dose of morphine sulphate solution (5 mg/kg or 10 mg/kg) as single s.c. injection between the 
left thigh and the spinal cord. The subcutaneous route of administration was previously shown 
to be an effective and quick route for morphine administration (Stuart-Harris et al., 2000), 
causing minimal discomfort to the animals. The two different doses of morphine were selected, 
based on previous data from our group regarding the connection between morphine loading-
dose and antinociception (137). The weight of all animals was recorded prior to the 
administration of morphine. The BMI of rats was calculated based on the formula: BMI = body 
weight (g) / body length2 (cm2) as described previously (477,478). The animals were tested 
side-by-side by the same operator in the same testing environment, but extensive cleaning and 
hygiene procedures were undertaken to ensure that the younger animals were not exposed to 
the scent of the older animals and vice versa. A schematic diagram represents the different 
time-points before and after morphine treatment of 8 and 24-week old animals (Fig. 23). 
 
Figure 23. Schematic diagram of the morphine treatment and assessment protocol. TFL: tail‐
flick  latency; HPL: hot‐plate  latency, OF: open‐field  test; BWT: body‐weight; BMI: body mass 
index; 0 min: base‐line before treatment. 
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4.2.3. Nociception Measurements 
Nociception was determined independently by tail-flick and hot-plate assays performed in 
random sequence, separated by a 1-minute interval between the two assays, using specialised 
apparatuses (Ugo Basile, Comerio, Italy). Maximum exposure of the animals to the nociceptive 
thermal stimuli (cut-off time) was 15 s for the tail-flick and 30 s for the hot-plate assay, as 
previously described (137,152,437,438). The infrared intensity of the tail-flick photocell was 
set at 30, whereas the plate temperature of the hot-plate was set at 54 ± 0.5 °C. All rats were 
tested immediately prior to morphine administration (basal measurement) and at 15, 30, 60, 
120, 180 and 240 min post-administration in both assays. The maximum possible effect (MPE) 
was defined as % MPE = 100 X [(test latency – baseline latency)/(cut-off time – baseline 
latency)] as previously described (436). 
Nociception experiments were conducted blindly and results were recorded by averaging three 
independent measurements for each time-point with a 1 min difference between measurements 
to minimise ‘handling’ effects. No differences in basal nociceptive thresholds were observed 
in both antinociception assays between 8 and 24-week old rats, which supports two previous 
studies, that also observed no age-related differences in basal antinociception (479,480).  In 
addition, no differences in antinociceptive latencies over a period of 2 h were detected (data 
not shown). Similarly, over a period of 2 weeks of repeated testing, basal levels of 
antinociceptive latencies also remained unchanged (Fig. 9, chapter 3; Suppl. Fig. S4 in (137)), 
which both indicate that ‘testing fatigue’ did not affect the experimental results of this study. 
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4.2.4. Behavioural Measurements 
The behavioural testing used six different activity parameters (total distance travelled, rearing 
time, the ratio of presence in periphery versus centre, clockwise rotation, anti-clockwise 
rotation and moving time). Behaviour was tested in an open-field arena in a Multi-Conditioning 
System (MCS) (TSE GmbH, Homburg, Germany) 2 min after nociception-testing at 0 min 
(pre), 30 and 180 min after administration of morphine over a period of 5 min. Measurements 
in open field arena over a period of 5 min are commonly used (192,446,450,481) and allowed 
the concurrent measurements of antinociception in the same group of animals in this study. The 
MCS platform included an internal noise/light/temperature insulation system and a 3D infrared-
beam frame that provided fast and accurate animal movement detection (100Hz), combined 
with a high-resolution video monitoring and automated movement tracking system. 
Quantification and visualisation of the MCS data were processed by integrated system software 
(TSE ActiMot). The open-field arena was thoroughly cleaned between each animal using paper 
towels soaked in the diluted F10 solution. Background white noise (20 dB) was used during all 
experiments to cancel out environmental sounds.  
4.2.5. Tissue Collection 
Immediately after testing antinociception at 240 min post-administration of morphine, animals 
were anesthetised with 5% (w/v) isoflurane in oxygen at a flow rate of 1 L/min, until loss of 
consciousness was observed (usually 5-7 min) and the animals were decapitated. Blood was 
collected from the decapitated body by gravity flow using 15 ml centrifuge tubes (Corning 
Centristar) and immediately centrifuged at 1500 rpm for 10 min to collect serum. The serum 
was stored at -80 C until used in experiments. Serum, spleen, kidney, liver, heart, lungs and 
brain were collected from decapitated bodies and snap-frozen in liquid nitrogen for the 
estimation of residual morphine in the animals treated with 5 mg/kg morphine.  
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4.2.6. Residual Morphine Concentration in post-mortem Tissues 
Spleen, kidney, liver, heart, lung and brain tissues were homogenised by an electric 
homogeniser immersed in ice-cold RIPA buffer. Tissue homogenates were centrifuged (1500 
g, 4º C, 10 min) before supernatants were collected for morphine measurements. Residual 
amounts of morphine were detected in tissue lysates using a morphine ELISA-Kit (#KA0935; 
Abnova, Taipei, Taiwan) and a Thermo Scientific Multiskan GO microplate spectrophotometer 
(Thermo Scientific Inc, Waltham, MA, USA). The results were expressed as µg morphine per 
tissue weight (g) as well as µg morphine per protein content (g) of the tissues extracts. Protein 
contents of tissue extracts were determined using a commercial protein assay kit (#5000111; 
Bio-Rad, Hercules, CA, USA) according to the manufacturer’s recommendations.  
4.2.7. Statistical Analysis 
Data is presented in graphs or tables as mean ± SEM from n measurements as stated in the 
figure legends. Student’s t-test was used for comparison of BMIs, one-way ANOVA with 
Sidak’s multiple comparison post hoc test was used to compare motor behaviours and body 
weights, and  two-way ANOVA with Sidak’s multiple comparison post hoc test were used for 
statistical comparison of antinociception and residual morphine estimation of post-mortem 
tissues, using GraphPad Prism V6.01 software (GraphPad Software Inc., La Jolla, CA, USA). 
Repeated measures one- or two-way ANOVA with Sidak’s multiple comparison post hoc test 
were conducted to measure the differences between different time points of the same group of 
animals. However, comparisons between two or more groups of animals were made using non-
repeated one- or two-way ANOVA with Sidak’s multiple comparisons post hoc test.  
Significance was set at p < 0.05.  
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4.3. Results  
4.3.1. Body weight and BMI analysis 
Significant differences in body weight between 8 week (253.3 ± 9.6 g) and 24 week old animals 
(582.1 ± 21.2 g) were observed prior to the initiation of experiments [non-repeated measure 
one-way ANOVA; F (5, 26) = 57.77; p < 0.0001] (Table 17). Consistent with increased 
bodyweight, a significant BMI difference between 8 week (0.83 ± 0.02) and 24 week old 
animals (1.10 ± 0.05) [unpaired t-test; t (6) = 5.50; p < 0.01] was detected (Table 17). No weight 
differences were detected after randomisation between the two different morphine subgroups 
(5 mg/kg and 10 mg/kg morphine) in the 8 and 24 week old animals (Table 17).  
Table 17. Differential body weights and body mass index of 8 week and 24 week old rats 
 
*No significant differences between 5 mg/kg and 10 mg/kg morphine dose‐groups at the same age 
 
4.3.2. Morphine-induced antinociception in 24 week old rats is prolonged compared to 8 
week old rats 
No significant differences in basal antinociception were detected for the 8 and 24 week old 
animals, using both tail-flick and hot-plate assays (Fig. 24). The time-dependent 
antinociception profiles (herein antinociception “curves”) of the 8 and 24 week old animals in 
response to a single subcutaneous injection of morphine were comparable when measured by 
tail-flick (Fig. 24 A, C) and hot-plate (Fig. 24 B, D) assays. Antinociception peaked 30 min 
after morphine injection in both assays, followed by a gradual decrease thereafter. In the tail-
  Body Weight  BMI 
Age group  Combined  5 mg/kg 
morphine group 
10 mg/kg 
morphine group* 
Combined 
8 week old  253.3±9.6  261.0±16.7  245.7±11.3  0.83±0.02 
24 week old  582.1±21.2  617.2±28.3  547.0±24.7  1.10±0.04 
p value  <0.0001  <0.0001  <0.0001  <0.01 
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flick assay, antinociception reached the cut-off value in the early post-injection (15-60 min) in 
both age groups. When the data set of Fig. 24 was analysed using repeated measures two-way 
ANOVA to identify whether post-morphine administration time and animal age are 
determinants of morphine-induced antinociception, I observed that both parameters were 
highly significant [time, F (6, 96) = 786.7, p < 0.0001;  age, F (3, 16) = 80.90, p < 0.0001]. 
Significantly higher levels of antinociception were observed in 24 week old rats between 60-
240 min post-injection for both morphine doses [e.g. 5 mg/kg: Sidak’s p < 0.0001 (120 min); 
10 mg/kg: Sidak’s p < 0.0001 (180 min)], which explains the significant differences in AUC 
values of total antinociception between the two age groups (Fig. 24 A, C; Table 18). In the hot-
plate assay, differences in antinociception for both age groups were more pronounced than in 
the tail-flick assay. These differences became visible for both morphine doses (5 mg/kg and 10 
mg/kg) 15 min post-administration [Sidak’s p < 0.0001] (Fig. 24 B, D). Repeated measure two-
way ANOVA underlines that time [F (6, 96) = 479.9, p < 0.0001] and age [F (3, 16) = 60.34, p 
< 0.0001] are the main parameters, with 24 week old animals showing significantly higher 
antinociception levels after 3 h [Sidak’s p < 0.001] and 4 h [Sidak’s p < 0.05] post 10 mg/kg 
morphine administration (Fig. 24 D). Noticeably, in both assays, total antinociception over 4h 
by a single morphine injection was significantly higher in the 24 week compared to the 8 week 
old animals, which is reflected by the Area Under the Curve (AUC) values (Table 18) [non-
repeated measure one-way ANOVA; F (3, 16) = 89.10; p < 0.0001 (tail-flick); non-repeated 
measure one-way ANOVA; F (3, 14) = 46.22; p < 0.01 (hot plate)]. The corresponding tail-
flick and hot-plate antinociceptive latencies are shown in Fig. 25. 
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Figure 24. Antinociceptive effect of morphine in 8 and 24 week old rats. Antinociceptive profile 
of acutely‐treated 8 and 24 week old rats with subcutaneous morphine (5 and 10 mg/kg) at pre‐ 
and different post‐administration times (15‐240 min), measured using a tail‐flick assay (A, C) and 
a hot‐plate assay (B, D). Antinociceptive curves of morphine 5 mg/kg (A, B) and 10 mg/kg (C, D) 
are presented as the maximum possible effect (MPE) against pre‐ and post‐administration time‐
points  as  described  in Methods.  All  data  are  presented  as  mean  ±  SEM,  n=5  per  group. 
Statistically significant differences compared against 8 week old animals at the same time‐point 
(*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001) using repeated measure  two‐way 
ANOVA with Sidak’s multiple comparison post hoc test. Error bars are present in all graphs but 
are sometimes too small to be visible. 
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Table 18. Total antinociception (as area under the curves, AUC) of morphine‐treated rats  
 
Total antinociception of morphine:  
AUC values (x103) from antinociceptive curves 
Tail‐flick assay  Hot‐plate assay 
Morphine dose  5mg/kg  10mg/kg  5mg/kg  10mg/kg 
8 week old  11.33 ±0.35  16.45 ±0.59  6.99 ±0.42  13.03 ±0.22 
24 week old  15.86 ±0.47  21.22 ±0.21  11.72 ±0.55  16.23 ±1.01 
p value  <0.0001  <0.0001  <0.001  <0.01 
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Figure 25. Antinociceptive latencies of morphine in 8 and 24 week old rats.  Antinociceptive 
profiles of 8 and 24 week old rats treated with subcutaneous morphine (5 and 10 mg/kg) pre‐ 
and post‐administration (15‐240 min) was measured using a tail‐flick (A, C) and hot‐plate assay 
(B, D). Antinociceptive curves of morphine 5 mg/kg (A, B) and 10 mg/kg (C, D) are presented as 
latency (in sec) against pre‐ and post‐administration time‐points as described in Experimental 
design,  Materials  and  Methods.  All  data  are  presented  as  mean  ±  SEM,  n  =  5  per  group. 
Statistically significant differences compared against 8 week old animals for the same time‐point 
were generated using repeated measure one‐way ANOVA with Sidak’s multiple comparisons test 
(*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001). Error bars are present in all graphs but 
are sometimes too small to be visible. 
 
4.3.3. Morphine-induced behavioural effects post-antinociception of older animals 
Despite their differences in weight and BMI (Table 17), 8 week old animals showed higher 
basal physical activity (distance travelled x rearing(s) occurred) compared to their 24 week old 
counterparts (Fig. 26; Table 19). Consistently, 30 min after morphine administration, physical 
activity significantly decreased for both age-groups compared to their basal activity levels [non-
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repeated measure one-way ANOVA; F (5, 14) = 9.40; p < 0.05 (8 week old); p < 0.01 (24 week 
old)] (Table 19; Fig. 26). After 180 min, activity levels in both 8 and 24 week old animals were 
indistinguishable from their basal levels. Notably, after 180 min the physical activity of 24 
week old animals was significantly lower compared to the 8 week old animals [non-repeated 
measure one-way ANOVA; F (3, 11) = 14.44; p <0.05] (Table 19). Overall, 24 week old rats 
showed significantly decreased physical activity compared to 8 week old rats before and after 
morphine administration (Table 19).  
 
 
Figure 26. Effects of morphine on total physical activity. Effects of a single dose of morphine (5 
mg/kg, s.c.) on the physical activity of 8 and 24 week old rats were recorded in an open‐field 
arena. The pattern of physical activity (A) was acquired using automated video‐tracking software 
that presented the path of movement (brown lines) and rearing (blue lines) during the recorded 
session. One representative activity pattern for each weight group is shown. Animals were tested 
at basal (prior to morphine administration), 30 and 180 min post‐administration. All data are 
presented as mean ± SEM, n = 5 per group.  
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Table 19. Effect of morphine (5 mg/kg) on total physical activity  
  Total Physical Activity 
† 
0 min  30 min  180 min 
8 week old  3252 ± 832  531.5 ± 126.2  4374 ± 730.3 
24 week old  1544 ± 484  70.88 ± 39.37  1706 ± 1058 
p value  <0.05  <0.01  <0.05 
  † = Distance travelled x rearing incidence (rearing numbers) 
 
 
Detailed 3D video-tracking analysis of individual behaviour in 8 and 24 week old animals 
treated with a single dose of morphine (5 mg/kg) confirmed this effect for three basic 
behaviours: moving distance, rearing and topology (Fig. 27). The measurement of moving 
distance (Fig. 27 A) is a marker of locomotion and kinetic behaviour in rodents (191,193,194). 
A significant reduction of moving distance compared to basal scores was observed in the 8 
week old animals at 30 min post-treatment [repeated measure one-way ANOVA; F (1.2, 4.8) 
= 47.47; p < 0.01]. These animals also showed a marked increase of moving distance after 180 
min, which was significantly higher than their basal values [repeated measure one-way 
ANOVA; F (1.2, 4.8) = 47.47; p < 0.05]. Over the same time period, the 24 week old animals 
showed a very similar response to morphine but at a lower level (Fig. 27 A). Noticeably, 
moving distances of 8 and 24 week old rats were significantly different for basal [non-repeated 
measure one-way ANOVA; F (5, 24) = 32.89; p < 0.05] and 180 post-administration [non-
repeated measure one-way ANOVA; F (5, 24) = 32.89; p < 0.05] time-points (Fig. 27 A). As 
the second marker of behaviour, rearing activity was assessed, which is a behavioural marker 
of exploration or anxiety and has been previously linked to brain excitability (205,206,207). In 
this analysis, 8 week old animals, after a dramatic reduction at 30 min [repeated measure one-
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way ANOVA; F (1.5, 6.2) = 74.68; p < 0.01], showed a marked recovery after 180 min 
[repeated measure one-way ANOVA; F (1.5, 6.2) = 74.68; p < 0.001], whereas the 24 week 
old animals failed to recover from this low level (Fig. 27 B). In contrast, the topology scoring 
analysis (the distance-travelled ratio for periphery over the centre of arena), which is a 
behavioural marker for locomotion or anxiety (450,481), differed from the previous two 
parameters (Fig. 27 C). The 8 week old animals presented an increased topology score after 30 
min [repeated measure one-way ANOVA; F (1.4, 5.7) = 8.79; p < 0.05] compared to the basal 
score and showed recovery at 180 min time-point [repeated measure one-way ANOVA; F (1.4, 
5.7) = 8.79; p < 0.05] (Fig. 27 C). In contrast, in the 24 week old animals, morphine did not 
affect the topology behaviour, which remained low throughout the test (Fig. 27 C). A score of 
nearly 1 for the topology behaviour of 24 week old rats indicated that these animals moved to 
a similar extend in the periphery or the centre of the arena (Fig. 27 C). Turning behaviour 
(clockwise and anticlockwise rotation time) and moving time were similar in both groups for 
basal levels (0 min) and 180 min post-injection of morphine (Fig. 28). However, 24 week old 
rats showed a significant reduction of turning behaviours compared to 8 week old rats 30 min 
post-treatment (Fig. 28). The behavioural data of both 8 and 24 week old animals treated with 
10 mg/kg morphine showed a similar response to animals treated with 5 mg/kg morphine (Fig. 
29). Morphine induced behavioural and antinociceptive effects among the 8 and 24 week old 
rats are presented in Table 20. 
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Figure 27. Detailed analysis 
of  morphine‐induced 
behavioural changes. Three 
distinct animal behaviour (A. 
total  distance,  B.  rearing 
time,  C.  Topology:  ratio  of 
distance  travelled  in 
periphery  vs  centre)  were 
recorded after a single‐dose 
of morphine  (5 mg/kg,  s.c.) 
in 8 and 24 week old rats and 
analysed  using  ActiMot 
software  (TSE  Systems). 
Measurements  were  taken 
prior  to  morphine 
administration  (basal),  30 
and  180  min  post‐
administration.  The 
differences between the 30 
min time point and basal or 
the 180 min time point were 
significantly  different  (*p  < 
0.05,  ***p  <  0.001  and 
****p  <  0.0001,  using 
repeated measure  one‐way 
ANOVA with Sidak’s multiple 
comparison post hoc test) or 
the  significant  differences 
against  8 week  old  animals 
at  each  time  points  (##p  < 
0.01 and ###p < 0.001, using 
non‐repeated measure one‐
way  ANOVA  with  Sidak’s 
multiple  comparison  post 
hoc  test).  All  data  are 
presented as mean ± SEM, n 
= 5 per group. Error bars are 
present in all graphs but are 
sometimes  too  small  to  be 
visible. 
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Figure 28. Detailed analysis of 
low‐dose  morphine‐induced 
behavioural  changes.  Three 
distinct  animal  behaviour  (A. 
Moving time, B. Clockwise (CW) 
rotation  time,  C.  Counter‐
clockwise (CCW) rotation time) 
were  recorded  after  a  single‐
dose  of  morphine  (5  mg/kg, 
s.c.)  in 8 and 24 week old rats 
and  analysed  using  ActiMot 
software  (TSE  Systems). 
Measurements  were  taken 
prior  to  drug  administration 
(basal),  30  and  180 min  post‐
administration, as described in 
Experimental design, Materials 
and  Methods.  Differences 
between the 30 min time point 
and the basal or 180 min time 
points  were  significantly 
different  (*p  <  0.05,  ***p  < 
0.001  and  ****p  <  0.0001, 
using  repeated  measure  one‐
way  ANOVA  with  Sidak’s 
multiple  comparison  post  hoc 
test).  Likewise,  significant 
differences against 8 week old 
animals  were  observed  for 
some  time  points  (##p  <  0.01 
and  ###p  <  0.001,  using  non‐
repeated  measure  one‐way 
ANOVA  with  Sidak’s  multiple 
comparison  post  hoc  test).  All 
data are presented as mean ± 
SEM, n = 5 per group. Error bars 
are present in all graphs but are 
sometimes  too  small  to  be 
visible. 
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Figure 29. Detailed analysis of high dose morphine‐induced behavioural changes. Six distinct 
animal behaviour (A. Moving time, B. distance, C. rearing time, D.  clockwise (CW) rotation time, 
E.  Counter‐clockwise  (CCW)  rotation  time,  and  F.  topology:  ratio  of  distance  travelled  in 
periphery vs centre ) were recorded after a single‐dose of morphine (10 mg/kg, s.c.) in 8 and 24 
week old rats and were analysed using ActiMot software (TSE Systems). Measurements were 
taken prior to drug administration (basal), 30 and 180 min post‐administration, as described in 
Experimental design, Materials and Methods. Differences between the 30 min time point and 
the basal or 180 min time points were significantly different (*p < 0.05, ***p < 0.001 and ****p 
< 0.0001, using repeated measure one‐way ANOVA with Sidak’s multiple comparison post hoc 
test). Likewise, significant differences against 8 week old animals were observed for some time 
points (##p < 0.01 and ###p < 0.001, using non‐repeated measure one‐way ANOVA with Sidak’s 
multiple comparison post hoc test). All data are presented as mean ± SEM, n = 5 per group. Error 
bars are present in all graphs but are sometimes too small to be visible. 
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Table 20. Overall differences of morphine‐induced antinociceptive and behavioural effects in 
24 week old compared to 8 week old rats. 
  Morphine induced behavioural effects 
Tests  Anti‐
nociception 
Speed 
travelled 
Distance 
travelled 
Rearing  Topology#  Rotation 
 
Effects for 24 
vs 8‐week 
old animals 
 
Prolonged   Similar  Prolonged inhibition  
Prolonged 
inhibition   No effect  
Prolonged 
inhibition 
#Topology: the distance‐travelled ratio for periphery over the centre of the arena  
 
4.3.4. Increased residual morphine in the brain of older rats  
To understand whether the observed stimulatory effects of morphine post-antinociception were 
related to tissue concentrations, residual tissue morphine levels were quantified at the end of 
the behavioural stimulatory phase (Fig. 30). The analysis of morphine per tissue-weight showed 
significant differences between 24 and 8-week old animals for several tissues (spleen, heart and 
lung). Using non-repeated measure two-way ANOVA, age [F (1, 28) = 45.82; p < 0.0001] and 
tissue type [F (6, 28) = 28.44; p < 0.0001] were identified as the main effectors. Most 
importantly, the analysis revealed that significantly higher morphine concentrations were 
detected in the brain [Sidak’s p < 0.05] of 24-week old animals compared to the 8-week old 
group (Fig. 30 A). Since the weight gain in 24-week old animals could be attributed to increased 
muscle mass or increased amount of fat deposition in the tested tissues, I also standardised 
residual morphine levels on tissue protein content to compensate for the fact that morphine can 
accumulate in fatty environments. Using non-repeated measure two-way ANOVA, significant 
effects of age [F (1, 28) = 49.26, p < 0.0001] and tissue type [F (6, 28) = 16.86, p < 0.0001] 
with morphine tissue concentrations were observed. Also, significant differences were 
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observed in serum [Sidak’s p < 0.0001], spleen [Sidak’s p < 0.0001]  and kidney [Sidak’s p < 
0.05] compared to a standardisation against tissue weight (Fig. 30 B). Tissues with previously 
significant age-dependent differences in residual morphine between such as heart, lung and 
brain, largely lost that significance when the morphine levels were standardised on tissue 
protein concentrations. Finally, I displayed the ratio of morphine present 24 week versus 8-
week old rats either as morphine per tissue weight or morphine per tissue protein content to 
explore if tissue fat content could affect the results (Fig. 30 C). No obvious differences were 
observed in most tissues except the heart and brain. The corresponding amounts of morphine 
shown in Fig. 30 are also represented in Table 21 to illustrate the difference between 8 and 24-
week old animals. 
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Table 21. Residual Morphine content in post‐mortem tissues after 4 hours of injections of 5 mg/kg morphine 
 
 
 
Residual morphine (μg) (± SEM) 
     Tissue 
8 week   24 week 
p value 
8 week  24 week 
p value per tissue 
weight(g) 
per tissue weight (g) 
per protein content 
(g) 
per protein content 
(g) 
Serum  4.47 ± 1.72  23.32 ± 1.61  > 0.05  0.49 ± 0.12  3.39 ± 0.34  < 0.0001 
Spleen  22.45 ± 2.93  68.41 ± 7.05  < 0.001  0.89 ± 0.14  4.63 ± 0.35  < 0.0001 
Kidney  58.66 ± 5.65  56.14 ± 5.95  > 0.05  2.42 ± 0.53  4.23 ± 0.15  < 0.05 
Liver  40.12 ± 6.46  44.52 ± 1.01  > 0.05  3.25 ± 0.37  2.81 ± 0.71  > 0.05 
Heart  1.62 ± 0.31  20.49 ± 2.31  < 0.0001  0.43 ± 0.31  1.20 ± 0.62  > 0.05 
Lungs  17.38 ± 3.61  63.22 ± 14.8  < 0.001  0.96 ± 0.32  2.28 ± 0.54  > 0.05 
Brain  1.21 ± 0.49  7.47 ± 0.82  < 0.05  0.25 ± 0.11  0.41 ± 0.18  > 0.05 
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Figure 30. Residual morphine content in post‐mortem tissues. Levels of residual morphine were 
detected in tissues from 8 and 24 week old rats treated with a single‐dose of morphine 5 mg/kg 
after 240 min post‐administration, as described in Methods. Amounts are expressed as μg of 
morphine per total weight (g) of tested tissues (A) and as μg of morphine per protein content (g) 
in the tested tissues (B). Residual morphine in specific tissues was also displayed as morphine per 
tissue weight versus morphine per tissue protein content  (C). Significant differences against 8 
week old animals are  listed for each tissue (*p < 0.05, **p < 0.01, ***p < 0.001), using non‐
repeated measure two‐way ANOVA with Sidak’s multiple‐comparison post hoc test. All data are 
presented as mean ± SEM, n = 5 per group.  
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4.4. Discussion 
Current clinical practice for administering morphine to elderly patients involves appropriate 
dose adjustments based on the patient’s weight to provide appropriate analgesia and to 
minimise adverse effects (482,483,484). To achieve adequate pain-relief in elderly individuals, 
a lower morphine dose can be necessary due to age-related changes in pharmacodynamics or 
pharmacokinetics (482,484). This study aimed to investigate the possible correlation between 
antinociception and behavioural changes, which I compared in older and younger animals after 
a single morphine dose standardised to body weight. Initially, I compared the antinociception 
profiles of older and younger animals before and after treatment with two different morphine 
doses. Secondly, compared the behavioural responses of older and younger morphine-treated 
animals were recorded. In the final component of the study, residual morphine levels in 
different tissues of older and younger animals were compared. 
At present, evidence for differences in age-dependent morphine-induced antinociception in pre-
clinical animal models is inconclusive. In addition, there is also a paucity of studies that 
describe age-dependent behavioural data as a surrogate marker of morphine-induced side-
effects in rats. In this study, I showed that 24 week old rats exhibited morphine-induced 
analgesia over a longer time period compared to 8 week old rats. This result supports clinical 
data that described a longer duration of analgesia in elderly patients (416). In addition, in two 
clinical studies, younger patients required higher doses of opioids to provide similar levels of 
pain-relief compared to older patients (485,486). 
However, at the same time, my results appear to contradict several pre-clinical studies, where 
older animals either showed lower antinociceptive responses compared to younger animals 
receiving a weight-adjusted morphine dose (417,418,419,420,421) or no difference at all (422). 
169 
 
 
These differences are likely the consequence of differences in animal species, age of animals, 
testing methods and experimental conditions between these and my study. All these studies 
used different strains of mice or rats and tested antinociception under significantly different 
experimental conditions compared to the present study (417,418,419,420,421,422).In contrast 
to my study, 3-6 month versus 24 month old animals was compared in one study (Van Crugten 
et al. 1997), while other studies used multiple age groups between 2 and 31 months, which 
makes direct comparisons nearly impossible (417,418,419,420,421).  
Morphine-induced behavioural effects are not commonly studied in combination with its 
antinociceptive effects. In the present study, older animals showed significantly lower levels of 
physical activity compared to the younger animals. While 3 hours after morphine injection this 
activity in the younger animals returned to basal levels, this effect was not observed in the older 
animals. More pronounced changes were observed in the topology of locomotion (ratio of 
distance travelled between periphery/centre), which is an indicator of an anxiety as well as an 
exploratory activity (450,481). The decreased topology of locomotion in older animals in the 
present study suggests that older animals were less anxious compared to their younger 
counterparts, as younger animals travelled more in the periphery of the open field arena. 
However, at the same time, along with decreased physical activity and distance, it indicates 
older animals were less explorative than younger animals. The reduced physical activity of 
older animals compared to younger animals could be explained with the observation that older 
animals generally display reduced levels of natural activity. Therefore this might not 
necessarily reflect anxiety-like behaviour. A previous study reported no differences in 
locomotor activity between older (24-27 months) and younger (3-6 months) mice during a 2 
hour observation period after the administration of 10 mg/kg morphine (421). Since this study 
used much older animals of a different species compared to the present study, differential 
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locomotor activities are not necessarily unexpected. In addition, this study only described 
horizontal locomotor activities (421), which is insufficient to reflect the total motor behavioural 
effects of morphine (193). In contrast, the present study describes the behavioural effects of 
older and younger rats using six different types of motor behaviour that are related to horizontal 
locomotion, rearing and turning.  
Morphine-induced detailed locomotor activities were measured as behavioural effects of the 
animals that allowed me concomitant measurements of nociception and behaviour. Behavioural 
measurements like addiction, anxiety and mood disorders need new groups of animals, 
additional drug-dosing regimen and different protocols for habituation, treatment and 
measurements (170,487,488,489). Most importantly, those testing schedules would not allow 
a concomitant antinociception measurement. Therefore, my study focussed specifically on 
detailed locomotor activities to measure different opioid-induced behavioural changes. Acute 
treatment of morphine excites dopamine neurons (DA) to release the neurotransmitter 
dopamine in the ventral-trigeminal area (VTA) and nucleus accumbens (NAc) 
(490,491,492,493). The nigrostriatal pathway transmits dopamine from the substantia nigra 
pars compacta (SNc) to the dorsal striatum (494). Dorsal striatum coordinates motor functions 
by receiving neurotransmission from different parts of the brain. DA neurons also synapse into 
GABAergic neurons, which releases the neurotransmitter GABA (494). Studies also show that 
morphine-induced MOP receptor activation reduces local GABAergic transmission, which is 
responsible for the stimulation of dopamine release DA of VTA (493,495,496). The activation 
of dopaminergic neurons in both VTA and NAc regions by acute or repeated morphine can 
induce the firing of DA and dopamine release, which also depends on the activation of NMDA 
receptors (493,497). The increased dopamine in the VTA and NAc regions controls locomotor 
activities (reduced or biphasic locomotion), which also depends on the frequency of 
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administration of opioids (491,493,498). The inhibitory or stimulatory effects of morphine on 
locomotor activities are probably controlled by the neurotransmission of dopamine and GABA 
in the brain. In agreement with previous reports, this study confirmed that morphine produces 
a biphasic behavioural profile for most motor behaviours (191,193,441,447), where an initial 
suppressive phase is followed by a phase of overcompensation 180 min after drug 
administration. However, my data clearly show that this biphasic effect is absent for most 
morphine-induced behaviours in 24-week old rats, where the inhibitory phase prevails over the 
entire observation period up to 180 minutes post-administration. It is important to note that the 
suppression of behavioural activities observed the older animals in this study could be simply 
interpreted as the result of their higher body weights. Although the higher body weight of the 
older animals in the present study is likely a consequence of increased muscle and/or fat 
content, the exact estimation of these parameters was beyond the scope of this study design and 
will have to analyse in more detail in future studies.  
The present study also showed that the morphine-induced biphasic behaviour was inversely 
correlated with the analgesic profile of morphine, where the time points for highest 
antinociception aligned with the time points for lowest behavioural activity. Similarly, the over-
active behaviour coincided with the time-period when the antinociception effect of morphine 
had dissipated. However, in contrast to this pre-clinical study, the analgesic and behavioural 
side-effects of morphine appear to be poorly correlated in the clinic (190) and clinical studies 
furthermore appear to contradict each other. While some studies reported drug-induced 
drowsiness or lethargy (452,499), others described euphoria or anti-depressant activity 
(453,500). Therefore, the translation of the preclinical results of this study to the clinic has to 
be approached with significant caution. 
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When I analysed tissue morphine levels 4 hours after injection, increased residual morphine 
was detected in some tissues of older animals. However, this effect was dependent on the 
method of standardisation. While increased morphine levels were detected in the spleen, heart, 
lung, and brain after standardisation to tissue weight, I only observed significantly increased 
levels of morphine in serum, spleen and kidney after standardisation to tissue protein content. 
However, two previous reports failed to observe age-dependent differences in brain morphine 
(421,422). The reason for this discrepancy is not clear, but could be the consequence of 
different rat strains (hooded Wistar rats, Van Crugten et al.), animal species (ICR mice, Hoskins 
et al.), significantly shorter test periods (only up to 150 min post-injection, Van Crugten et al.), 
different methods of tissue analysis (HPLC analysis, Van Crugten et al.; radioactivity 
measurement, Hoskins et al.) as well as different methods of statistical analysis (unpaired t-
test, both studies) (421,422). In the present study, residual morphine was not determined for 
the higher morphine dose of 10 mg/kg, as both the 5 and 10 mg/kg doses showed similar 
maximum antinociception and behavioural inhibition at 30 min post-injections with a 
prolonged duration of these effects. Since both morphine doses showed similar differences 
between the 8 and 24 week old animals, residual morphine concentrations in tissues of the 
higher dose group were not measured. 
Due to the widespread experimental heterogeneity of pre-clinical studies (417,420,501,502), 
the largely inconsistent data come as no surprise. One uncertainty generally associated with 
pre-clinical models is the definition of animal age and its translation to human age (503,504). 
Most studies defined animals aged between 2 and 12 months as ‘young’ and animals aged 12 
to 30 months as aged. However, one important age-dependent parameter that cannot be ignored 
in this context is the increased body weight of older animals. Rats in captivity accumulate 
significant body weight, which is thought to be the consequence of age-dependent increases in 
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lipid content (505,506). Consequently, pre-clinical rat models confront us with the challenge 
that drug-dependent effects could be modulated simultaneously by both age-dependent and 
body weight-dependent mechanisms, which are intrinsically linked under standard animal 
husbandry conditions and have to be seen as a limitation of this approach. In this context, I 
acknowledge that the present study did not explore the age-dependent pharmacokinetics of 
morphine. Apart from time-resolved plasma levels, future studies will have to test, for example, 
if the fat pads in the animals could act as a reservoir for residual morphine, which could produce 
a delayed drug-release over time.  
Although the mechanism behind this prolonged antinociceptive and behavioural inhibition of 
morphine in older rats is not clear, it is reasonable to hypothesise that this effect is related to 
the significantly higher accumulation of morphine in the brain of older animals. It has to be 
noted that the average weight difference between 24 and 8-week old rats was only 2.3-fold, 
while an up to 6.2-fold higher residual morphine concentration was detected. This could 
suggest the presence of predominantly age-related pharmacokinetic and pharmacodynamic 
differences in this study, which are not predominantly dependent on body weight. However, 
this interpretation is not necessarily supported by clinical data, where a lower dose of morphine 
was required in older subjects to maintain similar levels of pain-relief compared to younger 
patients (482,484). In one of these studies, elderly patients showed significantly lower body 
weight than younger patients (484). These discrepancies highlight the likelihood that the 
physiological responses to morphine are governed by multiple age-dependent parameters that 
most certainly include patient weight, fat content and ADME parameters.  
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Apart from the differences in body weight, body composition and drug-drug interactions 
(423,424), altered ADME parameters represent a potential cause for different responses to 
morphine treatment in aged patients. Older patients with impaired cytochrome P450 (CYP) 
enzyme activity and/or renal impairment, are known to be susceptible to opioid toxicity 
(424,425,426,427,428). Similarly, G protein-coupled receptor kinases (GRK2, GRK6) and β-
arrestin expression decrease in an age-dependent manner (507). Repeated opioid exposure 
leads to inactivation of opioid receptors by G protein-coupled receptor kinases (GRKs) by 
phosphorylation and subsequent β-arrestin binding, which reduces the efficacy of opioids 
(508,509,510). Therefore, reduced β-arrestin binding and GRK activity in older animals could 
increase antinociceptive effects compared to younger animals at the same morphine dose. 
Detection of CYP, GRKs and β-arrestin expression was beyond the scope of this study and 
thus, age-dependent changes in these proteins cannot be ruled out as the underlying reason for 
the observed effects and will have to be investigated in future studies. My study did not explore 
any possible differences of antinociceptive or behavioural tolerance of morphine between 
younger and older animals, as the animals were culled to analyse the residual morphine content 
present in different post-mortem tissues after acute treatment. Since any possible differences 
are highly relevant for the clinical setting with an increasingly older population that uses 
opioids, future studies should explore age-related differences in the development of 
antinociceptive tolerance after chronic opioid treatment.  
In summary, my study identified differences in the antinociceptive and behavioural effects of 
morphine between older and younger rats. Prolonged morphine-induced antinociception and 
sustained inhibition of motor behaviour in older compared to younger animals were observed 
for weight-adjusted morphine dose, which was likely a consequence of higher residual 
morphine in the brain of older rats. My results will inform future studies that aim to investigate 
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age-dependent behavioural effects of morphine in relation to its analgesic effects and it will be 
interesting to see if similar effects can be observed for related anaesthetics and narcotics. The 
findings of the present study support previous studies that infer that older patients should 
experience sufficient pain-relief with a lower dose of morphine compared to younger patients 
(482,484,511). Although my study cannot be used to explain the clinically observed differences 
in the response to morphine treatment between older and younger patients, my observations, 
together with previous results can aide future studies to thoroughly investigate the 
pharmacokinetics of morphine and other analgesics specific to the elderly population. 
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CHAPTER FIVE  
 
Opioid receptor-dependent modulation of insulin-
release in pancreatic beta-cells  
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Preface to chapter five  
The previous chapters (chapters two, three and four) described different aspects of opioid use 
such as antinociception, antinociceptive tolerance and behaviour. Pre-clinical studies 
demonstrated increased MOP receptor expression in the liver and muscles of diabetic rats 
(390,512,513,514), but the actual consequences of this altered expression on the diabetic 
phenotype are obscure. To investigate a possible influence of opioids for the management of 
diabetes, extensive studies are required to understand the relationships between the opioidergic 
and the pancreatic metabolic system. Currently, a major gap exists in the literature on the effects 
of the three major opioid receptors (MOP, DOP and KOP receptors) on insulin homeostasisThis 
chapter (chapter five) aimed to understand the individual roles of the classical opioid receptors 
on insulin secretion. 
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Chapter 5. Opioid receptor-dependent modulation of insulin-release in pancreatic beta-
cells 
 
 
Abstract 
In this study, I aimed to look at the effects of opioid-receptor selective agonists and antagonists on 
insulin secretion in the pancreatic β-cell line RIN-5F. Cells were treated for 24 hours with 1μM of 
selective agonists (DAMGO for MOP, DPDPE for DOP, U50488 for KOP) in the presence or 
absence of 10μM of selective antagonists (CTOP for MOP, naltrindole for DOP, norBNI for 
KOP). An enzyme-based immunoassay was used to detect the amount of insulin in the 
supernatant, using standard curve generated from known concentrations of rat insulin. A trypan 
blue viability assay was performed to assess the toxicity of each treatment and the secreted insulin 
was expressed as per 103 viable cells. Treatment with the DAMGO or DPDPE caused an increase 
in secreted insulin by 94.2% and 76.3% respectively, compared to the non-treated controls. Co-
treatment of DAMGO and CTOP was able to cancel out the agonists’ effect. However, CTOP 
itself was able to increase insulin secretion by 72% when compared to control. These results 
suggest that opioid-induced insulin secretion may be based on G-protein independent 
mechanisms. In addition, none of the KOP-receptor selective ligands was able to significantly 
affect insulin secretion compared to control, whereas naltrindole was highly toxic to pancreatic β-
cells since it induced maximum cell death. Collectively, these findings suggest that MOP and DOP 
receptor-binding opioids might be more relevant in increasing insulin secretion from pancreatic β-
cells than KOP receptor ligands.  
 
Keywords: Opioid; insulin; morphine; pancreas; diabetes; glucose; hyperglycemia 
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5.1. Introduction 
Diabetes mellitus is a metabolic disease that is characterised by a disturbance in glucose and 
insulin homeostasis. Insulin is excreted centrally by the nervous system and locally by the 
pancreatic β-cells in response to plasma glucose levels and other endocrine signals (515). 
Diabetes is clinically divided in two types: Type 1 (T1DM) results from failure of the pancreas’ 
ability to produce enough insulin to regulate the body’s metabolism, mainly due to an 
autoimmune degeneration of pancreatic β-cells (516). Type 2 (T2DM) manifests as an initial 
phase of cell desensitisation to prolong insulin secretion (called insulin resistance) and a second 
phase of declined insulin secretion; manifestation which is linked to excessive plasma glucose 
levels and increased body weight (355,356). Based on this classification, one can conclude that 
glucose and insulin are key players in diabetes mellitus since their dysregulation, along with 
other endocrine substances such as glucagon released from pancreatic alpha-cells (517), play a 
catalytical role in the development and the progression of diabetes. 
Insulin secretion, as shown by Ammala et al, is triggered by glucose treatment in the same 
manner as the repetitive electrical stimulations, through a calcium-dependent exocytosis (518). 
However, since the glucose effect on pancreatic cells follows a step-wise format, insulin 
secretion follows a characteristic biphasic time-dependent format, with the first phase of 
secretion within 10–15 mins, followed by a slower second phase (519). This biphasic insulin 
secretion is important in understanding opioid-induced insulin secretion. Since impaired insulin 
secretion from pancreatic β-cells is a major factor in the pathology of both types of diabetes 
mellitus, it is only rational that many studies have focused on investigating the effect of 
different drugs on this process. Although there are a number of regulators of insulin secretion, 
such as plasma glucose levels, circulating hormones, paracrine and autocrine signals, the main 
player in the regulation of β-cell secretion is insulin itself, since it has been reviewed in 
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maintenance and regulation of β-cell function (515,520), another reason why insulin secretion 
is such a critical factor in the pathophysiology of diabetes.  
Patients with diabetes mellitus may develop different types of painful neuropathies. About 30% 
of diabetic patients experience neuropathic pain due to nerve injury induced by diabetes and 
about 20% of patients will develop chronic pain at some point during their life (361,362). 
Although opioids like morphine and fentanyl are considered ideal medications for medium-
severe pain, their efficacy in diabetic neuropathy is as limited as in other types of neuropathic 
pain (363). Nevertheless, the combination of opioids with non-opioid drugs that are effective 
in neuropathic pain (such as α2 adrenoceptor agonists and serotonin/noradrenaline reuptake 
inhibitors) has proven to offer certain therapeutic advantages (521), while it is being used in 
cases of diabetic neuropathies where first-line treatment with anticonvulsants or 
antidepressants was ineffective (363,522,523). 
Opium has been used for thousands of years due to its various therapeutic and recreational 
properties (i.e. analgesia, euphoria, drowsiness). However, it was only after the discovery of 
the three classical opioid receptor types (mu, MOP; delta, DOP; kappa, KOP) (524) and their 
endogenous ligands (endorphins, enkephalins and dynorphins respectively) that I increased our 
understanding of the opioid system and made opioid drugs one of the few classes of compounds 
that have been studied for so long (525). Opioid receptors are found in a wide variety of tissues, 
including the hypothalamic-pituitary system, while their role and effect in endocrine regulation 
has been well-studied during the last decade (526,527). All opioid receptors (MOP and DOP 
primarily, KOP in less extent) have been shown to be expressed in the pancreas and liver, while 
endogenous opioid peptides and their receptors have been shown to be present in pancreatic α- 
and β-cells (528,529,530).  
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Nevertheless, the first published work on the identification of endogenous opioids in the 
pancreas (531) gave rise to studies that focused on the ambiguous mechanisms involved in the 
endogenous opioid-mediated glucose and insulin homeostasis (387,392,532).  Green et al first 
showed that morphine and met-enkephalin were able to stimulate glucose-induced insulin 
release in isolated pancreatic isles (392), an effect that was observed to develop rapidly, 
representing the first phase of pancreatic insulin release and which could be blocked by 
naloxone pre-treatment and therefore, showing an opioid-receptor mediated effect. A number 
of studies that followed confirmed the results of Green et al either directly (395,396,397) or 
indirectly by showing a decrease in insulin secretion by administration of naloxone in healthy 
humans (398) and which highlighted the role of endogenous opioids on pancreatic function.  
Blockage of endogenous opioids by naloxone (an opioid antagonist) was reported to improve 
hypoglycaemia in type-1 DM patients (388). The study indicates that opioids can reduce blood 
glucose levels in human subjects (388), which is in line with the observation that opioids can 
stimulate insulin secretion in a pancreatic β-cell line (390). However, although more than 30 
years have passed since the first studies on the endocrine effects of opioids, there hasn’t been 
a sufficient progress towards a clear understanding about the role of opioid receptors and 
endogenous opioids in insulin secretion, as reflected by the small volume of published work on 
this area of research compared to the length of period studied.  Part of the reason for this delay 
in progress is the considerable controversy that exists in the literature regarding the contribution 
of the three classical opioid receptors and their ligands to the mechanisms and pathways 
mediating glucose-induced insulin secretion. A number of studies have shown a stimulatory 
effect of opioid agonists (392,393,394,395,396,397,398), while others have shown the opposite 
inhibitory effect (399,400,401,402,403,404).  
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A major hypothesis for this inconsistency is the different methodologies employed and the 
different models used in detecting insulin levels (515,533). The insulin signalling system is 
auto-regulated through different homeostatic mechanisms that involve glucose and glucagon 
secretion (among others). It is, therefore, most likely that observations of insulin secretion using 
high-complexity models (e.g. animal studies, perfused organs, mixed-cells tissues, etc.) would 
differ from observations performed in primary β-cell lines. Many in vitro studies that I discuss 
later in this chapter, have used isolated pancreatic islets to study glucose-induced insulin 
secretion, although these isolates include different types of cells (α-cells, β-cells, γ-cells) that 
produce different signals under certain conditions (e.g. glucagon, insulin, neuropeptide Y, 
amyloid peptide, ATP, GABA and other peptides) which can contribute differentially to the 
resulted insulin secretion (515). Τhis heterogeneity may qualify studies using β-cells (the main 
cells secreting insulin in the pancreas) as more accurate in terms of drug-screening on insulin 
secretion (534).  
Nevertheless, a major gap in the literature is the investigation of the individual role of the three 
classical opioid receptors in insulin secretion, using receptor-selective agonists and antagonists. 
Interestingly, no one looked at the effects of selective activation of MOP, DOP and KOP 
receptors in glucose-mediated insulin release in a pancreatic β-cell line. A detailed investigation 
into the role of the different opioid receptors involved in opioid-mediated insulin secretion and 
glucose homeostasis may lead to the identification of new target strategies in diabetes therapy. 
A major step towards this aim is to understand the individual role of the classical opioid 
receptors in insulin secretion.  
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Here, I report the effect of different opioid receptor-selective ligands, agonists and antagonists, 
to glucose-induced insulin release in a pancreatic β-cell line.  In this study, I am using the well-
characterised pancreatic β-cell line, RIN-5F, which releases insulin in glucose-containing 
media (534).  
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5.2. Methods 
5.2.1 Materials 
The pancreatic β-cell line (RIN-5F) was purchased from the American Type Culture Collection 
(ATCC® CRL-2058™; P.O. Box 1549 Manassas, VA 20108 USA). The insulin immunoassay 
kit was purchased by Merck Millipore (EZRMI-13K; Massachusetts 01821, USA). All tissue 
culture media and supplements were obtained from Life Technologies (GIBCO®, Paisley, 
U.K.). [D-Pen2|5]-enkephalin (DPDPE), nor-binaltorphimine (nor-BNI) and the D-Phe-Cys-
Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) were purchased by Abcam Biochemicals. The [D-
Ala2 N-Me-Phe4 Gly5-ol]-enkephalin (DAMGO) was purchased by AdipoGen. The (-)-U-
50488 hydrochloride (U50488) was purchased by Tocris Bioscience. Naltrindole hydrochloride 
and the trypan blue solution (0.4%,100 ml/bottle) were purchased by Sigma-Aldrich. All other 
reagents used were purchased with the highest quality available.  
5.2.2. Cell culture and treatment 
Cells were cultured and maintained in a similar way as previously described (349). Briefly, 
RIN-5F rat pancreatic β-cells were grown in 25cm2 flasks in RPMI-1640 media containing L-
glutamine, substituted with 10% heat-inactivated foetal calf serum, 100 IU ml-1 penicillin, and 
100 mg ml-1 streptomycin. Stock cultures were grown at 37 C with 5% CO2 95% humidity 
and were sub-cultured twice a week as required using phosphate buffered saline and 
trypsin/0.5mM EDTA. Cells were used for experiments as they approached confluence. An 
appropriate volume of cells was seeded in the wells of a 96-well plate, in the presence or 
absence of drugs in a total volume of 200μl and was incubated for 24 hours. Prior to the main 
experiment, the cell number-dependent basal insulin secretion levels of RIN-5F cell line(1x104, 
2x104 and 4x104 cells/well) were determined.  
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5.2.3. Drug treatment 
Cells were treated with a selective opioid-receptor agonist at 1μM final concentration 
(DAMGO, a MOP agonist; DPDPE, a DOP agonist; U50488, a KOP agonist) to determine 
their effect on insulin secretion (n = 4 - 5 per ligand). A combination treatment of an opioid 
agonist plus the respective opioid-receptor antagonist at 10μM final concentration (CTOP: a 
MOP antagonist, naltrindole: a DOP antagonist, nBNI: a KOP antagonist) was used in some 
wells to determine if the potential effect of the agonist was receptor-mediated (n = 4 - 5 per 
group). Antagonists where used at a higher concentration than the agonist in order to ensure 
sufficient displacement of the agonist from their receptor binding site. In addition, cells in some 
wells were also treated with an antagonist alone (n = 4 - 5 per ligand), to determine the effect 
of these ligands on insulin secretion. Cells that were not treated with any compound were used 
as a negative control.  
5.2.4. Immunoassay for insulin detection 
An enzyme-based immunoassay (sandwich ELISA) was used to detect the amount of insulin 
secreted by RIN-5F cell line, in the presence or absence of test compounds, according to the 
manufacturer’s instructions. In brief, after incubation of cells with test compounds for 24 hours, 
a supernatant sample of 10μl was taken from all wells and transferred to a microtiter plate pre-
coated with a monoclonal mouse anti-rat insulin antibody. The captured insulin was then 
detected by a second, biotinylated polyclonal anti-insulin antibody. Unbound materials were 
thoroughly washed away with manufacturer’s washing buffer prior to the binding of 
streptavidin-horseradish peroxidase to the immobilised biotinylated antibodies. Another step 
of thorough washing of free enzyme conjugates followed before the final quantification of 
immobilised antibody-enzyme conjugates. The quantification was performed by monitoring the 
horseradish peroxidase activity in the presence of its substrate (3,3’,5,5’-tetramethylbenzidine).  
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The enzyme activity was measured by spectrophotometry at 450 nm, corrected from the 
absorbance of 590nm, after the acidification of formed products with 0.3M HCl. Since the 
increase in absorbance is directly proportional to the amount of captured insulin in the samples, 
the latter was derived by interpolation from a reference curve generated within each performed 
assay using reference standards of known concentrations of rat insulin. The dose-response 
curve produced by the internal standards was fitted to a sigmoidal 4-parameter logistic equation 
according to the manufacturer’s instructions by plotting the corrected absorbance at 450nm 
minus 590nm, against the concentration of rat insulin standards.  
5.2.5. Viability assay 
A trypan blue exclusion assay was used to determine the viability of the pancreatic cells in the 
presence of test compounds, according to the Strober method (535). Trypan blue is 
impermeable to intact healthy cells but can enter cells with a compromised cell membrane 
creating an intracellular blue staining that can be detected by light microscopy. Trypan blue 
staining can be therefore used as a marker of cell death. Cells treated for 24 hours with test 
compounds were trypsinised, stained with 0.04% trypan blue. Before the number of stained 
cells versus the total number of cells was counted using a haemocytometer under a light 
microscope. Viability was defined as viable cells per well. 
5.2.6. Data analysis 
Concentration-response curves were analysed by non-linear regression or by a 4-parameter 
sigmoidal fit, as appropriate. GraphPad Prism V6.0 software (San Diego, CA, USA) was used 
for statistical analysis. Students t-test and analysis of variance (ANOVA) with multiple 
comparison testing were used as required and as described in the table and figure legends 
(minimum significance set at p<0.05). Data are presented as mean ± SD from (n) number of 
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experiments as indicated in the respective figure or table legends.   
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5. 3. Results 
5.3.1. Optimisation of insulin detection 
RIN-5F cell line physiologically secretes insulin when incubated in an appropriate glucose-
contained growth medium. Since the amount of secreted insulin/well is dependent on cell 
numbers, I first optimised cell numbers per well for a 96 well format to obtain absorbance 
values that fall within the range of values of the standard curve. Three different concentrations 
were used (1x104, 2x104 and 4x104 cells/well) with five parallel wells per group.  
Known amounts of insulin (0, 0.5, 1, 2, 5, 10 ng/ml) were used in triplicates as internal 
standards to produce a standard curve (Fig. 31), which was initially  fitted using linear 
regression analysis (R2 = 0.9898), producing a significant slope (0.1191 0.004; p<0.0001) and 
confirming the linearity of the internal standards (Fig. 31 A). Subsequently, the same data was 
fitted more efficiently to a sigmoidal 4-parameter logistic equation (Figure 31 B; R2 0.9990, 
EC50 5.62, HS 0.23), which did not produce any significant normality of residuals (D’Agostino 
& Pearson’s test; p = 0.583). These data confirmed the manufacturer’s suggestion for using the 
sigmoidal fitted curve for interpolation of data derived from samples. Absorbance values from 
the three cell concentrations tested were plotted against the derived insulin values from the 
sigmoidal standard curve (Fig. 31 C). Although all three groups produced large amounts of 
secreted insulin (> 20 ng/ml) using 104 cells per well produced the least variability (variation 
coefficient 2.80 %) and a mean absorbance value of 2.65, which translated to 23.8 ng/ml of 
insulin per well. Since the minimum acceptable density for optimum growth of the RIN-5F cell 
line in a 96-well is 104, this cell density was chosen to be used for all subsequent experiments. 
The rationale was that the collected samples of these wells would be diluted 4 times before 
processing by ELISA and therefore the secreted basal insulin value would be expected to fall 
within the EC50 of the curve (e.g. 23.8 ng.ml-1  4 = 5.95  EC50 5.62).  
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Figure 31. Optimisation of  the 
insulin detection method using 
an  enzyme‐based 
immunoassay  (ELISA).  A 
standard  curve  was  generated 
by  using  known  amounts  of 
insulin (0, 0.5, 1, 2, 5, 10 ng/ml) 
in  triplicates which were  fitted 
using  linear  regression analysis 
(A) producing a significant slope 
(0.1191 ± 0.004; p < 0.0001) and 
confirming  the  linearity  of  the 
internal  standards.  The  same 
data  were  fitted  more 
efficiently  into  a  sigmoidal  4‐
parameter logistic equation (B) 
which  did  not  produce  any 
significant  normality  of 
residuals  (D’Agostino  & 
Pearson’s test; p = 0.583). Three 
different  cell  densities  (1x104, 
2x104  and 4x104) were  seeded 
in  individual  wells  and  the 
corresponding  standard  curve 
was used to calculate the total 
amount of secreted  insulin per 
well  (C).  Absorbance  was 
measured at 450 nm corrected 
for  the absorbance at 590 nm. 
All data are shown as mean ± SD 
from n = 4 ‐ 5. 
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5.3.2. Total secreted insulin after opioid treatment 
After determining the optimal cell density numbers per well, I measured insulin secretion of 
cells seeded and treated with test compounds. An internal standard curve was generated within 
this assay and analysed using both analysis methods (linear regression and the 4-parameter 
sigmoidal logistic equation; Fig. 32 A, B). In agreement with the previous data, the sigmoidal 
standard curve provided a better fit compared to a linear fit and was therefore used to interpolate 
the absorbance values produced by the samples.   
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Figure 32. Detection of total insulin secreted in the well, using an enzyme‐based immunoassay 
(ELISA). A standard curve was generated by using known amounts of insulin (0, 0.5, 1, 2, 3.8, 5, 
7.8, 10 ng/ml) in triplicates which were fitted using linear regression analysis (A) and a sigmoidal 
4‐parameter logistic equation (B); the latter used to calculate the total insulin concentration in 
wells  treated  or  non‐treated  with  opioid‐receptor  selective  ligands  (C).  Absorbance  was 
measured at 450 nm corrected for  the absorbance at 590 nm. One‐Way analysis of variance 
(ANOVA)  was  used  with  a  Sidak multiple  comparison  test  (*  p  <  0.005  and  **  p  <  0.0005 
compared to non‐treated control; # p < 0.0001 compared to DPDPE). All data are shown as mean 
 SD from n = 4 ‐ 5. 
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After taking into account the dilution factor used to dilute the samples (x 4), the concentration 
of secreted insulin by the seeded cells was calculated and expressed as a bar-chart (Fig. 32 C). 
Compared to the untreated control, treatment of cells with the selective MOP receptor ligands 
DAMGO, CTOP and combination of both, significantly increased insulin secretion. Treatment 
with the DOP receptor-specific agonist DPDPE also significantly increased insulin secretion. 
A more peculiar relationship was observed for the KOP receptor, where the selective agonist 
U50488 and the antagonist nBNI did not elicit any effects, while conversely their combination 
significantly increased insulin secretion (Fig. 32 C). Finally, naltrindole-treated cells (with or 
without DPDPE) showed a highly significant decrease of insulin secretion, reflecting the high-
toxicity of naltrindole that I previously observed in non-pancreatic cell line (non-published 
observation).  
5.3.3. Secreted insulin/cell numbers at endpoint 
Since the test compounds can potentially affect cellular viability and proliferative capacity, 
which is likely to affect the extent of secreted insulin, it is important to account for these 
potential effects when evaluating the stimulatory or inhibitory effects of drug-induced insulin 
secretion. I, therefore, measured cellular viability using trypan-blue (TB) exclusion, 
immediately after the collection of the supernatant. Since the assay provides information on the 
number of dead and alive cells in each treated well, it allows the expression of the total results 
as a ratio of secreted insulin/live cells at the endpoint. Taking the number of live cells in the 
non-treated wells as a baseline, I calculated the live cells per treated well. Different opioid 
treatments differentially affected cell viability and proliferation over the same time-period 
(Table 22). Consistent with our previous results (unpublished), TB staining revealed that 
naltrindole was highly toxic to pancreatic RIN-5F cell line, with no viable cells after 24-hour 
incubation with this DOP-selective antagonist.   
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Table 22.  Cell viability data from cells treated with different opioid ligands compared to non‐
treated control using a trypan‐blue exclusion assay. Results are expressed a mean number of 
cells viable per well after 24 h treatment ( SD from n = 4 ‐ 5). One‐way analysis of variance 
(ANOVA)  was  used  with  a  Sidak  multiple  comparison  tests  (*p  <  0.005  and  **p  <  0.0005 
compared to non‐treated control). 
 
Treatment 
Number  of  viable 
cells per well  
(x 102; mean   SD) 
No ligand (control)  520  80 
DAMGO  346  166 
DAMGO + CTOP  520  153 
CTOP  410  167 
DPDPE  370  9 
DPDPE + naltrindole  120  15 * 
Naltrindole  0 ** 
U50488  430  92 
U50488 + nBNI  530  92 
nBNI  320  16 
 
After determining the number of viable cells per well after 24 hours of treatment, and 
standardised insulin concentrations on cell numbers (Fig. 33). The insulin values of Fig. 33 are 
shown in Table 23, as mean insulin secretion and as a percentage increase or decrease compared 
to the baseline control. Untreated control cells produced insulin levels of 2.24 ( 0.85) 
ng/ml/103 cells, while in comparison the MOP receptor agonist DAMGO nearly doubled the 
measured insulin levels (12.12  0.81 ng/ml/103 cells; a 94.2 % increase compared to control). 
In parallel, the DOP receptor agonist DPDPE also significantly stimulated insulin secretion 
(11.00  2.55 ng/ml/103 cells; a 76.3 % increase compared to control). Interestingly, compared 
to DPDPE the MOP receptor antagonist CTOP on the other hand, also prolonged insulin 
secretion (10.73  3.11 ng/ml/103 cells; a 72 % increase). Co-treatment of CTOP and DAMGO 
194 
 
 
was able to reduce the effect of their individual administration, although showing a trend 
towards increased insulin secretion, which was not significant from control. Contrary to the 
MOP and DOP ligands, none of the KOP agonist and antagonist tested significantly affected 
insulin levels, despite a small trend towards higher insulin levels.  
 
 
Figure  33.  Detection  of  insulin  secreted  per  103  viable  cells  by  using  an  enzyme‐based 
immunoassay (ELISA).  The absorbance recorded as the differences of absorbance from 450 nm 
minus 590 nm. The chart was produced by combining the total insulin data per well from Figure 
32 C and the cell viability data from Table 22. One‐Way analysis of variance (ANOVA) was used 
with a Holme‐Sidak multiple comparison test (* p < 0.05 and ** p < 0.005 compared to non‐
treated control; # p < 0.05 compared to DAMGO and ## p < 0.0005 compared to DPDPE). All data 
are shown as mean  SD from n = 4 ‐ 5. Key: nd, not detected. 
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Table 23. Secreted insulin concentration per viable cells after treatment with opioid‐receptor 
selective ligands, compared to basal (non‐treated control). Concentration data are extracted 
from Figure 33 and are shown as a percentage of significant change from the control. One‐Way 
analysis of variance (ANOVA) was used with a Holme‐Sidak multiple comparison test (* p < 0.05 
and ** p < 0.005 compared to non‐treated control; # p < 0.05 compared to DAMGO and ## p < 
0.0005 compared  to DPDPE). All data are  shown as mean   SD  from n = 4  ‐ 5. Key: nd, not 
detected. 
 
Treatment 
Secreted insulin 
(mean  ng/ml/103 
viable cells  SD) 
Significant %  
change 
from control 
No ligand (control)  6.24  0.85  ‐ 
DAMGO  12.12  0.81  + 94.2 (**) 
DAMGO + CTOP  8.06  2.17  ‐ (#) 
CTOP  10.73  3.11  + 72.0 (*) 
DPDPE  11.00  2.55  + 76.3 (*) 
DPDPE + naltrindole  3.02  0.48  ‐ 51.6 (##) 
Naltrindole  nd  nd  
U50488  8.43  2.49  ‐ 
U50488 + nBNI  7.68  1.53  ‐ 
nBNI  8.96  0.70  ‐ 
 
Finally, since naltrindole completely killed the treated cells over a period of 24 hours, the ratio 
of insulin release/cell number could not be determined. However, the total insulin reduction in 
the naltrindole-treatment shows that naltrindole’s toxicity is so rapid that it inhibited the basal 
glucose-induced insulin excretion. In addition, the increase of insulin seen with DPDPE was 
significantly abolished by naltrindole co-treatment (3.02  0.48 ng/ml/103 cells; a 51.6 % 
decrease) due to naltrindole’s toxicity, but it was not to zero. DPDPE’s concentration in the co-
treatment group was 10 % of that of naltrindole and was still able to contain some of 
naltrindole’s toxicity, insinuating a competitive behaviour for both actions (DPDPE’s insulin 
stimulation and naltrindole’s toxicity) which most likely is mediated through the DOP receptor.   
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5.4. Discussion 
Opioids represent an important drug class in diabetic pharmacotherapy due to their role in 
diabetic neuropathy and their complex and under-explored endocrine effects. Although opioids 
are not considered very effective as a stand-alone treatment for diabetic neuropathic pain, their 
strong analgesic effect offers a potential co-administration solution to drug-resistant and 
persistent neuropathic pain (536).  In addition, the remarkably wide range of tissues that express 
the classical opioid receptors constitutes the basis of their non-analgesic side effects, some of 
which are currently explored for conditions other than pain (537,538,539). The expression of 
opioid receptors in pancreas and liver (537) initiated early studies to investigate the role of 
endogenous opioids in processes associated with the endocrine and autocrine system (540), 
such as glucose homeostasis (512) and insulin release (533), as well as in related conditions 
such as diabetes (541), obesity (542), exercise-associated autonomic failure (543), 
hypoglycemia-associated failure (388) and polycystic ovary syndrome (544) among others.  
Since insulin plays a central role in glucose homeostasis, in pancreas autocrine function and in 
diabetes, the effect of opioid ligands (endogenous and synthetic) on glucose-induced and 
glucose-independent insulin secretion has attracted significant attention. However, the 
convoluted relationship between different feedback systems in pancreatic endo-/autocrine 
function, as well as the different pharmacology of the three classical opioid receptor types, has 
created some inconsistency in the literature and a certain level of complexity in the 
interpretation of published data. The main question posed was: do opioids increase or decrease 
glucose-induced insulin secretion? Answering this question is not a simple task, given the 
different cell types in the pancreas, the effect of glucagon and other peptides on pancreatic 
function, the cross-talk between liver and pancreas on glucose homeostasis and the central 
nervous system effect on the pancreas (e.g. insulin secretion and opioidergic neuron activation). 
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The majority of these studies on opioids and insulin secretion have directed on the effect of 
endogenous opioid ligands (e.g. enkephalins, endorphins) or clinically used opioids (e.g. 
morphine, fentanyl) on insulin secretion in isolated pancreatic islets. To the best of my 
knowledge, there are no current data in the literature regarding opioid receptor-specific agonists 
and antagonists and their effect on insulin secretion in a single study. In this thesis, I provide 
the first data for MOP, DOP and KOP selective agonists and antagonists in terms of their effect 
on insulin secretion in pancreatic β-cell line (RIN-5F) (Fig. 34). RIN-5F cell line was originally 
generated from tumours of islets of Langerhans of male rats and was purchased from the 
American Type Culture Collection (as described in the section 5.2.1 of this thesis) (545). MOP 
receptors are expressed in the islets of Langerhans of mice and their expression has been 
reported to regulate glucose homeostasis (546). For example, MOP receptor (MOP-1) knock-
out mice showed increased glucose tolerance, which resulted from enhanced insulin secretion 
from β-cells (546). The expression of the DOP and KOP receptors were also verified for the 
islets of Langerhans in rats (547). Therefore, there is the possibility that the RIN-5F cell line 
could also express the MOP, DOP and KOP receptors similar to the original tissue. However, 
due to a lack of data regarding the expression of specific opioid receptors in RIN-5F cells, I 
have no evidence that all opioid receptors are actually expressed in this cell line. This is an 
obviouslimitation of my current study and should be investigated in future studies.     
Our outcomes provide preliminary evidence that MOP and DOP selective ligands DAMGO 
and DPDPE respectively can stimulate overall glucose-induced insulin secretion from a β-cell 
line, measured after 24 hours of treatment; a time-period which would include both phases of 
insulin’s biphasic secretion. These data fit with the majority of the previous studies on opioid-
mediated insulin release, which show a stimulatory effect of opioids as described in the 
introduction section above. 
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Similarly to Qian et al (402), who used an MTT viability assay to assess whether opioid effect 
cellular toxicity of the opioid concentrations used, I used the TB viability assay to account for 
the potentially different effects of the different opioids used.  
In addition, I have observed that the MOP-selective antagonist CTOP also significantly 
increased insulin secretion in our cells, which clearly shows that a MOP receptor antagonist 
can also increase insulin secretion similarly to MOP receptor agonist like DAMGO. The 
increased insulin secretion is presumably mediated either through a non-opioid receptor 
mechanism or through a G-protein-activation independent mechanism, but such measurements 
were out of scope of the current study. However, the reduced effect on insulin release by the 
co-treatment of DAMGO and CTOP compared to individual treatment presents a case of 
antisynergism, which insinuates an opioid-receptor mediated mechanism, although further 
investigation is needed to draw solid conclusions.   
In this thesis, I also show the insignificant contribution of the KOP receptor-specific opioids to 
insulin secretion, as shown by the non-significant change of insulin secretion by the KOP 
receptor agonist U50488 and the KOP receptor antagonist norBNI. Finally, I show in this thesis 
that the DOP receptor selective antagonist naltrindole possesses a significant toxicity to β-cells, 
which seems to be partially attenuated by the co-administration of the DOP receptor selective 
agonist DPDPE. Whether this effect of DPDPE is interpreted as a protection against 
naltrindole’s toxicity, or simply a result of a competition for DOP receptor binding, the 
conclusion drawn is similar. 
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Figure 34. Schematic  illustration of  the effects of different opioid‐receptor  selective opioid 
ligands on insulin secretion and cell viability in pancreatic RIN‐5F β‐cell line. Ligands (agonists 
at 1 μΜ; solid arrow, antagonists at 10 μM; blunt arrow) on insulin secretion of a pancreatic β‐
cell line, as generated from this study. Both the agonist and the antagonist targeting the MOP 
receptor  produced  an  increased  insulin  secretion  compared  to  control,  similar  to  the  DOP 
receptor  selective  agonist.  Naltrindole  was  highly  toxic,  whereas  none  of  the  KOP  receptor 
selective ligands produced a significant change in insulin levels compared to control. 
 
Since the present data suggest that insulin release can be increased by both agonists and 
antagonists of the MOP and DOP receptors (e.g. DAMGO, DPDPE, CTOP), it intrigued us to 
hypothesise an opioid-mediated insulin secretion which is dependent on opioid receptor-
binding but being independent of G-protein activation. This hypothesis fits with a study by 
Green et al (395) that ascertained a cAMP-independent mechanism of opioid-induced 
stimulation of insulin secretion, as well as with data from Olianas et al (391) who observed a 
cAMP-independent mechanism of DPDPE-induced glucose uptake. DPDPE and DAMGO are 
both analogues of enkephalin (Tyr-Gly-Gly-Phe-Met/Leu) that possess different selectivity on 
opioid receptors (DOP and MOP receptors respectively), while CTOP is also a tyrosine and 
penicillamine containing peptide. It is, therefore, possible that these structurally similar ligands 
bind to MOP or DOP receptors and cause a cAMP-independent intracellular reaction that 
causes insulin-containing vesicles in β-cells to release their insulin.  
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The present study suggests that the KOP receptor targeted ligands U50488 and norBNI did not 
produce a significant insulin release compared to control. These two ligands are structurally 
very different from the rest of the opioids tested since they are not peptides. In addition, 
although it is questionable whether KOP receptors are expressed in pancreatic islets, higher 
concentrations of these ligands need to be tested in the future to check whether there is an effect 
on insulin secretion. However, in a recent study by Shang et al (372), treatment of STZ-mice 
with U50488 reduced hyperglycaemia but did not affect plasma insulin levels, which shows 
that KOP receptors may play a role in glucose-homeostasis rather than insulin secretion per se. 
Previous studies show that U50,488 (1-100 100 µM) can block neuronal voltage-gated sodium 
channels and produce visceral antinociception in rats, which indicates a KOP receptor 
independent effect (548,549). Other reports indicate that blockage of sodium channels in human 
β-cells can reduce glucose-stimulated insulin secretion and microRNA-375 can regulate the 
voltage-gated sodium channels in β-cells (550,551). A sodium channel activator (BDF-9148) 
has shown to inhibit insulin secretion, whereas a sodium channel blocker (carbamazepine) 
protected β-cells from cytokine-induced cell-death (552,553). Voltage gated potassium channel 
Kv2.1 activation induces efflux of potassium ions from pancreatic β-cells and reduces glucose-
stimulated insulin secretion in these cells, as Kv2.1 knockout mice (-/-) showed increased 
glucose-stimulated insulin secretion compared to the pancreatic β-cells of wild-type mice 
(554). Sulphonylureas block ATP-sensitive potassium channels and activate insulin secretion 
and is widely used to manage diabetes mellitus type 2 (T2DM) (555). Together a multifaceted 
network regulates insulin section and includes opioid receptors as well as several ion channels. 
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5.5. Conclusion 
My study furnishes evidence of the opioid-induced increase of insulin secretion, by receptor-
selective agonists and antagonists, which implies that the role of opioid receptors in insulin 
secretion in β-cell line is more complicated than G-protein dependent. Moreover, an 
investigation into the molecular pathways that are involved downstream the opioid receptor 
after ligand binding is needed to clarify the role of opioid receptors on insulin secretion. 
Understanding these pathways may provide an insight into novel pancreatic mechanisms of 
insulin secretion and the identification of novel drug targets for diabetes. My study shows that 
MOP receptor agonist increases insulin secretion in a pancreatic β-cell line, which is in 
agreement with clinical studies that show that these compounds reduce blood glucose levels 
(381,382,383,384,385,386). Therefore, the clinical significance of the effects of opioids on 
glucose or insulin sensitivity can be extrapolated from my in vitro study.   
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CHAPTER SIX  
 
In vitro characterisation of novel opioids 
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Preface to chapter six  
In the previous chapters (chapters one to five), I observed that morphine induces different 
adverse effects by interacting with both opioid and non-opioid receptors. This illustrates the 
need for better pharmacological alternatives to reduce the impact of the adverse effects of 
morphine. Previous studies showed that opioid ligands with mixed activity on different opioid 
receptors display reduced adverse effects compared to morphine. Different novel opioids were 
synthesised at the University of Tasmania and were investigated for their selectivity towards 
different opioid receptors. This chapter describes the pharmacological characteristics of a range 
of novel opioids (chapter six) to identify the best ligand for further preclinical investigations.  
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6. In vitro characterisation of novel opioids 
 
Abstract 
Opioids with mixed activity on different opioid receptor are known to be associated with less 
adverse effects than morphine or other clinical opioids. In particular, Dmt-Tic pharmacophore-
based opioids such as UFP-505 show MOP receptor agonist / DOP receptor partial agonist 
activity. In this study, I evaluated six ligands based on Dmt-Tic peptides. These compounds 
were tested for their receptor selectivity using different opioid receptor expressing Chinese 
Hamster Ovary (CHO) cells. For the most promising of these six ligands, termed UTA1003, 
dose-responses were established to determine its median effective concentration (EC50). 
Overall, UTA1003 showed efficacy as a MOP and KOP receptor agonist with a DOP receptor 
partial agonist, with better solubility and a similar pharmacological profile compared to the 
parental compound UFP-505. Therefore, UTA1003 represents an improvement over its 
parental compound and might be a starting point for a rational medicinal chemistry program to 
develop antinociceptive drugs without the severe adverse effects of morphine. 
Keywords: UFP-505; UTA1003, Dmt-Tic; opioid; MOP receptor agonist; DOP receptor. 
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6.1. Introduction 
Selectivity of novel opioids on multiple opioid receptors has been the focus of opioid research 
in recent years, due to the evidence of reduced antinociceptive tolerance and/or behavioural 
side-effects in different preclinical studies (160,178,337). A combination of an opioid receptor 
agonist (e.g. morphine) and opioid receptor antagonist (e.g. naltrindole, naltrexone) have 
shown better antinociception and less tolerance than an opioid agonist alone 
(122,123,124,125,278,279). However, compounds with selectivity on multiple opioid receptors 
may reduce the possibility of drug-drug interactions and improved pharmacokinetic or 
pharmacodynamic (PK/PD) profile than a drug combination (280,281,282). Many of these 
ligands act simultaneously on different opioid receptors (282,283) or a combination of an 
opioid receptor and a non-opioid receptor (284,285,286). Therefore, ligands with selectivity on 
multiple opioid receptors show better antinociception, less antinociceptive tolerance and other 
behavioural side-effects than the current clinical opioids (151,178,280,281,337). As a result, a 
potential strategy in recent years to avoid both antinociceptive tolerance and behavioural side-
effects could be the proposed use of a single mixed-selective compound and has been a topic 
of interest in the area of opioid pharmacology.  
Opioids with selectivity on multiple receptors are different in their structures, such as peptides 
(306,346,556), peptidomimetics (312,348,353,557) and alkaloids (558). Importantly, ligands 
with mixed activity on multiple receptors, such as UFP-505 and DIPPψNH2, showed reduced 
antinociceptive tolerance and behavioural side-effects than morphine (346,354). However, the 
potential clinical utility of these compounds is limited. DIPPψNH2 showed poor blood-brain 
barrier penetration and produced seizures after administration of a high dose (10-400 µg i.c.v.) 
(282,346). Similarly, UFP-505 was reported to induce antinociceptive tolerance and toxicity 
after intracerebroventricular (i.c.v.) administration, but it did not induce these adverse effects 
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after intrathecal administration (306,354). Importantly, UFP-505 did not appear to induce its 
antinociceptive effects after systemic (subcutaneous or intravenous) administration (354). 
(349,350,559) 
As a part of ongoing chemical and preclinical investigations on opioids with selectivity on 
multiple receptors, I am describing different novel UTA-opioids based on the prototype UFP-
505 (H-Dmt-Tic-Gly-NH-Bzl) (Fig. 35).  The current study has focused on different human 
opioid receptors in order to interpret the detailed pharmacological effects using recombinant 
human MOP, DOP, KOP or NOP receptors expressing Chinese Hamster Ovary (CHO) cells. 
Measurement of G-protein activation (or blockage) following a ligand binding to a G-protein 
coupled receptor (GTPγ35S binding assay) or measurement of its effects in downstream 
pathways, such as ligand-binding induced changes in cellular cAMP levels (cAMP assay), are 
typically used to characterise novel opioids (160,178,349,560). This study used the cAMP 
assay as a tool to characterise the specificity of UTA-ligands using MOP, DOP, KOP or NOP 
receptors expressing CHO cells. This approach was designed to select the best ligand with a 
full MOP receptor agonist / DOP receptor antagonist (or a partial agonist)  profile out of these 
six UTA-opioids for subsequent preclinical studies. 
 
Figure 35. Chemical structure of UFP‐505 (H‐Dmt‐Tic‐Gly‐NH‐Bzl). Key: Dmt: 2‘,6‘‐dimethyl‐l‐
tyrosine, Tic: 1,2,3,4‐tetrahydroisoquinoline‐3‐carboxylic acid, Gly: Glycine, Bzl: Benzyl. 
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6.2. Materials and methods 
6.2.1. Materials 
Cellular cAMP levels were measured in CHO cells with recombinant expression of different 
types of human opioid receptors. Wild-type CHO cells without recombinant opioid-receptor 
expression were also used to investigate whether the measured effects are associated to specific 
opioid receptors. The Promega cAMP-GloTM Max assay kit (V1681, Promega Corporation, 
Madison, USA) was used in this study. The commercial kit contained cAMP 100 mM cAMP, 
1 M MgCl2, cAMP-GloTM ONE-buffer, Protein Kinase A, Kinase-Glo® lyophilised substrate 
and Kinase-Glo® buffer. In addition, IBMX (3,7-Dihydro-1-methyl-3-(2-methylpropyl)-1H-
purine-2,6-dione) and Ro20-1724 (4-(3-Butoxy-4-methoxyphenyl)methyl-2-imidazolidone), 
Forskolin ([3R-(3α,4aβ,5β,6β,6aα,10α,10aβ,10bα)]-5-(acetyloxy)-3-ethenyldodecahydro-
6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho[2,1-b]pyran-1-one) were 
purchased from Tocris Bioscience, Bristol, UK.  IBMX and Ro20-1724 are phosphodiesterase 
inhibitors to prevent hydrolysis of cAMP (561). Forskolin as positive control activates adenylyl 
cyclase enzymes and increases intracellular levels of cAMP (562). IBMX and Ro20-1724 were 
diluted to 100 mM solution using 100% DMSO. The solution was further diluted to 500 µM 
IBMX and 100µM Ro20-1724 using PBS. Afterwards, complete induction buffer was prepared 
using 500 µM IBMX and 100µM Ro20-1724 and 25 mM MgCl2. The solution was used to see 
basal cAMP expression of cells in the wells without treatment. Forskolin was diluted to 200 
µM using DMSO, which was further diluted to 1- 50 µM with freshly prepared complete 
induction buffer immediately before the experiments. Forskolin was used as a positive control 
and all other UTA-ligands and standard compounds were diluted in forskolin solution. The 
cAMP detection solution was freshly prepared using 1:100 ratio of PKA and cAMP-Glo buffer 
(as stated in the supplier’s guide). Kinase-Glo® buffer and substrate was mixed and it was called 
as Kinase-Glo reagent.  The kinase-Glo reagent was stored at -20⁰C as 1 ml aliquots. Required 
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amount of kinase-Glo reagent aliquots were thawed at room temperature and used immediately.  
UTA- ligands were dissolved at 10 mM with 100% DMSO and the solution was further diluted 
to the required concentrations using diluted forskolin solution.  
6.2.2. Chemical synthesis  
The analogues of UFP-505 have been synthesised as a drug optimisation study and described 
in a previous report (563).  
6.2.3. cAMP assay  
CHO cells were grown in T-25 flasks containing F-12(Ham) media (1x) for the wild-type, 
MOP, DOP, KOP and NOP cells containing 10% foetal bovine serum and 100 IU/ml penicillin. 
All media contained L-glutamine. The cell culture media were additionally supplemented with 
200 mg/ml G418 (selection agent used with MOP, DOP, and KOP cells) and with additional 
200 mg/ml hygromycin B for the NOP cells once in every four passages. Cell cultures were 
kept at 37⁰C 5% v/v CO2 and 95% v/v humidified air. Trypsin/EDTA was used as the minimum 
required to split the cells during sub-cultures. The cells were used for experiments, as they were 
approached confluence. 
The assay was conducted using the supplier’s protocol. In short, the CHO-cells were seeded as 
8000-10000 cells/well in 96-well plates and incubated for 24 hours. On the following day, all 
reagents were thawed and prepared as per the supplier’s guidelines. Firstly, after removing 
media using an aspirator, cells were incubated in 40 µl of complete induction buffer (blank), 
no drug (forskolin 1-50 µM), UTA-opioids and reference drugs for 20 min at 37⁰C (incubator).  
Secondly, 10 µl freshly prepared cAMP detection solution was added to all wells and mixed 
by a plate shaker for 2 min. The plate was further incubated for 20 min at room temperature 
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(22-23⁰C). Afterwards, 50 µl kinase-Glo reagent was added to each wells and mixed by a plate 
shaker for a minute and the plate was incubated for 10 min at room temperature. Finally, 60 to 
80 µl solutions from each well were transferred carefully to a white round bottom plate and 
immediately put into a plate-reader to measure luminescence. The measurement was repeated 
twice (after 1 min of first measurement) to verify the luminescence signals. Each drug was 
tested using six different wells and the average value was used for statistical analysis.  
6.2.4. Calculations and statistical analysis 
For a direct comparison between the UTA ligands, standard compounds and for the 
concentration response curves, the pharmacological effect was calculated as % of inhibition of 
forskolin-induced cAMP production and the values were used for statistical analysis. 
Antagonist effects of UTA1003 were calculated as follows, Kd = [opioid]/(CR-1), where CR is 
the ratio of the EC50 of DPDPE in the presence and absence of UTA1003, [opioid] is the 
concentration of UTA1003 used with DPDPE in the antagonism test (160,560). All data are 
expressed as mean ± SEM (n = 6) and analysed by one-way ANOVA with Dunnett’s multiple 
comparisons test using GraphPad Prism V6 software (GraphPad Software Inc., La Jolla, CA, 
USA). Multiple comparisons (Dunnett’s test) was employed when F achieved p < 0.05 and 
there was no significant variance in homogeneity. A ‘p’ value less than 0.05 was considered 
statistically significant.   
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6.3. Results 
6.3.1. Structures of novel UTA-opioids  
In this study, six analogues of UFP-505 were generated with the objective to increase their 
solubility and also to sequentially reduce their peptidic structure (Fig. 36). These chemical 
changes were hypothesised to improve the ADME characteristics and metabolic stability of the 
compounds while retaining their antinociceptive effects. The detailed synthesis of the six novel 
UTA-ligands (Fig. 36) has been described in detail in a previous study (563). 
   
UTA1003 (i) UTA1004 (ii) UTA1005 (iii) 
   
UTA1006 (iv) UTA1009 (v) UTA1011 (vi) 
Figure 36. Chemical structures of six UTA‐opioids 
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6.3.2. Specificity of novel UTA-opioids on different opioid receptors 
The specificity of the six UTA ligands for different opioid receptors was measured using 
several recombinant human opioid receptors expressing Chinese Hamster Ovary (CHO) cell-
lines. Firstly, the ligands were evaluated for their effects on untransfected Chinese Hamster 
Ovary (CHO-WT) cells to confirm that the UTA-ligand mediated effects are opioid receptor 
specific (Fig. 37). Using this assay, UTA1006, UTA1009 and UTA1011 had a slightly but 
significant (p < 0.01) inhibitory effect on forskolin-stimulated cAMP production (Fig. 37). This 
effect was not observed for UTA1003-1005, UFP-505 and DAMGO (a MOP receptor agonist).   
 
Figure 37. Opioid receptor specificity 
assessment  of  UTA‐opioids  using 
wild‐type cells. Inhibition of forskolin‐
stimulated  cAMP  levels  were 
measured in the absence (“no drug”) 
or  presence  of  100µM  UTA‐  and 
reference  opioids.  Statistically 
significant  (p  <  0.05)  differences 
against  the  effect  of  1  µM  forskolin 
(no drug) are expressed as p < 0.01 or 
p  <  0.001 and were  calculated using 
one‐way  ANOVA  with  Dunnett’s 
multiple  comparisons  test.  Values 
represent  the  mean  ±  SEM  (n  =  6). 
Error bars are present in all graphs but 
are sometimes too small to be visible. 
 
To investigate whether the novel UTA-opioids are MOP receptor agonists, all ligands were 
measured for their specificity in MOP receptor-expressing Chinese Hamster Ovary (CHO-
MOP) cells (Fig. 38). All opioids significantly (one-way ANOVA, F (7, 36) = 368, p < 0.0001) 
inhibited forskolin-stimulated cAMP production (Fig. 38) and therefore, these ligands acted as 
MOP receptor agonists. Notably, all responses were comparable to those of the reference 
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compounds UFP-505 and DAMGO (Fig. 38).  
 
Figure 38. Effects of UTA‐opioids on 
µ‐opioid  (MOP)  receptor 
expressing  cells.  Inhibition  of 
forskolin‐stimulated  cAMP  levels 
were measured in the absence (“no 
drug”) or presence of 100µM UTA‐ 
and  reference  opioids.  Statistically 
significant  (p  <  0.05)  differences 
against the effect of 1 µM forskolin 
(no drug) is expressed as p < 0.0001 
and were calculated using one‐way 
ANOVA  with  Dunnett’s  multiple 
comparisons test. Values represent 
the mean ± SEM (n = 6). Error bars 
are  present  in  all  graphs  but  are 
sometimes too small to be visible. 
 
Since UFP-505 is described as a MOP receptor agonist / DOP receptor antagonist, I assessed 
whether the novel UTA-ligands showed any affinity towards the DOP receptor (Fig. 39).  In 
this study, significant inhibition of forskolin-induced cAMP release was observed for all 
opioids. Both UFP-505 and UTA1003 showed significantly lower specificity than DPDPE (a 
DOP receptor agonist) (one-way ANOVA, F (8, 32) = 52.09, p < 0.0001) (Fig. 39). Beyond 
that, both ligands (UTA1003 and UFP-505) induced identical effects with regards to the DOP 
receptor. The remaining five UTA-opioids (UTA1004-006, UTA1009 and UTA1011) showed 
significant inhibition of forskolin-induced cAMP production (one-way ANOVA, F (8, 32) = 
52.09, p < 0.0001), which was similar to the effects of DPDPE (Fig. 39).  
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Figure 39. Effects of UTA‐opioids on 
δ‐opioid  (DOP)  receptor  expressing 
cells.    Inhibition  of  forskolin‐
stimulated  cAMP  levels  were 
measured in the absence (“no drug”) 
or  presence  of  100µM  UTA‐  and 
reference  opioids.  Statistically 
significant  (p  <  0.05)  differences 
against  the  effect  of  1  µM  forskolin 
(no drug) is expressed as p < 0.01, p < 
0.001  or  p  <  0.0001  and  were 
calculated  using  one‐way  ANOVA 
with Dunnett’s multiple comparisons 
test.  Values  represent  the  mean  ± 
SEM (n = 6). Error bars are sometimes 
too small to be visualised. 
 
UFP-505 has been described as a partial agonist (pKi 6.29) of the KOP receptor in a previous 
report (349). In this study, the specificity profile of UTA-opioids was measured using CHO-
KOP cells with U50,488 (a KOP receptor agonist) as a reference compound (Fig. 40). Most 
ligands showed specificity for the KOP receptor except UTA1005 and UTA1006 (Fig. 40). 
 
Figure 40. Effects of UTA‐opioids on 
κ‐opioid  receptor  expressing  cells. 
Inhibition  of  forskolin‐stimulated 
cAMP  levels  were  measured  in  the 
absence  (“no  drug”)  or  presence  of 
100µM UTA‐ and  reference opioids. 
Statistically  significant  (p  <  0.05) 
differences against the effect of 1 µM 
forskolin (no drug) are expressed as p 
<  0.01  or  p  <  0.0001  and  were 
calculated  using  one‐way  ANOVA 
with Dunnett’s multiple comparisons 
test.  Values  represent  the  mean  ± 
SEM (n = 6). Error bars are sometimes 
too small to be visualised. 
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UFP-505 is known to be a partial agonist of the NOP receptor with a pKi of 5.86 (349). In this 
study, all UTA-ligands were assessed for their effects on the non-opioid receptor (NOP 
receptor) using CHO-NOP cells (Fig. 41). In this experiment, most UTA-opioids except 
UTA1006 significantly inhibited forskolin-stimulated cAMP levels. However, their efficacy 
was significantly lower than the reference compound, nociceptin (a NOP receptor agonist) 
(one-way ANOVA, F (8, 32) = 52.09, p < 0.0001) (Fig. 41). 
 
Figure  41.  Effects  of  UTA‐opioids 
on Non‐opioid receptor expressing 
cells. Inhibition  of  forskolin‐
stimulated  cAMP  levels  were 
measured  in  the  absence  (“no 
drug”) or presence of 100µM UTA‐ 
and  reference  opioids.  Statistically 
significant  (p  <  0.05)  differences 
against the effect of 5 µM forskolin 
(no drug) are expressed as p < 0.001 
or p < 0.0001 and were calculated 
using  one‐way  ANOVA  with 
Dunnett’s  multiple  comparisons 
test. Values  represent  the mean ± 
SEM  (n  =  6).  Error  bars  are 
sometimes too small to be visible. 
 
6.3.3. Detailed agonistic effects of UTA1003 towards different opioid receptors 
From the specificity profile assessment undertaken for this study, UTA1006, UTA1009 and 
UTA1011 are shown to be non-selective, as these ligands induced their effects on wild-type 
cells. In addition, UTA1004 and UTA1005 appeared to be full agonists of both MOP and DOP 
receptors. Based on the specificity profiles of UTA-1004, 1005, 1006, 1009 and 1011, it was 
concluded that these compounds were unlikely to provide achieve an improved adverse effect 
profile in comparison to opioids currently used in clinical practice for long-term treatment. 
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Therefore, UTA1003 was chosen as the most suitable ligand for further pharmacological 
characterisation, as it likely represented a MOP receptor agonist / DOP receptor partial agonist 
that promised the desired characteristics. Subsequently, EC50 values for UTA1003 and 
reference compounds (DAMGO, DPDPE, U50,488 and nociceptin) were determined from the 
dose-response curves for different opioid receptors. 
In this study, the efficacy of UTA1003 for the MOP receptor was determined from a dose-
response curve in CHO-MOP cells, where UTA1003 appeared to display similar effects to 
DAMGO, as their pEC50 and Emax values were indistinguishable (Fig. 42, Table 24).  
Figure  42. Dose‐response  of 
MOP‐receptor agonistic effect of 
UTA1003.  The  MOP  receptor 
agonistic  effect  of  UTA1003 was 
assessed  as  inhibition  (%)  of 
forskolin‐stimulated  cAMP  levels 
in  CHO‐cells  expressing  human 
MOP  receptor.  The  cAMP  was 
stimulated  using  1µM  forskolin 
and DAMGO (1 nM ‐ 100 µM) was 
used  as  positive  control.  Values 
are represented as mean ± SEM (n 
= 6). Error bars are sometimes too 
small to be visualised. 
 
Since UTA1003 displayed a similar effect to DAMGO in cells expressing the MOP receptor, I 
determined its efficacy (as EC50) in cells expressing the DOP receptor (Fig. 43). A parallel 
dose-response curve and EC50 were determined for the selective DOP receptor agonist, DPDPE 
(Fig. 43). The pEC50 value of UTA1003 was similar to DPDPE (Table 24), but the magnitude 
of the efficacy (Emax) of UTA1003 was lower than the Emax of DPDPE (Fig. 43). Therefore, 
UTA1003 appears to be a partial agonist for the DOP receptor. 
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Figure 43. Dose‐response of DOP‐
receptor  agonistic  effect  of 
UTA1003. DOP receptor agonistic 
effect of UTA1003 was assessed as 
inhibition  (%)  of  forskolin‐
stimulated  cAMP  levels  in  CHO‐
cells  expressing  human  DOP 
receptor.  The  cAMP  was 
stimulated  using  5  µM  forskolin 
and DPDPE (1 nM ‐ 100 µM) was 
used  as  positive  control.  Values 
are represented as mean ± SEM (n 
= 6). Error bars are sometimes too 
small to be visualised. 
 
During the screen with CHO-KOP cells, 100 µM UTA1003 induced a similar agonistic effect 
compared to U50,488 (Fig. 40). To investigate the magnitude of agonism of UTA1003 towards 
the KOP receptor, UTA1003 was further assessed in CHO-KOP cells (Fig. 44). Although 
UTA1003 at higher concentration showed similar efficacy to U50,488, the agonistic activity of 
this ligand is noticeably weaker than U50,488 (Fig. 44, Table 24). 
  
Figure  44.  Dose‐response  of 
KOP‐receptor agonistic effect of 
UTA1003.  KOP  receptor 
agonistic effect of UTA1003 was 
assessed  as  inhibition  (%)  of 
forskolin‐stimulated cAMP levels 
in  CHO‐cells  expressing  human 
KOP  receptor.  The  cAMP  was 
stimulated using 5 µM forskolin 
and  U50,488  (1  nM  ‐  100  µM) 
was  used  as  positive  control. 
Values are represented as mean 
±  SEM  (n  =  6).  Error  bars  are 
sometimes  too  small  to  be 
visualised. 
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Although UTA1003 showed significantly lower agonistic effects than nociceptin at high 
concentration (100 µM) (Fig. 41), I further investigated the agonistic effect of UTA1003 (0.1 
nM to 100 µM) in CHO-NOP cells (Fig. 41). UTA1003 showed partial agonism (EC50 1.79 
µM) towards the NOP receptor. However, this effect was much lower compared to the results 
of the full agonist nociceptin (EC50 0.69 nM) (Fig. 41, Table 24).  
Figure  45.  Dose‐response  of  NOP‐
receptor  agonistic  effect  of 
UTA1003. The  NOP  receptor 
agonistic  effect  of  UTA1003  was 
assessed  as  inhibition  (%)  of 
forskolin‐stimulated  cAMP  levels  in 
CHO‐cells  expressing  human  NOP 
receptor. The cAMP was stimulated 
using 5 µM forskolin and nociceptin 
(0.1  nM  ‐  100  µM)  was  used  as 
positive  control.  Values  are 
represented as mean ± SEM (n = 6). 
Error bars are sometimes too small to 
be visualised. 
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Table 24. Summary of receptor specificity and efficacy of UTA1003 for the major opioid receptors. 
 
Cells  EC50 of 
UTA1003 
pEC50  
of UTA1003  
Emax  
(%) 
Ref. 
compound 
EC50 of Ref. 
compound 
pEC50  
of  reference  
Emax  
(%) 
Antagonist 
effect (Kd) 
CHO‐MOP  6.89 nM  8.16  82.44  DAMGO  12.5 nM  7.90  88.76   
CHO‐DOP  26.6 nM  7.58   28.20  DPDPE  20.7 nM  7.68  68.18  47.8 nM 
CHO‐KOP  30.9 nM  7.51  94.47  U50,488  0.20 pM  12.70  95.94   
CHO‐NOP  1.79 µM  5.75  28.34  Nociceptin  0.69 nM  9.16   90.73   
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6.3.4. Antagonistic effect of UTA1003 on DOP receptors  
A previous study found that some compounds that demonstrate low agonistic activity towards 
a particular receptor can also exhibit antagonistic effects (564). Since UTA1003 appeared to be 
a partial agonist (Emax 28.2 %) of the DOP receptor (Fig. 43), I further investigated its potential 
antagonism of this receptor using CHO-DOP cells (Fig. 46). The antagonist effect of UTA1003 
was calculated as described in previous studies (160,349,560). The percentage (%) inhibition 
of forskolin-stimulated cAMP production was calculated for different concentrations of 
DPDPE with or without 2 µM UTA1003 in DOP receptor-expressing Chinese Hamster Ovary 
(CHO-DOP) cells (Fig. 46). Since the addition of UTA1003 (in DPDPE solution) shifted the 
dose-response curve of DPDPE (dose range: 10 nM to 10 µM) towards the right, expressed the 
characteristics of a DOP receptor antagonist (Fig. 46). The Kd value of UTA1003 was 
calculated as Kd = 47.8 nM using the formula, Kd = [UTA1003] / (CR-1), where CR is the ratio 
of the EC50 of DPDPE in the presence and absence of UTA1003 (160,306,560) (Fig. 46, Table 
24).  
Figure  46. Antagonistic  effect  of 
UTA1003  against  the  effect  of 
DPDPE  on  the  δ‐opioid  receptor 
(DOP)  expressing  cells.  Different 
molar  concentrations  (M)  of  DPDPE 
(1 nM ‐ 100 µM) vs a combination of 
2  µM UTA1003  and DPDPE used  to 
assess the antagonism of UTA1003 in 
human  DOP  receptor  expressing 
Chinese  Hamster  Ovary  cells.  The 
effects  were  assessed  as  inhibition 
(%)  of  50  µM  forskolin‐stimulated 
cAMP levels. Values are represented 
as mean ± SEM (n = 6). Error bars are 
sometimes too small to be visualised. 
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6.4. Discussion 
Several ligands with specificity on multiple receptors have been developed and characterised 
pre-clinically as this class of compounds promises to overcome some of the limitations of 
classical opioid ligands during long-term treatment in the clinic (150,155,160,337). 
Importantly, several compounds based on “Dmt-tic”-containing peptides have also been 
described to display MOP receptor agonist / DOP receptor antagonist profiles 
(348,351,352,353). UFP-505 is a peptide based on ‘Dmt-Tic’ structure that was characterised 
in vitro and in vivo.  Currently, it is thought that the “Dmt-Tic” moiety of the peptide ligand is 
required for DOP receptor antagonism, while the Bzl (Benzylamine) and spacer (Gly-NH) 
moieties are required for MOP receptor agonism (347,348). Noticeably, UFP-505 induced 
antinociception with a reduced antinociceptive tolerance after intrathecal injections but did not 
show efficacy after systemic or oral administrations (354). In the current study, I tested 
structural analogues of UFP-505 to gain more information about a structure-activity 
relationship of this class of compounds. This project was initiated to evaluate the possibility to 
develop an analogue of UFP-505 that shows antinociception after systemic administration.  
In this study, I measured the functional activities of the structural analogues of UFP-505 (UTA-
ligands) by measuring their effects on cellular cAMP levels in a similar way to previous studies 
(178,560). the cAMP assay is a high-throughput and sensitive assay for screening G-protein 
coupled receptor (e.g. opioid receptors) mediated physiological pathways (565). This assay is 
user-friendly, as it does not require radioactive materials, which are required for classical radio-
ligand binding and [35S]GTPγS assays (565,566). However, a compound like a forskolin is 
needed to increase the production of cellular cAMP levels by stimulating adenylyl cyclase, as 
basal cellular cAMP levels are typically low (567). A previous study found that cAMP assay 
produced similar specificity profile of opioids to the receptor binding assay, but it produced 
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better resolution than [35S]GTPγS assay (560). Therefore, an evaluation of downstream 
signalling (e.g. cAMP assay) might be comparatively a better tool than [35S]GTPγS assay to 
measure the specificity profile of an opioid. 
In this study, UFP-505 appeared to be a MOP receptor agonist / DOP receptor partial agonist 
as previously reported (348,349,353). However, these results are in conflict with another study 
that characterised UFP-505 as a full agonist of the DOP receptor with partial agonism for MOP 
and KOP receptors (560). Surprisingly, this study found no significant efficacy of UFP-505 
(maximum stimulation < 10 %) for all major opioid receptors (MOP, DOP and KOP) using a 
[35S]GTPγS binding assay (560). In the same study, morphine and endomorphine only 
produced about 50 % effects for the MOP receptor (560), indicative of a low sensitivity of the 
employed [35S]GTPγS binding assay. Thus, the differential pharmacological profiles of UFP-
505 reported by previous studies may be a consequence of variations in assay methods and the 
experimental settings used by different laboratories. On the other hand, the results of this study 
agree with my results in that UFP-505 showed partial DOP receptor agonism with a 28 % 
inhibition of forskolin-induced cAMP stimulation (560), which is very similar to my result (31 
% inhibition).  
The pharmacological profile of UFP-505 is not fully clear in the existing literature. UFP-505 
was initially described in the literature as a DOP antagonist by Dietis and colleagues, having a 
strong affinity for DOP receptors (pKi 9.82 in radio-ligand displacement assays) with a non-
significant EC50, but a significant antagonistic potency of pKb 9.81 in a GTPγ35S assay and a 
pA2 9.15 in the electrically stimulated guinea pig ileum, both against DPDPE (349). However, 
in a recent study published by Dietis and co-authors (350), looking at UFP-505’s 
characterisation in more depth, the ligand was shown to produce a weak partial agonism in cell 
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systems with very high DOP-receptor expression (Emax approximately 7% normalized for 
DPDPE Emax 100% in a GTPγ35S assay; Emax approximately 18% with DPDPE at Emax 78% in 
forskolin-stimulated cAMP inhibition assay). The authors (Dietis et al.) concluded that UFP-
505 “displays a variable expression-dependent efficacy at the DOP receptor” (350). This 
phenomenon has been previously described for other ligands (559). These data agree with the 
findings in my thesis (Fig. 39) and provide an explanation of the characterisation of UFP-505, 
which we now know that behaves as a DOP antagonist in systems with receptor expression 
closer to that of primary tissues, but as low efficacy partial agonist in systems with very high 
DOP receptor expression levels. 
The replacement of a benzene ring from the “Tic” peptide of UFP-505 in this study produced 
UTA1003 that subjectively displayed better solubility in aqueous solution, in line with a 
significantly reduced logP value (-0.11 versus 0.41), although I did not perform detailed 
solubility experiments. At the same time, this structural change resulted in comparable MOP 
receptor agonism with slightly reduced DOP receptor antagonism (pKb: 7.32) on compared to 
UFP-505 (pKb: 9.81(349); 10.50 (348)). The dose-dependent efficacy of UTA1003 towards the 
MOP receptor was similar to DAMGO, but its efficacy towards DOP and NOP receptors was 
substantially lower than the specific reference compounds DPDPE and nociceptin. On the other 
hand, at high (≥ 1 µM) concentrations UTA1003 acted as an agonist of the KOP receptor similar 
to U50,488, which was noticeably lower than U50,488 at low concentrations (˂ 1 µM). The 
detailed dose-response analysis of UTA1003 indicates that UTA1003 is also a KOP receptor 
agonist / NOP receptor partial agonist, which is similar to previous reports regarding UFP-505 
(349). UFP-505 was described to have affinity at low µM range (pKi 6.26 in CHO-KOP cells) 
using radio-ligand binding assay and a non-significant efficacy using the GTPγ35S assay (349). 
Therefore, deletion of the benzene ring from “Tic” pharmacophore in UTA1003 appears to 
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have only a minor impact on the pharmacological efficacy of “Dmt-Tic” peptides apart from 
increased efficacy towards KOP receptor.  
Previous studies hypothesised that the “Gly-NH-Bnz” peptide moiety is essential for the MOP 
receptor agonistic activity of peptide opioid ligands (347,348,349). However, in contrast to this 
hypothesis, the replacement of glycine (Gly-NH) with a hydrocarbon chain in UTA1009 and 
UTA1011 retained their agonistic activity towards the MOP receptor. Since this structural 
change also generated non-selective compounds that acted on both opioid and non-opioid 
receptors, the “Gly-NH” moiety appears to be important to maintain opioid receptor specificity 
overall. However, one possibility to reconcile the conflicting data could be that instead of the 
Gly-NH motive, the benzyl (Bnz) group could be responsible for the MOP receptor specificity. 
However, although I did not investigate this hypothesis, due to restrictions with regards to the 
number of UFP-505 analogues that could be synthesised. 
In this chapter, the roles of “Dmt-Tic” and “Gly-NH” peptide moieties for the pharmacological 
profile of different UFP-505 analogues are described. I also identified a novel opioid ligand 
(UTA1003) with MOP and KOP receptor agonist and DOP receptor partial agonist profile (i.e. 
mixed activity on multiple opioid receptors). The specificity of the UTA-compounds was 
determined by measuring their efficacy on different types of opioid receptors, which could be 
measured as selectivity in a radio-ligand binding assay. This is a limitation of my study, which 
can be addressed in future studies. In this study, single concentration of UTA-opioids (100 µM) 
were used to determine the specificity of the ligands, which is probably difficult to draw the 
conclusion on the pharmacological profile of every ligand. The study provided substantial 
information to screen the ligands to select the best compound for the preclinical study (chapter-
7). The cAMP assay is now widely used to characterise opioid ligands (160,178,560) and 
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therefore the inference from the results is valid. I also agree that full concentration curves of 
every ligand would provide a better basis for my conclusion. This experimental approach could 
not be completed due to the associated cost and time-restrictions for my work. I used the cAMP 
assay to choose the best ligand by determining its specificity profile of through screening by 
using a single concentration of all ligands and then chose the best ligand (UTA1003) for the 
full concentration curves of its agonism on all types of opioid receptors and antagonism for 
DOP receptor. The selectivity profile of UTA1003 is complete as its efficacy is measured using 
6-7 concentrations of UTA1003 and compared with reference opioids selective for a particular 
opioid receptor (e.g. DAMGO, DPDPE). I conducted this study in a way to reduce the cost 
without affecting ultimate objective of the research project. I can not exclude the possibility of 
an antagonistic effect of another ligand such as UTA1006 on the DOP or KOP receptors. A 
detailed screening with multiple concentrations could investigate more UTA-ligands with 
mixed activity on multiple receptors in the future. Nevertheless, these experimental results were 
the prerequisite for a preclinical in vivo study with UTA1003 to assess its effects on 
antinociception, antinociceptive tolerance and motor behavioural effects using a repeated 
treatment regimen.  
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CHAPTER SEVEN 
 
Differential effects of UTA1003 on antinociceptive 
tolerance and behaviour 
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Preface to chapter seven  
The novel opioid ligand UTA1003 was described in chapter six and was selected as the most 
promising ligand due to its mixed activity on multiple opioid receptors. In this study (chapter 
seven), I investigated the role of UTA1003 on antinociception and behaviour after acute 
treatment compared to morphine. Furthermore, repeated treatment of UTA1003 and morphine 
over a period of eight days was carried out to observe the role of UTA1003 on the development 
of antinociceptive tolerance and behavioural effects. 
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7. Differential effects of the UTA1003 on antinociceptive tolerance and behaviour 
 
Abstract 
Analgesic tolerance is a major problem in the clinic for the maintenance of opioid-induced 
long-term pain-relief. Opioids with mixed activity on multiple opioid receptors promise 
reduced antinociceptive tolerance in preclinical studies, but these compounds typically have 
poor bioavailability upon oral, subcutaneous, intraperitoneal or intravenous administration. 
UTA1003 is a novel opioid that acts as MOP and KOP receptor agonist and as a partial agonist 
for the DOP receptor. In the present study, its antinociceptive effects, as well as its effects on 
antinociceptive tolerance and motor behaviour were investigated in male rats. Acute 
antinociception was measured before (basal) and at different time-points after subcutaneous 
injection of UTA1003 and/or morphine using tail-flick and hot-plate assays. Different motor 
behaviours, including horizontal locomotion, rearing and turning were automatically measured 
in an open-field arena. The repeated twice-daily dosage of UTA1003 and morphine was also 
conducted over a period of eight days. In these experiments, UTA1003 induced mild 
antinociceptive effects after acute administration but induced no tolerance after repeated 
treatment. UTA1003, as a co-treatment with morphine also prevented morphine tolerance. 
UTA1003 showed less motor suppression than morphine in both acute and sub-chronic 
treatment regimens, while it did not affect morphine-induced motor suppression or hyper-
excitation. Based on these activities, I speculate that UTA1003 crosses the blood-brain barrier 
after subcutaneous administration and therefore could be developed as a lead molecule to avoid 
opioid-induced antinociceptive tolerance and motor suppression. However, further structural 
modifications to improve its antinociceptive effects, its toxicity profile and ADME parameters 
are nevertheless required.  
 
Keywords: UTA1003; UFP-505; morphine; antinociception; antinociceptive tolerance; motor 
behaviour; mixed opioid; mixed activity. 
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7.1. Introduction 
Opioids, especially morphine and other MOP receptor agonists, are widely used drugs for the 
clinical treatment of chronic pain, (22,568,569). However, long-term repeated use of clinical 
opioids such as morphine is often limited by their liabilities to induce a significant range of 
side-effects, such as respiratory depression, sedation, constipation, addiction, dependence, 
withdrawal symptoms, behavioural suppression and analgesic tolerance (111,112). Tolerance 
is a phenomenon of reduced efficacy of an effect of a drug over repeated use of particular dose 
(113). Previous studies also showed that there are differences in onset or magnitude of tolerance 
to antinociceptive and other behavioural effects, such as sedation, nausea, ventilatory or 
respiratory depression (172,570). For example, antinociceptive tolerance to morphine did not 
show tolerance to its ventilatory depressant effects in the rat (571). Similarly, tolerance to 
respiratory depression is relatively slower than tolerance to euphoric effect (572). On the other 
hand, tolerance to constipation develops slower than respiratory depression, sedation or nausea 
(573,574).  
Antinociceptive effects and antinociceptive tolerance of morphine are both dependent on dose, 
dosing frequency and duration of treatment (137). In contrast, morphine-induced behavioural 
side-effects in the clinic are both reported as dose-dependent (e.g. pruritus) or dose-independent 
(e.g. nausea, vomiting) (250,251,440).  At present, the collective evidence suggests that 
antinociceptive tolerance to morphine does not necessarily translate to tolerance against 
behavioural side-effects.  
Therefore, many studies investigated different ways to prevent antinociceptive tolerance to 
morphine. Early studies showed that repeated administration of a combination of morphine (a 
MOP receptor agonist) and naltrindole or another DOP receptor antagonist showed better 
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antinociception and less antinociceptive tolerance compared to morphine alone 
(122,123,124,125). To achieve this, a significant effort was made to identify single ligands that 
are non-selective or have mixed activity on multiple opioid receptors, as these compounds 
promise better pharmacokinetic/pharmacodynamic profiles than a combination of drugs 
(280,282,346). As a result, MOP and DOP receptor selective opioid ligands with mixed activity 
have been described that indicated reduced antinociceptive tolerance compared to clinically 
used opioids (150,151,155,160,178,184,337). Especially, MOP receptor agonist / DOP receptor 
antagonist ligands showed less antinociceptive tolerance compared to morphine or fentanyl 
(150,155,160,337,346). A few of these MOP receptor agonist / DOP receptor antagonist ligands 
showed less physical dependence or reward-responses compared to clinically used opioids 
(337,346).  Similarly, some MOP / DOP receptor agonists also reduce antinociceptive tolerance 
(151,171,178,184), which indicates MOP and DOP receptor interactions are essential to 
manage antinociceptive tolerance, although the detailed mechanisms underlying this effect are 
not understood. On the other hand, MOP / KOP receptor agonists reduce cocaine abuse after 
co-administration (280,575), while MOP / NOP agonist ligands have been reported as non-
addictive analgesics and are effective to treat neuropathic pain (283,308). However, repeated 
administration of the MOP / NOP receptor agonist ligand BU08028 induced earlier 
antinociceptive tolerance compared to morphine, (152), which illustrates that the entire activity 
profile of all novel bi-functional ligands has to be determined to be in a position to predict their 
clinical usefulness. Noticeably, for many new opioids, their antinociceptive tolerance induction 
after repeated treatment (see chapter one) has not been reported, which significantly hinders 
the detailed interpretation of experimental data and their clinical development. 
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UTA1003 is an opioid ligand recently developed at the University of Tasmania, Australia that 
showed a pharmacological profile as MOP and KOP receptor agonist and displayed variable 
effects (partial agonist and antagonist) towards the DOP receptor. UTA1003 is based on the 
previously described bi-functional opioid UFP-505 and shows similar activity (EC50 6.89 nM) 
as the standard MOP receptor agonist DAMGO (EC50 12.5 nM), while also antagonising the 
DOP receptor (pKb 7.32) (unpublished data, see chapter six). In a recent study, UFP-505 is also 
reported as a partial agonist of DOP receptor shown to produce a weak partial agonism in cell 
systems with very high DOP-receptor expression (350). In this study, Dietis and colleagues 
concluded that UFP-505 “displays a variable expression-dependent efficacy at the DOP 
receptor” (350). A similar phenomenon has been described previously for other ligands (559). 
I hypothesised that the UTA1003 may induce less antinociceptive tolerance and behavioural 
side-effects than morphine, as UTA1003 is a MOP receptor agonist / DOP receptor partial 
agonist. In addition, I speculated that after co-administration with morphine over a period of 
several days, UTA1003 might also reduce the antinociceptive tolerance and behavioural side-
effects of morphine. Therefore, the current study investigated the motor behavioural side-
effects, antinociception and antinociceptive tolerance after repeated administration of 
UTA1003, morphine and their combination. This study, for the first time, describes that the 
novel ligand UTA1003 is a potential drug-candidate to induce antinociception with reduced 
adverse effects compared to morphine. 
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7.2. Materials and methods 
7.2.1. Materials 
Dimethyl sulfoxide (DMSO) and sodium chloride were purchased from Sigma-Aldrich. 
Morphine sulphate was obtained as 30 mg/ml stock solution (Hameln Pharmaceuticals GmbH, 
Germany), while UTA1003 and the reference compound UFP-505 were synthesised by A/Prof 
Jason Smith (School of Chemistry, University of Tasmania). Stock solutions and final dilutions 
of these drugs were prepared under aseptic conditions using 10 % DMSO in 0.9 % sodium 
chloride solution as a vehicle.  
7.2.2. Animal maintenance and care 
Thirty male Sprague-Dawley (SD) rats (253.6 ± 3.9 g, 8 week old), obtained from the 
University of Tasmania animal services were housed as three littermates per cage at 22 ºC with 
50-60 % humidity under an automated 12-hour day/night cycle (lights on at 7:00 am) with free 
access to food (Barastoc rodent cubes, Ridley Corporation, Melbourne, Australia) and water. 
Only male rats were used to avoid hormonal effects in female rats (336). All procedures and 
handling were approved by the University of Tasmania Animal Ethics Committee (A0013864) 
and were conducted according to The Australian Code for the Care and Use of Animals for 
Scientific Purposes (434). The experiments were conducted in compliance with the ARRIVE 
guidelines (435).  
7.2.3. Treatment protocol 
Animal body weights were recorded daily, immediately prior to experiments in order to 
determine the dosage for each rat. The dosage of UFP-505, UTA1003 and morphine were 
calculated based on individual body weights. All drugs were administered as daily 
subcutaneous injections between the left thigh and the spinal cord. All rats were randomly 
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divided as previously described (448) into five subgroups (n = 6, each) (morphine 3 mg/kg 
b.i.d.; UFP-505 27.1 mg/kg acute administration; UTA1003 24.6 mg/kg b.i.d.; a combination 
of morphine (3 mg/kg b.i.d.) and UTA1003 (24.6 mg/kg b.i.d.); or vehicle (DMSO 10% in 
0.9% sodium chloride solution, acute administration). Opioids were administered twice daily 
(mornings and evenings) over a period of 8 days (except for UFP-505 and vehicle). Vehicle 
and UFP-505 were excluded from long-term testing due to their negligible antinociceptive in 
vivo effects on day 1. UFP-505 and UTA1003 doses were calculated to provide the same molar 
concentrations compared to 40 mg/kg morphine sulphate. The amount of injected DMSO was 
kept equal for all used solutions. Reduced laboratory illumination intensity prior and during 
experiments minimised any potential discomfort to the animals.  
7.2.4. Assessment of antinociception  
Nociceptive thresholds were determined using two independent assays (tail-flick & hot plate) 
using commercially available equipment (Ugo Basile, Comerio, Italy). Maximum exposure to 
the nociceptive thermal stimulus was 15 sec for the tail-flick and 30 sec for the hot-plate assay. 
The infrared intensity of the tail-flick photocell was set to 30, whereas the temperature of the 
hot-plate was set to 54 ±0.5 °C. On the first treatment day, all animals were tested in both assays 
immediately prior to the vehicle or opioid administration to obtain basal measurements as well 
as values for 15, 30, 60 and 120 min post-administration. On all other days, the rats were tested 
prior- and 15, 30 min post-injection. Nociception measurements were conducted in a blinded 
manner and the mean of three independent measurements for each time-point with a 1 min 
interval between measurements was recorded to minimise the ‘handling’ effects. The maximum 
possible effect (MPE) was defined as MPE % or antinociception = 100 X [(test latency – 
baseline latency)/(cut-off time – baseline latency)] as previously described (436). The area 
under the curves (AUC) were calculated by the trapezoid method using GraphPad Prism V6 
233 
 
 
software (GraphPad Software Inc., La Jolla, CA, USA). 
7.2.5. Behavioural Measurements  
Behaviour was tested in the open-field arena of a fully automated Multi-Conditioning System 
(MCS, TSE GmbH, Homburg, Germany) that is able to assess and simultaneously analyse a 
large range of behavioural parameters of animals kept under controlled conditions. The MCS 
platform included an internal noise/light/temperature insulation system and a 3D infrared-beam 
frame that provided fast and accurate animal movement detection (100Hz), combined with a 
high-resolution video monitoring and automated movement tracking system. Quantification 
and visualisation of the MCS data were processed by integrated system software (TSE 
ActiMot). The open-field arena was fully cleaned and dried after testing of each animal. A 
background white noise (10 dB) generator was used during all experiments in order to cancel 
out any unexpected laboratory sounds. On the 1st treatment day, behaviour was assessed 1 min 
after nociception testing at all time-points over a period of 5 min, while the rats were tested 
only 30 min post-injection on the subsequent treatment days. Behavioural testing for this study 
included six different activity parameters (moving time, total distance travelled, rotation 
numbers, rearing numbers, rotation time and rearing time). Rotation numbers were summarised 
from clockwise and counter-clockwise rotations as detected by the MCS. The area under the 
curves (AUC) for behavioural parameters were calculated by multiplication of behavioural 
effects (e.g. moving time) and treatment period (min or day). At the end of the observation 
period, animals were anesthetised with 5% (w/v) isoflurane in oxygen at a flow rate of 1 L/min, 
until the animal was unconscious (usually 5-7 min), before decapitated.   
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7.2.6. Statistical analysis 
Data are expressed as mean ±SEM and analysed by one-way ANOVA with Dunnett’s multiple 
comparisons test or unpaired t-test, using GraphPad Prism V6 software (GraphPad Software 
Inc., La Jolla, CA, USA). Multiple comparison (Dunnett’s or Sidak’s test) was employed when 
F achieved p < 0.05 and there was no significant variance in homogeneity. A ‘p’ value less than 
0.05 was considered statistically significant.  
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7.3. Results 
7.3.1. Toxicity of UTA1003 
In the present study, I did not observe any physiological or behavioural toxicity in our animals 
after subcutaneous administration of UTA1003 and UFP-505. Repeated morphine dosing is 
known to induce itching (253,254,576), which was absent in the UTA1003-treated animals in 
this study. This is an important advancement as a previous study reported behavioural toxicity 
for two MOP / NOP receptor agonists after subcutaneous administration (283).   
7.3.2. Antinociceptive effect of UTA1003 after acute administration  
Two opioids with mixed selectivity on different opioid receptors, UFP-505 and UTA1003 were 
evaluated for their antinociceptive effects after acute sub-cutaneous injections using male 
Sprague Dawley rats on day 1. Their antinociceptive effects were compared to morphine or 
vehicle on day 1.  Before opioid administration, no significant differences in nociceptive levels 
were observed in the five different treatment groups using both the tail-flick and hot-plate 
antinociception tests (Fig. 47). It indicates that none of the animals used in this study 
demonstrated hyperalgesia or increased pain-sensitivity. Baseline antinociception 
measurement is very important from a clinical perspective, as people experience hyperalgesia 
after long-term treatment with low dose opioids (577,578). Hyperalgesia has also been 
observed in preclinical studies, although the exact mechanism by which it occurs is not 
completely understood (180,579). Previous studies show that hyperalgesia is not mediated by 
the brain MOP receptor and is also not associated with plasma concentration of morphine-3-
glucuronide, but rather a consequence of protein kinase C gamma (PKCγ) and NMDA receptor 
subtype NR1 upregulation in the spinal cord (257,258). Vehicle-treated animals did not show 
any antinociceptive effects or hypersensitivity in both antinociception tests over a period of 120 
min after administration (Fig. 47 A, B). However, 15 min post administration, morphine-
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induced significant antinociception compared to vehicle-treated animals (unpaired t-test; t (6) 
= 17.49; p < 0.0001) before it decreased gradually until 120 min (unpaired t-test; t (8) = 5.96; 
p < 0.001) (Fig. 47 A, B). UTA1003 induced significant antinociception already 15 min post-
injection in the hot-plate assay (unpaired t-test; t (9) = 2.53; p < 0.05) and from 30 min onwards 
in both assays (unpaired t-test; t (5) = 4.544; p < 0.01 (tail-flick); t (7) = 3.35; p < 0.05 (hot-
plate)) (Fig. 47 A, B). The antinociceptive effect of UTA1003 was significantly different from 
the effects of vehicle until 60 min (unpaired t-test; t (9) = 4.08; p < 0.01) using hot plate (Fig. 
47 B) and 120 min (unpaired t-test; t (9) = 2.483; p < 0.05) using tail-flick assay (Fig. 47 A) 
respectively.  
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Figure 47. Antinociceptive effects of different opioids after acute treatment. Antinociceptive 
effects after single subcutaneous  injections of UFP‐505 (27.1 mg/kg), UTA1003 (24.6 mg/kg), 
Morphine (MS, 3.0 mg/kg) or vehicle were measured in Sprague Dawley rats. Antinociception 
was measured over a period of 120 min using tail flick (A) and hot plate (B) assays. Statistical 
significance against the effect of vehicle is shown as *p < 0.05 or **p < 0.01 for the same time‐
point  was  calculated  using  unpaired  t‐test.  Additionally,  statistically  significant  differences 
between MS and MS+UTA1003 treated animals for the same time‐point was calculated using 
unpaired t‐test and are shown as ##p < 0.01 or ###p < 0.001. Values are presented as Mean ± SEM 
(n = 6 animals per group). Error bars are present in all graphs but are sometimes too small to be 
visible. 
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The combination of UTA1003 and morphine-induced significant antinociception from 15 min 
post-administration (unpaired t-test; t (4) = 4.30; p < 0.05) in the tail-flick assay while 
antinociception peaked at 30 min in both antinociceptive assays (unpaired t-test; t (7) = 29.44; 
p < 0.0001 (tail-flick); t (10) = 11.47; p < 0.0001) (Fig. 47 A, B). Subsequently, the 
antinociceptive effect of this drug combination gradually declined over the 120 min observation 
period (unpaired t-test; t (10) = 4.25; p < 0.01) (Fig. 47 A, B). However, the antinociceptive 
effect of the UTA1003 / morphine combination produced significantly less antinociception than 
morphine alone at 15 min (unpaired t-test; t (6) = 7.25; p < 0.001 (tail-flick); t (9) = 4.16; p < 
0.01) and 60 min (unpaired t-test; t (7) = 6.55; p < 0.001; tail-flick assay) post-administration 
(Fig. 47 A, B). In comparison, over the 2 hour observation period UFP-505 only showed some 
minor but statistically significant antinociception at 15 min post-injection (unpaired t-test; t (7) 
= 3.18; p < 0.05)  (Fig. 47 A, B). 
7.3.3. Effect of UTA1003 on morphine-induced antinociceptive tolerance 
To investigate the effects of UTA1003 on antinociceptive tolerance and its interaction with 
morphine, opioids were administered individually or in combination twice daily over a period 
of 8 days. Antinociceptive effects of these opioids were measured daily using tail-flick and hot 
plate tests 30 min post-administration. Antinociceptive effects of UTA1003 were 27 ± 3.73 % 
and 22.57 ± 1.77 % MPE respectively in the tail-flick and hot-plate assays respectively (Fig. 
48 A, B).  However, there was no significant reduction (tolerance) or increment (hyperalgesia) 
of antinociception observed in this group of animals over the course of the 8 day observation 
period (Fig. 48 A, B). Therefore, UTA1003-induced antinociception (% MPE) on day 8 was 
20.52 ± 2.13 % and 15.47 ± 2.55 % respectively for tail-flick and hot-plate assays (Fig. 48 A, 
B). 
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Figure 48. Antinociceptive effects of chronic administration of opioids. Antinociceptive effects 
after twice‐daily subcutaneous treatment with UTA1003 (24.6 mg/kg), morphine (MS, 3 mg/kg) 
or  their combination were measured  in Sprague Dawley rats. Antinociception was measured 
daily at 30 min post injections over a period of 8 days using tail flick (A) and hot plate (B) assays. 
Statistical significance (p<0.05) against the effect of day‐0 was calculated using One‐way ANOVA 
and is shown as *p < 0.05, **p < 0.01, ***p < 0.001 or ****p < 0.0001. Additionally, statistically 
significant differences between MS and MS+UTA1003 treated animals for the same time‐point 
was calculated using unpaired t‐test and are shown as #p < 0.05, ##p < 0.01 or ###p < 0.001. Values 
are presented as Mean ± SEM (n = 6).  Error bars are sometimes too small to be visible. 
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On the other hand, morphine produced complete antinociception (100 % MPE) on day 1 in the 
tail-flick assay. The combined treatment of UTA1003 and morphine also showed similar 
antinociception levels comparable to morphine itself on day 1 (Fig. 48 A, B). The full 
antinociceptive effects of morphine were maintained until day 2 and then a statistically 
significant reduction was observed on day 4 (one-way ANOVA; F (7, 27) = 23.33; p < 0.0001) 
using tail-flick assay (Fig. 48 A). Beyond that, morphine-induced antinociception gradually 
declined over the observation period (Fig. 48 A). In contrast, the UTA1003 / morphine-treated 
animals showed tolerance from day 3 (one-way ANOVA; F (7, 29) = 25.20; p < 0.0001) and 
the effect was (51.94 ± 4.46 %) (Fig. 48 A). These co-treated animals maintained the anti-
nociceptive effects of the drug combination until day 8 (43.17 ± 4.45 %), with no statistical 
differences between days 3 and 8 (Fig. 48 A). Noticeably, the combination of UTA1003 / 
morphine-induced significantly higher antinociception levels from days 5 (unpaired t-test; t (8) 
= 3.16; p < 0.05) to 7 (unpaired t-test; t (6) = 4.36; p < 0.01), compared to morphine-treated 
animals (Fig. 48 A).  
The antinociception of morphine and the combination of UTA1003 / morphine were further 
investigated using the hot-plate assay where both groups showed similar antinociception on 
day 1 (72.77 ± 7.30 % and 74.28 ± 6.41 % MPE respectively) (Fig. 48 B). Morphine-treated 
animals showed antinociceptive tolerance from day 2 (one-way ANOVA; F (7, 29) = 16.02; p 
< 0.01), which decreased gradually over time until day 8 (Fig. 48 B). UTA1003 did not show 
signs of antinociceptive tolerance until day 3 (one-way ANOVA; F (8, 37) = 20.41; p < 0.01). 
Beyond that, a 50% antinociceptive effect was maintained until day 5 (Fig. 48 B). This effect 
further decreased over time until the end of my observation period (Fig. 48 B). Noticeably, the 
antinociceptive effects of morphine were significantly lower than those of the UTA1003 / 
morphine co-treatment on day 2 (unpaired t-test; t (5) = 5.38; p < 0.01) and from day 5 (unpaired 
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t-test; t (10) = 5.02; p < 0.001) to day 8 (unpaired t-test; t (6) = 6.15; p < 0.001) (Fig. 48 B). 
7.3.4. Effect of acute administration of UTA1003 on motor behaviour 
To gain a basic understanding of the behavioural effects of UTA1003, motor behaviour was 
analysed using an open-field paradigm over a period of 120 min after drug administration. 
These effects were compared to vehicle- and morphine-treated animals. The behavioural 
parameters assessed in the open-field arena were divided into three major categories: 
locomotion, rotation and rearing.  
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Figure 49. Acute time‐dependent effects of morphine and UTA1003 on locomotor activities. 
Open‐field locomotor activities after acute subcutaneous injections of UTA1003 (24.6 mg/kg), 
morphine (MS, 3.0 mg/kg) or vehicle were measured in Sprague Dawley rats. The behaviour of 
treated animals was measured as moving time (A, B) or distance travelled (C, D) over a period of 
120 min. Statistically significance (p < 0.05) against the effects of vehicle is shown as *p < 0.05 or 
****p < 0.0001 for the same time‐point and was calculated using unpaired t‐test. Values are 
presented as Mean ± SEM (n = 6 animals per group). Error bars are present in all graphs but are 
sometimes too small to be visible.  
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The locomotion parameter was further subdivided into the parameters moving time and 
distance gain a more detailed picture of the drug-induced effects (Fig. 49 A-D). Before 
administration of opioids or vehicle, no behavioural differences were observed between the 
animal groups (Fig. 49 A-D). After acute administration of UTA1003, significantly reduced 
moving time compared to the vehicle group at all time-points (unpaired t-test; t (7) = 2.42; p < 
0.05), while moving distance was unaffected (Fig. 49 A, C). On the other hand, morphine 
significantly reduced both moving time (unpaired t-test; t (8) = 18.60; p < 0.0001) and distance 
(unpaired t-test; t (7) = 2.91; p < 0.05) compared to vehicle, although this effect was restricted 
to the 30 min-post administration time point. In contrast to UTA1003, morphine increased 
moving distance (unpaired t-test; t (6) = 3.17; p < 0.05) 15 min after drug administration (Fig. 
49 B, D), while for all other time points no behavioural changes were detected compared 
vehicle-treated animals (Fig. 49 A-D).  
Rearing is a complex behaviour, controlled by the hippocampal formation of the brain 
(205,207). It is an exploratory, that can be affected by anxiety or escape behaviours and can 
also increase as a result of opioid withdrawal symptoms (205,206,207,580).  Reduced rearing 
time was observed from 15 to 60 min post-administration of both UTA1003 (e.g. at 15 min; 
unpaired t-test; t (10) = 2.24; p < 0.05) or morphine (e.g. at 15 min; unpaired t-test; t (8) = 3.51; 
p < 0.01) (Fig. 50 A, B). No rearing time differences were observed between vehicle-, 
morphine- or UTA1003-treated animals 120 min after drug administration (Fig. 50 A, B). 
However, both UTA1003 (e.g. at 15 min; unpaired t-test; t (9) = 3.83; p < 0.01) and morphine 
(e.g. at 15 min; unpaired t-test; t (8) = 2.76; p < 0.05) showed significantly reduced rearing 
numbers until 120 min post-administration (Fig. 50 C, D). Thus, UTA1003 and morphine both 
reduced overall rearing activities until 2 hours post-administration, while the vehicle-treated 
animals did not show any significant changes over the observation period (Fig. 50 A-D).  
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Figure 50. Rearing behaviour after acute UTA1003 and morphine administration. Open‐field 
rearing behaviour after acute subcutaneous injections of UTA1003 (24.6 mg/kg), morphine (3.0 
mg/kg) or vehicle was measured in Sprague Dawley rats. Opioid‐induced behavioural changes 
were measured  as  rearing  time  (A,  B)  or  rearing  numbers  (C,  D)  over  a  period  of  120 min. 
Statistically significant (p < 0.05) differences were compared against the effects of vehicle for the 
same time‐point are shown as *p < 0.05, **p < 0.01, ***p < 0.001 or ****p < 0.0001 and were 
measured using unpaired t‐test. Values are presented as Mean ± SEM (n = 6 animals per group).  
Error bars are present in all graphs but are sometimes too small to be visible. 
 
To investigate these opioid-induced effects on spontaneous behaviour further, rotation or 
turning behaviour was measured, which is generally believed to an indicator of movement 
coordination (581). In the present study, no differences were observed between clockwise and 
counter-clockwise rotations for both vehicle- or morphine-treated animals (data not shown). 
Similarly, total rotational activities (sum-total of clockwise and counter-clockwise rotation 
numbers or time) remained unaffected by UTA1003 over the entire observation period (Fig. 51 
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A, C). In contrast, morphine significantly reduced rotation numbers (unpaired t-test; t (9) = 
2.97; p < 0.05) and time (unpaired t-test; t (9) = 2.32; p < 0.05) 30 min after injection (Fig. 51 
B, D) in line with its maximal antinociceptive effect. Beyond this time point, rotation numbers 
in morphine-treated animals increased back to the basal levels over the 120 min observation 
period (unpaired t-test; t (7) = 3.00; p < 0.05) post-injection (Fig. 51 D).   
 
Figure  51.  Time‐dependent  turning  behaviour  after  acute  administration  of morphine  and 
UTA1003. Effects on turning or rotation after single subcutaneous injections of UTA1003 (24.6 
mg/kg),  morphine  (MS,  3.0  mg/kg)  or  vehicle  were  measured  in  Sprague  Dawley  rats.  The 
activities of treated animals were measured using an open field test over a period of 120 min. 
Opioid‐induced behavioural changes, such as rotation time (A, B) or rotation numbers (C, D) were 
compared against the vehicle. Statistically significant (p < 0.05) differences at the same time‐
points  compared  to  vehicle‐treated  animals  are  indicated  with  an  asterisk  (*)  and  were 
calculated using unpaired t‐test. Values are presented as Mean ± SEM (n = 6). Error bars are 
present in all graphs but are sometimes too small to be visible. 
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The motor behaviour of these animals was further investigated to check out the prevalence of 
anxiety among these animals (Fig. 52). Place-preferences in the open-field arena is a 
behavioural marker for anxiety and locomotion (450,481). In the current study, vehicle-, 
UTA1003- and UTA1003 / morphine-treated animals showed no differences with regards to 
basal place-preferences over the entire observation period (Fig. 52 A, C, D). On the other hand, 
morphine-treated rats spent significantly less time between 15 (one-way ANOVA; F (4, 23) = 
7.38; p < 0.05) and 60 min (one-way ANOVA; F (4, 23) = 7.38; p < 0.01) after administration, 
which indicates a sign of anxiety among the morphine-treated animals (Fig. 52 B). A reduction 
of travelled distance at 60 min post time-point (one-way ANOVA; F (4, 23) = 3.91; p < 0.05) 
was also observed (Fig. 52 B) suggestive of morphine-induced anxiety.   
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Figure 52. Place‐preferences after acute administration of opioids. Effects on time spent in the 
centre  (%  of  total  observation  period,  5 min)  or  distance  travelled  in  the  centre  (%  of  total 
distance travelled by the animal) after single subcutaneous injections of vehicle (A),  morphine 
(MS, 3.0 mg/kg) (B), UTA1003 (24.6 mg/kg) (C) or UTA1003 (24.6 mg/kg) / morphine (3.0 mg/kg) 
(D) were measured  in Sprague Dawley rats. The activities of  treated animals were measured 
using an open field test over a period of 120 min. Statistically significant (p < 0.05) differences 
compared to the basal behaviour of every group of animals are indicated with an asterisk (*) and 
were calculated using one‐way ANOVA with a Sidak’s multiple comparison post hoc tests. Values 
are presented as Mean ± SEM (n = 6). Error bars are present in all graphs but are sometimes too 
small to be visible. 
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7.3.5. Effect of chronic UTA1003 treatment on motor behaviour  
In addition to the acute effects of opioid treatment on behaviour, motor behaviour was also 
determined during long-term treatment of UTA1003.  In this study, animals were treated with 
morphine, UTA1003 or the combination of UTA1003 / morphine on a twice-daily dosage-
regimen over a period of eight consecutive days. Motor behaviour was measured daily as 
locomotion, rotation and rearing activities at 30 min post-administration using an open-field 
arena (Fig. 53).  
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Figure 53. Motor behavioural effects of  chronic administration of morphine and UTA1003. 
Open‐field motor behavioural effects after twice daily subcutaneous injections of UTA1003 (24.6 
mg/kg), morphine (MS, 3.0 mg/kg) or their combination were measured in Sprague Dawley rats. 
Opioid‐induced behavioural activities were measured daily at 30 min post‐injection over a period 
of 8 days, as described in methods. Several behavioural parameters, such as moving time (A), 
rearing  time  (B),  rotation  time  (C),  distance  travelled  (D),  rearing  numbers  (E)  or  rotation 
numbers (F) were measured. The blocked diamond, open circle and closed circle symbols show 
the  values  of UTA1003, MS and MS+UTA1003  respectively.  Statistically  significant  (p  <  0.05) 
differences for the same time‐point between the effects of MS and UTA1003 are shown as (#p < 
0.05,  ##p  <  0.01,  ###p  <  0.001  or  ####p  <  0.0001),  between  the  effects  of  UTA1003  and 
MS+UTA1003 are shown as (*p < 0.05, **p < 0.01, ***p < 0.001 or ****p < 0.0001), or between 
the effects of MS and MS+UTA1003 are shown as (φp < 0.05) and were calculated using unpaired 
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t‐test. Values are presented as Mean ± SEM (n = 6 animals per group). Error bars are present in 
all graphs but are sometimes too small to be visible. 
 
To compare the overall motor behavioural activities among different groups of animals (as 
shown in Fig. 53), the effect of morphine was first compared against UTA1003, where 
morphine significantly reduced moving time on the first (unpaired t-test; t (9) = 5.50; p < 0.001) 
and second days of treatment (Fig. 53 A). Beyond this, higher moving time was observed on 
day 8 in morphine-treated animals (unpaired t-test; t (9) = 3.18; p < 0.05) (Fig. 53 A). Moving 
distance, which is a reliable parameter for exploration or locomotor activities, morphine-
induced suppression was observed for this behaviour on day 1 (unpaired t-test; t (9) = 3.97; p 
< 0.01) (Fig. 53 D), while higher moving distance was noticed from day 5 (unpaired t-test; t (7) 
= 2.56; p < 0.05) to 8 (unpaired t-test; t (7) = 7.47; p < 0.001) (Fig. 53 D).  Thus, morphine-
induced biphasic locomotor activities (Fig. 53 A, D), that were previously described 
(191,193,441). Similar to moving distance, morphine-induced suppression of rotation time on 
day 1 (unpaired t-test; t (10) = 4.05; p < 0.01), but hyper-excitation between days 7 and 8 
(unpaired t-test; t (10) = 2.30; p < 0.05) (Fig. 53 C). Likewise, morphine-induced lower rotation 
numbers than UTA1003 on day 1 (unpaired t-test; t (6) = 10.57; p < 0.0001), but higher rotation 
numbers from day 5 (unpaired t-test; t (8) = 2.41; p < 0.05) to 8 (unpaired t-test; t (6) = 6.66; p 
< 0.001) (Fig. 53 F). Morphine also significantly reduced rearing time compared to UTA1003 
between days 1 (unpaired t-test; t (9) = 8.65; p < 0.0001) and 4 (unpaired t-test; t (8) = 3.89; 
p<0.01). Beyond that, no differences were observed between the effects of morphine and 
UTA1003 for the next four days (Fig. 53 B). In contrast to rearing time, morphine-induced 
lower rearing numbers only on day 1 (unpaired t-test; t (8) = 10.42; p < 0.0001), implying an 
overall shorter duration of rearing (i.e. seconds per rearing)  between days 2 to 4 (Fig. 53 B, E). 
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In contrast to morphine, UTA1003 induced almost no changes to basal behaviour (day 0) for 
all parameters over the course of the 8 day observation period (Fig. 53 A-F). 
The behavioural differences between the UTA1003 treated animals and animals treated with 
UTA1003 / morphine combination were further compared using the open-field test (Fig. 53). 
The UTA1003 / morphine co-treatment reduced moving time compared to UTA1003 on day 1 
(unpaired t-test; t (10) = 2.58; p < 0.05), but induced increased effects on day 8 (unpaired t-test; 
t (10) = 2.80; p < 0.05) (Fig. 53 A). On the other hand, differential moving distance was 
observed between the groups on days 4 (unpaired t-test; t (8) = 2.55; p < 0.05), 6 and 8 (unpaired 
t-test; t (9) = 5.60; p<0.001), indicating UTA1003 / morphine co-treatment induced hyper-
excitation of locomotion on these days (Fig. 53 D). In contrast to locomotor parameters, rearing 
time and numbers showed similar behavioural pattern over the course of 8 day period. 
UTA1003 / morphine co-treatment showed reduced rearing time and numbers than UTA1003 
treatment from days 1 to 3 (e.g. day 1: unpaired t-test; t (7) = 6.73; p<0.001 (rearing time); t 
(7) = 9.46; p < 0.0001 (rearing numbers)), with no statistical differences observed between days 
4 and 8 (Fig. 53 B, E). The rotation time of animals with UTA1003 / morphine treatment 
showed similar behaviour to UTA1003 treated animals every day except day 8 (unpaired t-test; 
t (10) = 5.60; p < 0.001) (Fig. 53 C). In contrast, rotation numbers of the UTA1003 / morphine 
treatment group were significantly lower than the UTA1003 treated group on day 1 (unpaired 
t-test; t (7) = 7.80; p < 0.001) (Fig. 53 F). Noticeably, UTA1003 / morphine induced increased 
rearing numbers on days 6 (unpaired t-test; t (8) = 2.98; p < 0.05) and 8 (unpaired t-test; t (7) = 
4.19; p < 0.01) (Fig. 53 F).  
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To investigate the differences between the morphine-treated animals and animals treated with 
the combination of morphine / UTA1003, the behavioural activities were further compared and 
similar activities were observed from day 0 to day 8 (Fig. 53 A-F). Although the drug 
combination showed an overall trend of reduced distance, rearing and rotation numbers, these 
effects were mostly statistically non-significant (Fig. 53 D-F). The only significant differences 
between these groups were observed for rearing numbers on day 7 (unpaired t-test; t (9) = 2.34; 
p < 0.05) and rotation numbers on day 8 (unpaired t-test; t (7) = 3.09; p < 0.05) (Fig. 53 E, F).   
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7.4. Discussion 
Long-term treatment with clinical opioids such as morphine is associated with a loss of 
therapeutic potential as analgesic tolerance and various types of behavioural side-effects 
manifest. Currently, all effective clinical analgesics are MOP receptor agonists (22,568,569) 
and unfortunately, opioid-induced adverse effects are typically transmitted via this receptor 
(23,24,25). Therefore, novel mixed activity ligands, especially MOP and  DOP receptor agonist 
ligands have come into focus, as these ligands promise to produce less antinociceptive tolerance 
than conventional, clinically used opioids (150,151,155,160,171,178,184,337,346).  
I previously described a novel opioid UTA1003 that is structurally based on the reference 
compound UFP-505 (349,354). It shares with UFP-505 a MOP receptor agonist / DOP receptor 
partial agonist in vitro specificity profile but displays higher solubility in aqueous solutions 
compared to UFP-505 (unpublished data, chapter six). The present study investigated the 
antinociceptive potential of UTA1003 as well as its effects on motor behaviour. I tested 
UTA1003, morphine and their combination for repeated treatment over a period of eight days 
to assess their effects on the development of antinociceptive and behavioural tolerance, to 
highlight functional differences between these compounds.  
Subcutaneous administration of morphine in the current study produced maximum 
antinociception 30 min after drug injection, similar to results described previously (137). 
UTA1003 showed a mild antinociceptive response, which was significantly (p < 0.001) better 
than UFP-505 at 30 min post injection, although previous reports did not describe any 
antinociceptive activity of UFP-505 after subcutaneous administration (354). In the present 
study, repeated morphine treatment induced antinociceptive tolerance from day 2-4, 
comparable to previous studies (137,171). Importantly, I showed that the combination of 
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UTA1003 / morphine reduced antinociceptive tolerance of morphine which was comparable to 
previous studies, that used morphine in combination with a DOP antagonist 
(122,123,124,125,279). In the present study, the UTA1003 / morphine combination did not 
prevent morphine tolerance on day 3 (in the tail-flick assay) but maintained nearly 50 % 
antinociception levels over the remainder of the 8 day period. This 50% antinociceptive effect 
was statistically significant compared to basal antinociception (day 0). Consequently, drugs 
like UTA1003 could be developed as a co-treatment with clinically used opioids, irrespective 
of their intrinsic antinociceptive activities.  
It has to be noted that the present study used identical molar equivalent doses of UFP-505 and 
UTA1003, which were 13 times higher than an equimolar morphine dose. Therefore, UTA1003 
appears to be only a weak antinociceptive compound after subcutaneous administration in 
comparison to morphine. In principle, this could be interpreted a consequence of its peptidic 
structure, as peptides are known to poorly cross the blood-brain barrier (BBB) (582). However, 
my data show that UTA1003 suppressed motor behaviour to some extent, similar to morphine. 
In addition, an approximately five times lower dose of UTA1003 (5 mg/kg/day, once daily) 
appeared to reduce oxidative damage in the hippocampus of severely depressed rats 
(unpublished data, Xin Yin), which supports the idea that UTA1003 can penetrate the BBB. 
This interpretation supports a previous report where several other opioid peptides (e.g. Dmt-
DALDA, ADAMB and MZ-2) were described to cross the BBB after systemic administration 
in animals (583).   
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In the present study, UTA1003 induced significant levels of antinociception between 30 and 
120 min post-administration in the tail-flick test, in contrast to the hot-plate assay, where it 
showed the highest efficacy 15 to 60 min post-injection. This difference could indicate that the 
antinociceptive effects of UTA1003 are preferentially supra-spinally mediated, as the tail-flick 
test measures predominantly spinal-mediated nociception, while the hot-plate assay largely 
measures a supra-spinal-mediated nociception (135,136,584). The present study deliberately 
employed two different assays to assess antinociception since the tail-flick assay reportedly 
overestimates morphine-induced antinociception. Consequently, the use of multiple 
antinociception tests within the present study aimed to exclude this bias, as previously 
suggested (136). In addition, a comparably low dose of morphine (3 mg/kg) was used to induce 
antinociception  (138,140,144,145,311), to avoid the tail-flick assay-based overestimation of 
morphine-induced antinociception (136).  The present study showed that the combination of 
UTA1003 and morphine clearly prevented antinociceptive tolerance when using the hot-plate 
assay. It is well known that morphine uniformly distributes within the brain stem and spinal 
cord after systemic administration and therefore its antinociception is seen to be mainly 
mediated by a spinal response (585,586,587,588). On the other hand, my current data suggest 
that antinociception of UTA1003 is supra-spinally-mediated since UTA1003 / morphine co-
treatment clearly prevented morphine tolerance in the hot-plate assay. Therefore, the 
combination of morphine and UTA1003 more effectively reduces peripherally mediated than 
centrally mediated antinociceptive tolerance. This hypothesis could be tested by the tool 
compound methylnaltrexone that blocks peripherally mediated opioid effects without affecting 
centrally mediated effects (337,589). As this experiment was beyond the scope of my current 
study, future studies could use methylnaltrexone pre-treatment to investigate whether 
UTA1003 induces central or peripheral responses. 
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Behavioural effects can be measured as changes to motor behaviour, physical dependence or 
place preference by measuring locomotor activities, movement coordination, exploratory 
behaviour, naloxone precipitated withdrawal symptoms, reward or drug-seeking behaviour 
(193,337,346,441,590). The present study assessed motor behaviour simultaneously with 
antinociception in the same animals as described previously (191,192,193,194). Morphine 
produced biphasic effects on locomotor activities after both acute and repeated administration 
in line with previous reports (191,193,441). Repeated treatment with morphine or the 
combination of morphine / UTA1003 initially produced similar levels of hypo-activity with 
subsequent recovery (tolerance) and hyperactivity as described previously (unpublished data, 
chapter three). In contrast, UTA1003 showed only a mild but significant suppression of motor 
activity on the 1st day that returned to basal levels over the 8 day observation period. 
Surprisingly, co-treatment of UTA1003 / morphine prevented morphine-induced 
antinociceptive tolerance, although it did not affect the biphasic morphine-induced changes to 
locomotor behaviour. Since locomotor activities are controlled by both opioidergic and 
dopaminergic neurotransmission systems, I speculate that UTA1003 mediated effects are 
mostly regulated by opioidergic neurons, with negligible effects on dopaminergic neurons, 
although I did not conduct any specific experiment to validate this hypothesis.   
 Although rearing activity is thought to be a reliable parameter to assess exploratory behaviour 
(192,205,210), the reduced rearing may be caused by a multitude of effects that include lack of 
interest, motor impairment, depression or anxiety (206). In this study, repeated morphine-
exposure suppressed rearing indicates reduced animal exploratory behaviour. This effect was 
reported previously (462) and was interpreted to reflect morphine-induced sedation or 
drowsiness in the clinic (451,454).  The current study observed a significant morphine-induced 
reduction of rearing behaviour indicative of reduced exploratory behaviour. However, repeated 
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morphine treatment over only a few days was reported to induce apoptosis in cortex and 
amygdala (591). Since the motor behaviour is known to be controlled mainly by the cortex, 
amygdala and hippocampus (592,593,594,595), this effect could theoretically be responsible 
for the observed motor impairment in these animals. However, this data overall do not support 
this hypothesis, as the animals showed hyper-excitation, especially at later time points which 
cannot be reconciled with an apoptotic loss of neurons that should be more prevalent after 
longer treatment intervals. Morphine-induced reduced rearing could also be a result of drug-
induced anxiety-like or depressive-like behaviour. However, this possibility stands in stark 
contrast to previous studies that reported both anxiolytic (596,597) and anti-depressant effects 
of morphine (598,599,600). The association between morphine and its anti-depressant effect 
was not observed in my study, which instead indicates morphine-induced anxiety may have 
been present in our animals as shown in previous studies (601,602). Therefore, based on my 
results, it cannot finally be determined if the lack of rearing activities of morphine-treated rats 
in my experimental system is a result of reduced exploratory behaviour or anxiety. 
As previously reported, morphine also reduced turning behaviour (459,460), which is a 
complex behaviour that is mainly mediated by the dopaminergic system (199,200,457). 
Abnormal turning or rotational behaviour can occur due to an imbalance of nigrostriatal 
function that controls dopaminergic neurotransmission (581). These dopaminergic neurons are 
connected to GABAergic neurons in the nuclear accumbens and substantia nigra, which 
therefore implicates these neurons in the control of turning behaviour (603,604). The observed 
suppression of turning behaviour after acute treatment of morphine replicates two earlier 
studies that reported similar levels of suppression (459,460). I show that morphine-induced 
rotation numbers are also subjected to tolerance after repeated administration (Fig. 53), which 
follow a similar pattern to morphine-induced antinociceptive tolerance (Fig. 48).  
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Although the described effects of morphine and UTA1003 on behaviour appear significant and 
replicate previous studies, my results raise significant concerns. This study observed significant 
reductions of moving distance, rearing and rotation numbers 30-120 min after exposure to 
vehicle (10% DMSO, 90% saline). These surprising results support a previous study that 
reported similar effects after intracerebroventricular (i.c.v.) and oral administration of DMSO 
in mice (605). Since DMSO metabolites can reduce motor behaviour (606),  I have to assume 
that DMSO in my study may have affected the motor behaviour of my vehicle-treated animals, 
although so far information related to subcutaneous treatment was not included in the previous 
study (605).  
The vehicle-induced reduction of motor activities in the present study may also be an indication 
of anxiety-related behaviour of these animals as repeated open-field measurement may induce 
behavioural changes in a time-dependent manner (607). After the first exposure in an open-
field arena, animals may have an increased level of anxiety with increased locomotion and 
rearing behaviours, which normally disappear after subsequent testing (607). Although the 
animals used in this study were habituated in the testing room for 2 h before the start of the 
daily experiments and an additional five minutes pre-exposure to the open-field apparatus 
before basal motor behaviour was recorded, the possibility of anxiety-related behavioural 
changes cannot be excluded. Since all animals were treated under the same experimental 
conditions, statistical comparisons at the same time-point between the vehicle and opioid-
treated animals should exclude any possible environmental bias. Decreased locomotion in the 
central area of the open-field indicates an anxiety-like behaviour (450,608,609,610,611). 
However, the vehicle-treated animals of this study did not show any changes in locomotion in 
the central area of the open-field over the whole observation period (Fig. 52 A).  Therefore, 
vehicle mediated effects are unlikely a sign of environment-or DMSO-induced anxiety 
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(605,612,613) and this effect has to be investigated in much more detail, using specialised 
behaviour paradigms to understand its origin. At present, however, this effect has to be seen as 
a major confounding factor of the current study.  
In summary, my results illustrate that UTA1003 produced no antinociceptive tolerance and 
prevented to some extent the morphine-induced antinociceptive tolerance after repeated 
administration. I also show that UTA1003 induced less motor suppression than morphine,  
although it did not interfere with morphine-induced suppression or hyper-excitation of motor 
behaviour after co-treatment of UTA1003 / morphine. Therefore, subsequent studies will have 
to focus on a detailed pharmacokinetic study of UTA1003 and its structural analogues to 
increase its efficacy with the systemic administration in preclinical models. Overall, UTA1003 
appears to represent a promising lead compound with an advantageous toxicity profile for 
future studies for the development of potent analgesics with reduced antinociceptive tolerance 
and other adverse effects. 
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CHAPTER EIGHT 
 
Summary  
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8. Summary 
Effective measures to ensure efficacy and safety of long-term use of opioids regarding pain-
relief are not well established in the clinic (249,614). In addition, abuse of opioids (both 
prescription and non-prescription opioids) has increased significantly in many countries, which 
is of great concern to regulatory agencies worldwide (615,616,617,618,619). This study 
intended to develop strategies to reduce opioid-induced antinociceptive tolerance and motor 
behavioural adverse effects over a period of long-term opioid treatment. After a general 
introduction to the topic (chapter one), the second and third chapters described an effective 
dosing strategy to reduce morphine-induced adverse effects. Chapter four described age-
dependent variations of morphine-induced antinociceptive and behavioural effects, which are 
important for dose-calculations of morphine for use in the elderly population. To highlight 
another opioid-induced adverse event, chapter five evaluated the role of opioid receptors on 
insulin homeostasis. Finally, chapters six and seven described the pharmacological profiles of 
novel opioids with mixed activity on multiple receptors generated at the University of Tasmania 
as well as their effects on the two main adverse events associated with opioids: antinociceptive 
tolerance and altered motor behaviour.  
The present study together with previous reports show that an optimised opioid dosage-regimen 
should consider: (i) the patient need (severity of pain, disease condition) (413,483,620,621), 
(ii) dose, (iii) frequency of daily dosing, (iv) duration of treatment, (v) opioid formulation (e.g. 
morphine- base, sulphate or hydrochloride), (vi) dosage form (immediate/sustained release 
formulation), (vii) route of administration (137,622), (viii) patient age (e.g. G protein-coupled 
kinases and β-arrestin expressions decrease with advanced age) (507), (ix) genetic factors 
(poor/rapid metaboliser of opioids) (424,425,426,427,428), (x) polypharmacy (multiple drug 
intake), (xi) multi-morbidity (such as patients with diabetes mellitus, obesity), (xii) drug-drug 
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interactions (423,424) and (xiii) the behaviour of individual patients (addiction or dependency 
on non-prescription narcotics or alcohol) (623,624,625,626).  
Surprisingly the results of the present study indicate that the ‘start low and go slow’ dosage 
regimen of opioids, proposed by all current clinical guidelines, does not appear to provide 
adequate pain-relief and furthermore facilitates tolerance induction. Although this study did not 
determine how much higher a morphine dose should be to provide effective antinociception 
without inducing adverse effects, my results indicate that the duration of treatment is an 
important parameter that further affects dosage-estimations. My results are supported by 
clinical and preclinical studies, which agree that long-term use of low-doses of opioids 
increases pain-sensitivity (hyperalgesia). This would suggest that higher opioid doses are 
required for effective analgesia and to avoid hyperalgesia (180,577,578,579).  
My results suggest that to avoid some of the opioid-induced adverse effects, optimised opioid 
dosing should include one or several of the following strategies: (i) a high dose at the start of 
treatment, (ii) reduced frequency of daily dosing, (iii) larger dose-increments after tolerance 
manifestation, (iii) co-treatment of an opioid (e.g. morphine) and a DOP receptor antagonist 
(e.g. naltrindole), (iv) combination of a clinical and an opioid with mixed selectivity on 
different opioid receptors (e.g. UTA1003), (v) rotation of opioids, (vi) changing administration 
routes, (vii) reduction of polypharmacy if possible, (viii) reduction of the use of psychoactive 
agents (e.g. benzodiazepines and alcohol) and (ix) age-related dose-adjustments (Fig. 54). 
263 
 
 
 
 
Figure 54. Strategies for optimised opioid dosing to reduce adverse effects. The information 
obtained from the current study (red circles) was combined with the reported literature (grey 
circles). 
 
Motor behavioural effects are common adverse effects of long-term opioid treatment. 
Activation of the MOP receptor by an agonist (e.g. morphine) increases dopamine levels in the 
brain (627,628), which are likely to decrease opioid-induced locomotor, rearing and turning 
behaviours (629) (Fig. 55). This study demonstrated that motor behavioural suppression by a 
MOP receptor agonist is paralleled by antinociceptive tolerance levels. Importantly, the hyper-
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excitatory motor behaviour of morphine appears to be directly linked to its antinociceptive 
tolerance. Therefore, the motor behavioural measurement could potentially alleviate the need 
for painful nociception tests (e.g. tail-flick, hot-plate tests), although further verification of this 
hypothesis using additional opioid ligands is required.  
 
Figure 55. Effects of UTA1003 and 
morphine  on  antinociception  and 
motor  behaviour.  The  receptor 
selectivity  profile  of  morphine  has 
been  adopted  from  IUPHAR‐BPS 
Guide  to  Pharmacology 
(12,630,631,632).  In  this  study, 
UTA1003  or  morphine  were  not 
assessed  for  their  pharmacological 
efficacy  on  dopamine  levels  in  the 
brain. The role of DOP receptor on 
motor  behaviour  is  obscure 
(633,634,635).  This  figure 
represents the results of the present 
study  combined with  the  reported 
literature.  Keys:  ↓:  stimulate;  ꓕ: 
inhibit or antagonise. 
 
Although elderly individuals are significantly more likely to use prescription opioids compared 
to younger individuals, an optimum dose-determination of opioids for this age-cohort is 
dependent on a multitude of parameters. However, general clinical practice only assesses a 
limited number of these and use them for necessary dose adjustments. These parameters are 
mainly related to altered age-dependent ADME characteristics and are further complicated by 
the prevalent polypharmacy as a consequence of age-related multi-morbidity (636,637,638). In 
particular, impaired renal function, altered cytochrome P450 activities, reduced GPCR kinase 
and β-arrestin expression is associated with progressive age, all of which could endanger the 
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elderly patient to opioid overdosing and subsequent toxicity (425,427,428,507).  The present 
study described a prolonged duration of action of morphine in older, compared to younger 
animals, which was related to opioid-induced antinociception as well as behaviour. Consistent 
with altered ADME characteristics, this study also demonstrated that these age-dependent 
effects were likely based on different residual opioid levels in the brains of older animals. To 
translate the observations of the present study into the clinic, appropriate opioid dose 
adjustments for older people should anticipate lower opioid doses, which is in agreement with 
previous clinical studies (485,486).  
Appropriate opioid dosing also depends on the physiological condition of patients that suffer 
from chronic and metabolic diseases. Type I diabetes (a metabolic disorder) is associated with 
the degeneration of pancreatic β-cells, which results in decreased plasma insulin levels (516). 
Type II diabetes is caused by reduced cellular insulin sensitivity and elevated plasma glucose 
levels (355,356). Both types I and II diabetes are associated with diabetic neuropathy, where 
patients experience neuropathic pain and therefore require analgesic medications (639). 
Optimum insulin secretion from pancreatic β-cells and glucose utilisation are required to 
manage type I diabetes mellitus, which may contribute to the reduced diabetic neuropathy of 
this patient cohort (640,641,642). The present study showed that MOP or DOP receptor 
activation induces insulin secretion in a pancreatic cell line, whereas the KOP receptor 
activation left insulin secretion unaffected (643). From a clinical perspective, MOP or DOP 
receptor-selective opioids may, therefore, provide some benefits to increase plasma insulin 
levels but at the same time also potentially interfere with diabetic medication schemes. 
Although further studies are required to gain more detailed insights into opioid-dependent 
insulin secretion, this effect should be carefully considered in diabetic patients to provide 
optimised treatment paradigms and to prevent unwanted adverse effects due to drug-drug 
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interactions.  
Opioids with mixed selectivity profile on multiple receptors produce less adverse effects 
(tolerance and motor behavioural effects) than morphine or other opioids that are selective for 
the MOP, DOP or KOP receptors (26,147,443,644,645,646) (Fig. 56). In this study, the novel 
opioid UTA1003 with a mixed activity profile on different opioid receptors was identified and 
characterised. UTA1003 appeared as a mild antinociceptive agent after acute subcutaneous 
administration but induced no antinociceptive tolerance after repeated treatment. More 
importantly, a combined treatment of UTA1003 and morphine reduced morphine-induced 
antinociceptive tolerance (Fig. 56). This study indicates for the first time that co-treatment of a 
clinically used opioid with an opioid with mixed selectivity profile on multiple opioid receptors 
can reduce the adverse effects of clinical opioids, although further investigations are required 
to strengthen this concept with regards to other adverse effects as well as for other opioids with 
mixed selectivity profile on multiple opioid receptors.  
In this study, acute UTA1003 treatment showed reduced but not absent behavioural suppression 
compared to morphine. Interestingly, no behavioural adverse effects were observed after 
repeated administration of UTA1003 (Fig. 56), which is likely due to its MOP receptor agonist 
/ KOP receptor agonist profile, since KOP receptor activation antagonises MOP receptor-
induced behavioural effects (Fig. 55). In contrast to the beneficial effects of co-administration 
of UTA1003 with morphine on tolerance induction, repeated co-treatment of both drugs could 
not protect against morphine-induced behavioural effects. As the behavioural effects are 
complex and controlled by both opioidergic and non-opioidergic (e.g. dopaminergic) neurons 
(Fig. 55), future studies need to investigate the detailed mechanism why UTA1003 shows 
differential effects on antinociception and motor behaviour.   
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Figure 56. Expected benefits of the co‐treatment of UTA1003 and morphine. Keys: MOPr, DOPr, 
KOPr  and  NOPr:  µ,  δ,  κ  and  non‐opioid  receptors  respectively;  “?”:  unknown/inconclusive 
evidence;  “↑”:  increased  effects;  “↓”:  decreased  effects;  “≈”:  no  effects.  The  informaƟon 
presented in this figure represent the results of the present study combined with the published 
literature in this field (25,140,147,153,172,231,233,645,647,648,649,650,651,652). 
 
In the present study, Sprague Dawley rats were used to assess the antinociceptive and 
behavioural effects, which could be tested on mice or another animal species. No vehicle-
treated animals were used as control groups in chapters 2-4, which is a significant limitation of 
my study. Future studies should investigate opioid-induced effects by comparing opioid-treated 
with vehicle-treated (0.9% w/v sodium chloride solution in water) control animals. Thermal 
nociception assays (tail-flick and hot-plate tests) were only used in this study to assess the 
268 
 
 
efficacy of the opioids, but the unchanged baseline antinociception and behaviour over two 
weeks of repeated treatment (chapters 2 and 3) can potentially indicate that the absence of 
adverse effects like hyperalgesia or allodynia. The selectivity profile of the novel UTA-opioids 
could be verified by using radio-ligand binding assay or GTPγ35S assay, although the use of 
cAMP assay potentially helped me to identify the potential ligand for preclinical assessment. A 
detailed pharmacokinetic study should be conducted in future to understand the effects of 
UTA1003 and UFP-505, which could not be fitted with the present study design with simultaneous 
measurements of antinociception and behaviour of the same animals. Further chemical 
modification in the structure of UTA1003 is warranted in future to increase its efficacy after 
subcutaneous administration.  
Adequate opioid use should maintain long-term antinociception and safety of patients in the 
clinic and the present study has provided new knowledge on the role of opioid dosing for the 
induction of antinociceptive tolerance. My study also indicated that detailed motor behavioural 
testing could have the potential to replace the widely used painful preclinical antinociception 
testing to investigate antinociceptive tolerance. This potential paradigm shift could 
significantly reduce of animal suffering in future studies of pain-research. I observed that older 
animals need less morphine to maintain effective antinociception and behavioural effects, 
which indicates additional dosage adjustment to avoid toxicity and to ensure safety for the 
elderly population. I also added additional knowledge to the literature on the role of MOP and 
DOP receptors on insulin homeostasis, which could be particularly important for opioid dosing 
adjustments in patients with diabetes. In this study, I identified and characterised a novel ligand 
UTA1003 with mixed activity profile on different opioid receptors. UTA1003 produced less 
adverse effects than morphine either alone or after co-treatment with morphine in rats. 
Therefore, an optimised opioid dosing can also include a combination of an opioid with an 
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opioid with mixed selectivity profile on multiple opioid receptors to maintain long-term safety 
for the patients. Finally, this study confirms that targeting multiple receptors is a promising 
pharmacological strategy to reduce opioid-induced adverse effects.  
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Appendix A. Additional behavioural effects of morphine  
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A.1. Qualitative behavioural effects of morphine  
 
Drowsiness, lethargy, hyperactivity, itching and respiratory depression are common adverse 
effects of morphine (230,250,251,653). Morphine is also responsible for itching sensation by 
signalling through heteromers of opioid- and itch-mediating G-protein receptors (253). I 
observed that some animals showed signs of itching and wheezing over time (Table A1). 
Consistent with the situation in patients where these effects are not dose-dependent (251), I 
also could not demonstrate a dose dependency in the rats of the current study.   
The detailed information regarding animals, dosage and treatment protocol is described in the 
Methods section of chapter 3 (section 3.2). 
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Table A1. Qualitative behavioural effects of daily morphine-treated rats. Homecase-
activity, itching and wheezing effects of daily morphine-treated Sprague Dawley rats (n=6 per 
group) over the course of 14 days (groups A and B) and the effects were measured daily using 
cautious subjective measurements on the animals in their home-case over a period of 60 min 
after morphine administration.    
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